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Abstract	
Over the last two decades, the options for treating cancer have been revolutionized by the rapidly expanding 
field of human immunotherapy, and the innate potential of T cells to target, attack and control malignant 
cell growth is now widely accepted. Some of the most powerful immunotherapeutic strategies rely on the 
retargeting of T cells via antibody-derived recognition domains. For instance, these can be embedded in a 
synthetic chimeric antigen receptor (CAR), combining an antibody-derived targeting domain, typically a 
single-chain variable fragment (scFv), and intracellular signaling domains derived from the T cell receptor 
(TCR) complex and various co-stimulatory molecules. Another approach for harnessing the cytotoxic 
potential of T cells involves the use of bispecific antibody-derived molecules comprising a tumor-targeting 
moiety together with an associated ‘bridging’ anti-CD3 recognition domain. Both strategies have been 
applied successfully to treat hematological malignancies, but achieving equivalent objective efficacy against 
solid tumors remains challenging, in part because of a relative absence of truly tumor-restricted antigen 
targets. 
Tumor endothelial marker 1 (TEM1, Endosialin) has been proposed as a marker of neo-vasculature in 
embryonic and cancerous tissues. Due to its upregulation in the stroma and vasculature of many solid tumors 
and absence in healthy adult tissues, TEM1 represents an attractive tumor-associated antigen. 
This thesis presents the de novo isolation and functional characterization of a diverse panel of fully human 
scFv binders targeting TEM1 from a naïve phage display antibody library. To accelerate antibody discovery, 
we have developed and validated a novel approach that integrates SpyCatcher/SpyTag covalent tag fusion 
technology into our phage display selection and screening workflows. Moreover, we have made significant 
progress towards the development of a powerful phenotypic selection strategy capable of flagging directly 
those scFvs in a library that possess cell-based CAR-activity. Using these approaches, we have identified 
several defined scFv candidates with distinct biophysical properties that recognize different domains of 
TEM1, and which have subsequently been investigated as targeting moieties for both CARs and soluble T cell 
engagers. In this latter context, both anti-CD3 and anti-TEM1 domains have been incorporated into a stable, 
trivalent bridging molecule (termed ‘TriloBiTE’) that permits either bivalent or biparatopic recognition of 
TEM1 on the surface of target cells.  
Among our panel of novel antibodies, two lead candidates specifically redirect human T cells to TEM1 
expressing target cells, both as CARs and as bispecific T cell engaging mediators, leading to the secretion of 
effector cytokines and lysis of tumor cells. From our investigations of these anti-TEM1 scFvs, target affinity 
and epitope location have emerged as two key parameters impacting on TEM1-directed T cell retargeting. 
Encouragingly, preliminary in vivo data for one of our candidate clones formatted as a soluble TriloBiTE 
suggests an ability to suppress TEM1+ tumor establishment and growth, paving the road for further, more 
detailed investigations.  
In summary, my thesis highlights two technological advances for the de novo discovery of functional antibody 
moieties and presents a first proof-of-principle for the immunotherapeutic targeting of TEM1.  
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Résumé	
Au cours des deux dernières décennies, les options pour le traitement du cancer ont été révolutionnées par le 
domaine en pleine expansion de l'immunothérapie humaine. Parmi les stratégies immunothérapeutiques les plus 
puissantes, certaines se concentrent sur la redirection des lymphocytes T grâce à des domaines de reconnaissance 
dérivés d'anticorps. Ces domaines peuvent être intégrés dans un récepteur antigénique chimérique (CAR) 
synthétique, combinant un domaine de ciblage dérivé d'un anticorps, des domaines de signalisation intracellulaire 
dérivés du complexe du récepteur des lymphocytes T (TCR) et des diverses molécules de costimulation. Une autre 
approche pour exploiter le potentiel cytotoxique des cellules T implique l'utilisation de molécules bispécifiques 
dérivées d'anticorps. Ces dernières associent un fragment ciblant la tumeur à un domaine de reconnaissance anti-
CD3. Les deux stratégies ont été appliquées avec succès pour traiter des tumeurs malignes hématologiques, mais 
il reste difficile d'obtenir une efficacité équivalente contre les tumeurs solides, en partie à cause de la rareté des 
cibles antigéniques véritablement limitées aux tumeurs. Dans ce contexte, le « tumor endothelial marker 1 » 
(TEM1, Endosialin) a été proposé comme marqueur de la néovasculature dans les tissus embryonnaires et 
cancéreux. En raison de son expression dans le stroma et le système vasculaire de nombreuses tumeurs solides et 
de son absence dans les tissus adultes sains, TEM1 représente un antigène tumoral attractif. 
Cette thèse présente l'isolement de novo et la caractérisation fonctionnelle d'un panel varié de molécules scFvs 
entièrement humains ciblant TEM1, à partir d'une librairie d'anticorps naïfs sélectionnée par phage display. Pour 
accélérer la découverte d'anticorps, nous avons développé et validé une nouvelle approche qui intègre la 
technologie de fusion covalente de l’interaction SpyCatcher/SpyTag dans notre processus de sélection et de 
screening par phage display. De plus, nous avons fait des progrès significatifs vers le développement d'une 
stratégie de sélection phénotypique puissante capable d’identifier directement les scFv qui possèdent une activité 
dans le format CAR. En utilisant ces nouvelles méthodologies, nous avons identifié plusieurs candidats scFvs avec 
des propriétés biophysiques distinctes qui reconnaissent différents épitopes de TEM1. Ces scFvs candidats ont été 
étudiés en tant que composants de molécules CARs et en tant que médiateurs bispécifiques de cellules T. Dans ce 
dernier cas, les domaines anti-CD3 et anti-TEM1 ont été incorporés dans une molécule trivalente stable (appelée 
« TriloBiTE ») qui permet la reconnaissance bivalente ou biparatopique de TEM1 à la surface des cellules cibles.  
Parmi nos nouveaux anticorps, deux candidats principaux redirigent spécifiquement les cellules T humaines vers 
des cellules cibles exprimant TEM1, à la fois comme CAR et comme TriloBiTE, aboutissant à la sécrétion de 
cytokines effectrices et à la lyse des cellules tumorales. Nos recherches sur ces scFvs anti-TEM1 ont permis 
d'établir que l'affinité avec la cible et la localisation de l'épitope sont deux paramètres clés qui ont un impact sur 
le reciblage des cellules T vers TEM1. De plus, les données in vivo préliminaires pour un de nos clones candidat 
formaté en TriloBiTE suggèrent une capacité à supprimer l'établissement et la croissance des tumeurs TEM1+, 
ouvrant la voie à des investigations plus détaillées.  
En résumé, ma thèse met en évidence deux avancées technologiques pour la découverte de novo de fragments 
d'anticorps fonctionnels et présente une première preuve de principe pour le ciblage immunothérapeutique de 
TEM1. 
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 Introduction	
 1.1 The	immune	system	
The human immune system comprises a variety of cells and molecules which together defend the body 
against infectious agents and their toxins. Most of the cells of the immune system, called white blood cells, 
or leukocytes, derive from the lymphoid and myeloid lineages of pluripotent stem cells, which in turn derive 
from the hematopoietic stem cells (HSCs) in the bone marrow. Once mature, they migrate to peripheral 
tissues or circulate through the bloodstream or the lymphatic system, constantly monitoring for invading 
pathogens and abnormal cells. 1.1.1 Innate	and	adaptive	immunity	
The immune system can be divided into two main components, the innate and the adaptive immune system 
(reviewed extensively in Janeway’s Immunobiology, 9th edition1). The innate immune system continuously 
defends the body against invading pathogens and is indispensable for the initiation of the adaptive immune 
response. The first line of defense is provided by anatomical barriers, such as the skin and mucosal surfaces 
of the oral cavity and gastrointestinal tract. Once pathogenic microbes penetrate this physical barrier and 
invade the underlying tissue, other components of the innate immune system are activated, such as the 
complement system, which plays a major role in the defense against invading bacteria2. Furthermore, cellular 
components of the innate immune system, such as macrophages, dendritic cells, and granulocytes, are 
rapidly activated to engulf and destroy invading microorganisms and induce inflammation1.  
Besides the non-specific innate immune system, the adaptive immune system enables highly specific 
responses to a vast array of proteinaceous and non-proteinaceous, usually polymeric molecules termed 
antigens. These highly specific lymphocytes, which comprise T cells and B cells, possess highly variable 
receptors that allow the recognition of virtually any foreign antigen3,4. Another important feature of the 
adaptive immune system is the generation of long-lasting immunological memory, conferring protective 
immunity against recurring infection1. For both B and T lymphocytes, antigen recognition through the antigen 
receptor (B cell receptor (BCR) or T cell receptor (TCR), respectively) induces activation and differentiation 
into so-called ‘effector’ and ‘memory’ lymphocytes. Antigen binding to the BCR causes B cells to proliferate 
and differentiate into effector cells, termed plasma cells. These plasma cells produce and secrete large 
quantities of antibodies, which circulate through blood and tissue fluids5.  
Similarly, T cells are endowed with a T cell receptor (TCR), which recognizes foreign antigens and, upon 
activation, induces the proliferation and differentiation of T cells into various effector subtypes. There are 
two main types of T cells. CD8 T cells, also known as cytotoxic T cells, which are characterized by the 
expression of the cluster of differentiation (CD) 8 co-receptor on their surface. Their main role is to kill 
abnormal or infected cells bearing foreign antigens, as further detailed below. The other key population of T 
cells, commonly referred to as helper T cells, express CD4 co-receptor on their surface and produce secreted 
cytokines and other signals that modulate the response of other cell types3,6. 
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1.1.2 Antigen	recognition	by	T	cells	
Each antigen receptor recognizes a specific antigenic determinant, or epitope, of any given antigen’s 
molecular structure. The TCR recognizes a foreign or aberrant peptide epitope, which is presented by 
glycoproteins of the major histocompatibility complex (MHC) family on the surface of the body’s cells1,7. 
There are two classes of MHC molecules, class I and class II. Both form a peptide-binding groove to display 
antigenic peptides, but they differ in their domain structure, peptide binding properties and in their 
expression pattern8.  
MHC class I molecules are encoded by three genes (HLA-A, HLA-B and HLA-C in humans), which are all highly 
polymorphic, and are recognized by CD8+ cytotoxic T cells. MHC class I molecules are expressed by almost all 
nucleated cells and present peptides derived from endogenously expressed and processed ‘self’ and foreign 
antigens, such as are present following viral infections8,9. In this way, they enable cytotoxic T cells to detect 
and eliminate infected or otherwise abnormal cells. Additionally, MHC class I molecules can present 
exogenous extracellular peptides through a process termed cross-presentation10. 
In contrast, MHC class II molecules are normally only expressed by antigen presenting cells (APCs), such as 
dendritic cells, macrophages and B lymphocytes, which take up and present circulating extracellular foreign 
agents and macromolecules8,11. The resulting processed antigens are recognized by CD4+ T cells, which upon 
activation release cytokines, which can enhance and modulate the effector functions of APCs and other cell 
types. Similar to MHC class I, class II molecules are encoded by three highly polymorphic genes (HLA-DR, HLA-
DQ and HLA-DP in humans), with hundreds of different alleles found in the human population12. This MHC 
polymorphism enables the presentation of a vast variety of different peptides and determines each 
individuals discrete ‘self’ immune ‘peptidome’13. Importantly, an extensive T cell sorting and selection 
process that takes place in the thymus ensures that the TCR repertoire is restricted to recognize specific 
endogenous MHC alleles and tuned to make weak binding contacts with the MHC molecule and any ‘self’ 
bound peptide antigens14.  
Following recognition of cognate peptide:MHC complexes by the TCR, proteins in the T cell membrane are 
actively rearranged to form an immunological synapse at the interface of the two interacting cell types15-17. 
The immunological synapse is crucial for enabling productive TCR signaling and is organized into distinct 
areas, the supra-molecular activation complexes (SMACs)18. At the center of the SMAC (cSMAC), the TCR and 
CD4/8 co-receptors cluster together with T cell co-stimulatory molecules, such as CD28. In a peripheral region 
of the synapse, the so-called pSMAC, cell adhesion molecules such as the T cell integrin lymphocyte function-
associated antigen 1 (LFA-1) reinforce the cell-cell interaction by binding to intercellular adhesion molecule 
1 (ICAM-1) on the APC. Larger molecules, such as the transmembrane tyrosine phosphatase CD45 are 
confined  to the distal edges of the interface (dSMAC)18.  
In addition to peptide:MHC recognition and TCR signaling, co-stimulatory signaling is required for full T cell 
activation, which typically takes place in secondary lymphoid organs, such as lymph nodes.19 (Fig. 1.1). This 
so-called two-signal model20 was proposed following the discovery of the co-stimulatory molecule CD28, 
which interacts with B7-1/2 (CD86/CD80) on the surface of an APC in order to fully activate a naïve T cell21. 
Without co-stimulation, activated T cells will go into anergy, a state of growth arrest and relative 
unresponsiveness22. Besides CD28, many other receptors can provide co-stimulation, such as 4-1BB, OX40 
and CD40L. Similarly, co-inhibitory receptors are essential to attenuate T cell responses, induce tolerance 
towards self-antigens, and protect tissues from excess T cell induced damage. Key among these are cytotoxic 
Introduction 
 
 
3 
T lymphocyte antigen 4 (CTLA4), which displaces CD28 from its ligand B7-1/2, and programmed death PD1. 
Together, co-stimulatory and co-inhibitory receptors modulate TCR signaling and T cell function19.  
 
 
 1.1.3 T	cell	receptor	structure	and	signaling	
The TCR is composed of two separate polypeptide chains, the TCR a and b chains, which are linked through 
a disulfide bond. The genes encoding the TCR chains are closely related to immunoglobulins and their 
structure resembles a membrane-bound fragment, antigen binding (Fab) domain, but, in contrast to 
antibodies, they are never secreted1. The majority of T cells express an a:b heterodimeric TCR, but some cells 
bear alternative g:d TCRs, whose functions are still being investigated23.  
Both TCR chains contain an N-terminal variable (V) region, which is primarily involved in antigen recognition, 
and a constant (C) region, followed by a transmembrane and short cytoplasmic domain. While the variable 
TCR a/b chains confer antigen specificity, they are required to associate with other molecules in order to 
transmit the information of antigen recognition to the cytosol. These signaling molecules are part of the CD3 
complex, which comprises a CD3de heterodimer, which associates with the TCR a chain, and a CD3ge 
heterodimer, which interacts with the TCR b chain (Fig. 1.2). Moreover, the CD3z chain, which forms a 
homodimer, associates with the TCR chains24,25. The assembly of the resulting TCR complex relies mainly on 
charge interactions between positively charged amino acids in the TCRa/b transmembrane (TM) regions, and 
negatively charged residues in the CD3 TM domains.26 Cell surface expression of the TCR requires the 
assembly of the whole TCR complex including all signaling components25. 
APC
CD4+ T cell
MHC 
class II
TCR CD4 CD28
B7 cytokines
cytokine 
receptor
Signal 1: 
antigen 
recognition
Signal 2: 
co-stimulation
Signal 3: 
instructive 
cytokines
Figure 1.1. Productive T cell activation requires three different signals. 
Signal 1 is delivered upon antigen recognition by the TCR. Co-stimulatory receptors such as CD28 mediate signal 2 upon ligand 
binding. Signal 3 involves instructive cytokines produced by primed antigen presenting cells (APCs) and directs T cell differentiation. 
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Figure 1.2. Composition of the TCR complex. 
The antigen-specific TCR a and b chains associate with the CD3 e/d and CD3 g/e heterodimers, as well as the CD3 z chains to form the 
TCR complex. The CD3 chains contain intracellular ITAM domains, which transmit the TCR signal to the cytosol. 
 
 
Upon antigen binding, immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic domains 
of the CD3g, d, e and z chains become phosphorylated at two tyrosines, respectively. This initial 
phosphorylation of ITAMs is executed by the Src-family kinase Lck, which is associated with the cytoplasmic 
domains of CD4 and CD827. Furthermore, the interaction through the co-receptors helps to stabilize the TCR 
– peptide:MHC interaction in order for signal transduction to occur. These initial phosphorylation events 
allow the recruitment of intracellular kinases containing tandem SH2-domains, such as ZAP-70 (z-chain-
associated protein), which in turn are phosphorylated and activated28 (Fig. 1.3). Further downstream of the 
TCR signaling cascade, ZAP-70 recruits and phosphorylates a number of adaptor proteins, such as linker of 
activated T cells (LAT) and SLP-76 (SH2 domain containing leukocyte protein of 76 kDa)29,30. Moreover, PI 3-
kinase is activated, generating phosphatidyl-inositol triphosphate (PIP3) at the inner membrane, which then 
together with the adaptor proteins mentioned above, recruits phospholipase C-g (PLC-g). PLC-g then cleaves 
the membrane lipid PIP2, generating membrane-bound diacylglycerol (DAG) and the cytosolic messenger 
inositol 1,4,5-triphosphate (IP3), which triggers the opening of calcium channels in the endoplasmic reticulum 
(ER) membrane and in the plasma membrane, causing a Ca2+ influx into the cytosol31. 
Among other effects, the cytoplasmic Ca2+ influx mediates activation of transcription factors of the nuclear 
factor of activated T cells (NFAT) family32 (Fig. 1.3). Specifically, Ca2+ is bound by calmodulin, which 
subsequently binds and activates the serine/threonine phosphatase calcineurin, leading to the 
dephosphorylation of NFAT. While phosphate groups usually mask the nuclear localization signal of NFAT, 
dephosphorylation causes NFAT to enter the nucleus, where it acts on the transcription of many genes 
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involved in T cell function. For instance, it activates the expression of interleukin-2 (IL-2)32. Furthermore, the 
membrane-conferred mediator DAG induces the activation of Ras and the mitogen-activated protein kinase 
(MAPK) cascade, as well as the activation of protein kinase C-q (PKC-q). These pathways lead to the activation 
of the transcription factors AP-1 and NF-kB, which both contribute to the control of T cell effector functions27. 
Finally, other consequences of TCR signaling are the upregulation of metabolic pathways via the 
serine/threonine kinase Akt, as well as enhanced integrin-mediated cell adhesion and reorganization of the 
cytoskeleton28. 
 
Figure 1.3. NFAT signaling in activated T cells. 
Early TCR signaling induces a Ca2+ influx, which activates transcription factors of the NFAT family. Figure adapted from Macian, F. Nat 
Rev Immunol, 5(6), 472–484 (2005)32.  
 
 1.1.4 T	cell	effector	functions	
Recognition of a specific peptide:MHC complex by the TCR is only the first step in the activation of a naïve T 
cell. Effective expansion and survival however require two additional signals: (i) a co-stimulatory signal (signal 
2) provided by the same APC (i.e. via CD28 – B7.1/2) and (ii) cytokines (signal 3), which direct the 
differentiation of the naïve T cell into a specialized T cell subset1 (see Fig. 1.1). This first antigen encounter 
and T cell priming typically takes place in peripheral lymph nodes. The primary cytokine produced by 
activated naïve T cells is IL-2, which induces accelerated cell cycling and proliferation33. Along with the 
production of IL-2, antigen encounter with appropriate co-stimulation induces the expression of CD25, the a 
chain of the IL-2 receptor, which upon association with the b and g chains creates a heterodimeric receptor 
with greatly increased affinity compared to the b/g IL-2 receptor expressed by naïve T cells34. Naïve T cells 
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activated in this way therefore undergo clonal expansion and during this process also differentiate into the 
different effector subtypes, a process that is primarily driven by the cytokine milieu. A key feature of effector 
T cells is their independence from co-stimulation, enabling for instance the killing of any cell infected with a 
virus and presenting viral peptides on MHC I molecules1. 
CD8 T cells are predisposed to differentiate into cytotoxic effector cells, whose key feature is the ability to 
recognize and destroy abnormal cells. Upon antigen recognition, CD8 effector cells release cytotoxic granules 
selectively at the immunological synapse. Biochemical conditions, particularly the pH, within the granules 
prevent the action of the cytotoxins stored in these granules, mainly perforin and granzyme, but they become 
active once released35-37. Perforin forms pores in the plasma membrane of the target cell, allowing the 
delivery of granzymes38. Granzymes are proteases which induce apoptosis of the target cell, both by cleaving 
caspases and by causing mitochondrial damage39. Additionally, CD8 T cells express membrane-bound death 
signals such as Fas ligand, which can induce apoptosis of target cells expressing Fas40,41. Moreover, activated 
cytotoxic T cells release cytokines such as interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a). IFN-
g stimulates antigen presentation on MHC class I molecules, activates macrophages and inhibits viral 
replication. TNF-a also activates macrophages and can induce apoptosis in cells expressing TNF receptor-I42.  
In contrast, CD4 T cells can differentiate into several effector subtypes, primarily dictated by fate-specifying 
cytokines provided by APCs and other innate immune cells43. The different CD4 effector subtypes are 
specialized to enhance the effector functions of other cells in order to eliminate a specific class of 
pathogens43. For instance, TH1 cells secrete IFN-g, which improves the eradication of intracellular pathogens 
by macrophages44. 
In summary, upon peptide:MHC recognition, the predominant effector function of CD8 T cells is the lysis of 
abnormal or virally infected cells, whereas CD4 T cells mainly carry out regulatory functions, instructing other 
immune cells via cytokines. However, it has been shown that certain CD4 T cell subsets can also exert 
cytotoxic effector functions45. The following section introduces another key player of the adaptive immune 
system, the B cells.  1.1.5 B	cell	activation	and	effector	functions	
Like T cells, B cells have the capacity to recognize a vast array of different antigens. In B cells, the antigen-
binding proteins are called immunoglobulins and any given B cell produces immunoglobulins of a single 
specificity1. The activation and clonal expansion of B cells occurs upon antigen recognition by the BCR, a 
membrane-bound form of immunoglobulin. 
Similar to the TCR, the antigen-specific BCR associates with invariant signaling molecules, in this case Iga and 
Igb. These single-chain proteins form a disulfide-linked heterodimer and associate with the heavy chains of 
the BCR via hydrophilic interactions46. The association with the Iga:Igb dimer enables the transport of the 
BCR to the cell surface and provides the ITAM-containing cytoplasmic domains necessary for signal 
transduction1,46. Cross-linking of BCR via a multivalent antigen activates the ITAM-associated Src-family 
kinases Fyn, Blk and Lyn, which phosphorylate tyrosine residues in the ITAMs. An SH2-domain containing 
tyrosine kinase, Syk, is recruited to the phosphorylated ITAMs and initiates a signaling cascade involving the 
scaffold protein SLP-65 as well as PLP-g and its products DAG and IP3. Antigen-dependent BCR signaling is 
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further enhanced by engagement and clustering of the B-cell co-receptor, a complex formed by the cell-
surface proteins CD19, CD21 and CD811,47. 
Ultimately, the BCR signaling pathway leads to increased survival, metabolic changes and a rearrangement 
of the actin cytoskeleton to create an immune synapse. In B cells, the immune synapse mainly serves to 
facilitate antigen uptake for subsequent presentation on MHC class II molecules48. Subsequently, activated B 
cells undergo clonal expansion and differentiate into plasma cells, which secrete large quantities of soluble 
antibodies49. 1.1.6 Antibody	structure	and	function	
Secreted IgG antibodies are structurally depicted as Y-shaped proteins with a molecular weight of of 
approximately 150 kDa. The structure of an antibody is shown in Figure 1.4. Antibodies combine several 
functionalities: Principal amongst these is the recognition of a variety of antigens through specific (and often 
high-affinity) binding mediated by the terminal regions of each ‘arm’. Other related functions are concerned 
with the activation of immune ‘effector’ functions, leading to the neutralization and elimination of the bound 
antigen. Additional elements in the antibody structure actively promote the persistence of the molecule 
within the circulation. The two ‘arms’ of the molecule represent the extremely variable, or V region, which 
allows the recognition of virtually any antigen, whether a small molecule (a hapten) or a large conformation 
epitope of a protein. The binding strength of one arm to its target dictates the ‘affinity’ of the molecule, while 
the combined binding strength conferred by both arms acting in concert is referred to as ‘avidity’. The 
remaining constant, or C region domains are conserved for a given antibody class and are responsible for 
eliciting and controlling the strength of the associated immune effector functions and for governing the 
circulating half-life of the antibody. The most abundant class of antibodies, the IgG, consists of four 
polypeptide chains, two identical heavy chains (HC) of approximately 50 kDa, and two identical light chains 
(LC) of around 25 kDa (Fig. 1.4)50-54. There are two types of light chains, termed l and k, which are 
represented in different ratios in different species. In humans, the average ratio of k to l light chains is 2:1, 
but in mice it is 20:155. The two heavy chains are linked by disulfide bonds in the ‘hinge’ region of the 
molecule, and each heavy chain is similarly linked through a disulfide to a light chain. Historically, proteases 
were used to study the antibody structure and the resulting nomenclature is still being used today. For 
instance, papain cuts the antibody into three different fragments, two antigen-binding fragments (Fab) and 
one readily crystallizable fragment (Fc)50,51,53,54. This enzyme cleaves in the hinge region of the antibody, a 
flexible stretch of amino acids that allows a certain range of motion of each Fab arm in order to allow the 
simultaneous binding of two antigens. 
Both heavy and light chains are composed of compactly folded immunoglobulin (Ig) domains, which show 
strong homology on the sequence- and on the structural level56. While heavy chains consist of four such Ig 
domains, the smaller light chains contain only two Ig domains. In both cases, the N-terminal Ig domain bears 
highly variable regions and is therefore termed variable (V) domain56. The V domains of heavy (HC) and light 
chains (LC) combined correspond to the antigen-binding V region of the antibody and they can be isolated 
genetically and linked synthetically to generate a single-chain variable fragment (scFv)57. In contrast, the 
constant domains of heavy and light chains make up the C region1,52. For the heavy chain, which contains 
three C domains, these are numbered CH1, CH2 and CH3 from the N- to C-terminus (Fig. 1.4), with CH2 and 
CH3 forming the Fc region. The constant region of the heavy chain defines the class, and/or isotype, and 
therefore the effector function of an antibody1,55. There are five major classes, IgM, IgD, IgG, IgA and IgE, with 
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IgG being further classified into four subclasses (i.e. IgG1, 2, 3 and 4), all conferring different structural and 
immunological properties55. 
Each Ig structural domain is composed of two b sheets, each built from several b strands, which are tightly 
packed together and stabilized by a disulfide bond. V and C domains share this immunoglobulin fold, but the 
V domains are slightly larger and contain additional b strands52,56.  
 
Figure 1.4. The structure of an IgG antibody. 
Schematic representation illustrating the structure of an IgG antibody. The molecular structure of the variable region of an exemplary 
human antibody is shown (PDB accession 4JHW, chain H and L), with the CDR loops highlighted in colors, and side chains shown in 
stick representation. The protruding red loop corresponds to the HC CDR3, the lighter hued loops correspond to HC CDR 1 and 2. CDR 
loops of the light chain are colored in orange. Fab, fragment, antigen-binding; VL, variable light; CL, constant light; VH, variable heavy; 
CH1-3, constant heavy 1-3; scFv, single-chain variable fragment; Fc, fragment, crystallizable. 
 
 
Importantly, each mature structural V domain contains three hypervariable regions, which are separated by 
four framework regions. These hypervariable regions, which are termed complementarity-determining 
regions (CDRs), form protruding loops at the edge of the Ig fold and define the antigen specificity of the 
antibody. Each antigen-binding site is thus composed of six CDR loops, three from the heavy chain and three 
from the light chain, which collectively contribute to antigen recognition (Fig. 1.4). However, not all CDRs 
have to directly engage in the antibody paratope (the amino acid residues responsible for binding the 
epitope), but rather help to orient those residues that do interact with the epitope55,58. 
VL
CL
VH
CH1
CH2
CH3
Fc
Fab
scFv
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1.1.7 Antibody	and	TCR	diversity		
The vast repertoire of immunoglobulins and TCRs represents the underlying principle of adaptive immunity, 
enabling the recognition of any antigen encountered. Several sequential gene rearrangement and splicing 
processes are required to realize this potential.  
Firstly, combinatorial diversity is created by somatic recombination of gene segments encoding the variable 
regions of heavy and light chains (VH and VL) or the variable regions of the TCR a and b chains (Va and Vb)59. 
The mature VL and Va regions are encoded by the splicing of two different gene segments, V (variable) and J 
(joining), while VH and Vb regions contain an additional D (diversity) gene segment spliced between the V and 
J elements. Both TCR and antibody genetic loci contain clusters of genes encoding each of the V, (D), and J 
repertoire segments  which are randomly, yet sequentially, recombined during lymphocyte development in 
a process called V(D)J recombination60. Subsequently, the rearranged variable domains are spliced to 
constant domain exons. Whereas the CDR1 and CDR2 domains are encoded directly in the germline V gene 
segment, the hypervariable CDR3 loops arise as a consequence of junctional V(D)J recombination59,60.  
Antibody and TCR V(D)J recombination is mediated by the RAG recombinase (encoded by the recombination-
activating genes 1 and 2), which recognizes and cleaves specific recombination signal sequences (RSSs) that 
flank each V, D, and J segment61,62. An RSS consists of a conserved heptamer and nonamer sequence, which 
are separated by a non-conserved spacer of either 12 or 23 base pairs. According to the 12/23 rule, a gene 
segment followed by an RSS with a 12bp-spacer can only be joined with a segment proceeded by an RSS 
containing a 23bp-spacer61. This ensures that each V segment can only be joined to a D segment, or in the LC 
(a) loci to a J segment. The RAG recombinase is only expressed in developing lymphocytes and induces a 
double-strand break in the DNA, which is then re-sealed by non-homologous end joining (NHEJ) while looping 
out the RSSs and redundant gene segments60,62,63. The formation of the so-called coding joint is prone to 
nucleotide insertions or deletions, further increasing the sequence variability of the rearranged V region 
CDR3s. Occasionally, the DNA is nicked in the region between gene segments rather than at the precise end. 
In this case, single-stranded DNA overhangs can occur, are filled with new nucleotides, the so-called 
palindromic ‘P nucleotides’, by the DNA repair machinery. Alternatively, the DNA can be nicked resulting in 
blunt ends, in which case non-templated ‘N nucleotides’ can be added randomly by the enzyme terminal 
dideoxy transferase (TdT) before re-ligation64. This insertion of N nucleotides can result in ultra-long CDR3 
loops, which usually occurs only in the HC, as the TdT gene is only expressed at earlier stages of B cell 
development/Ig gene rearrangement.  
The final dimension to the generation of diversity is achieved by the pairing of HC (b) and LC (a) chains in 
order to create a functional antibody (TCR). As lymphocyte precursors can undergo several rounds of cell 
division before LC (a) rearrangement, each HC (b) can be clonally paired with different LCs (a chains)55,59. 
Generally, the affinity of naïve/new B cell antibody molecules created by VDJ recombination is relatively low. 
However, after initial antigen encounter, the rearranged Ig loci are further diversified by the enzyme-driven 
introduction of mutations into the rearranged variable domains in a process termed somatic 
hypermutation65,66. In the event of beneficial affinity-improving mutations, the resulting B cells will undergo 
clonal expansion55,59. This iterative ‘affinity maturation’ process of continuous mutation and selection drives 
the generation of antibodies with affinity constants (KDs) typically in the picomolar to low nanomolar range. 
The mutation process is primarily driven by activation-induced cytidine deamidase (AID), an enzyme that is 
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exclusively expressed in germinal center B cells67-69. In actively transcribed regions, such as the Ig loci, the 
DNA is temporarily unwound and opened, allowing AID to deamidate cytosine residues, thereby converting 
them to uracil70. The resulting lesion is subsequently repaired by the mismatch repair and the base-excision 
repair pathways, using error-prone DNA polymerases71. These mutagenic processes do not occur at the TCR 
loci and their affinities are determined solely by V(D)J recombination. 
Additionally, AID initiates so-called class or isotype ‘switching’ by rearranging the genes in the CH locus69,72,73. 
The CH locus contains a series of different C regions, which correspond to the different antibody isotypes and 
which are fused to the VDJ segment by mRNA splicing. Naïve B cells initially express the HC isotypes µ or 
d and thus express IgM or IgD immunoglobulins as cell surface receptors. Each of the C genes is preceded by 
a repetitive intronic switch region, which lead to RNA polymerase stalling, enabling AID and other enzymes 
to attack the DNA. The resulting double-strand break is repaired by non-homologous recombination, excising 
intervening sequences72. The choice of isotype for class switching is primarily determined by the cytokine 
milieu, with different cytokines enhancing the transcription of different C isotypes74,75. Class switching to IgG 
isotypes yields the principle, secreted form of Ig present in peripheral blood. 1.1.8 Antibody	engineering	and	phage	display	
Their ability to recognize virtually any given target make antibodies an extremely valuable tool for numerous 
therapeutic and diagnostic applications. Moreover, since the structure and function of the different domains 
of the antibody are well characterized, they can be engineered to generate customized antibodies with the 
desired properties. Another key feature of the antibody molecule is its outstanding diversity, with the naïve 
antibody repertoire comprising at least 1011-1012 unique antibody clones76-78. Many efforts have thus focused 
on controlling and directing the output of this vast immunological repertoire, predominantly with the aim of 
identifying an antibody specific for a given antigen. In principle, this can be achieved via two different 
strategies: (i) the immunization of host animals, and (ii) the generation and in vitro selection of combinatorial 
antibody libraries79,80.  
Depending on the desired outcome, native combinatorial immune libraries can either be constructed from 
the immune repertoires of pre-exposed (or diseased) donors, or of non-immunized healthy individuals79,81-83. 
Harvested variable domain repertoires may derive from all or selected isotypes, whether naïve (IgM/D) or 
affinity matured/class-switched (IgG/A/E). In addition, synthetic and semi-synthetic libraries can be created 
by rational and controlled gene synthesis technologies, allowing a precise choice of V domain frameworks 
and CDR length/diversity. While antigen biased, or immune libraries may prove useful for the rapid isolation 
of high-affinity binders to the immunogen, these need to be regenerated for each antigen target of choice. 
Highly diverse naive (or ‘one pot’) libraries, on the other hand, can, in principle harbor binders to a broad 
diversity of different antigens and are powerful reusable tools for the in vitro isolation of fully human 
antibodies. Such naïve libraries are built by isolating mRNA from bulk peripherally circulating CD19+ B cells, 
and amplifying collectively the VH and VL regions  by polymerase chain reaction (PCR)84. These VH and VL 
chains are then randomly combined, often in scFv format, to generate large renewable libraries, typically 
exceeding 1x1010 distinct entities. Although well validated for antibody discovery applications, a concern of 
such approaches is the loss of the original B cell clone VH/VL Fv domain pairing. In B cells, the heavy and light 
chains of an antibody have undergone several rounds of selection and editing in order to eliminate 
combinations that bind to self-molecules or that are structurally unstable85. However, as Fv formation 
through VH/VL pairing is highly degenerate, artificial combinatorial libraries create many novel variants 
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capable of breaking such native immune tolerance, which allows the isolation of fully human antibodies that 
recognize therapeutically important human target antigens86. 
 
 
 
The underlying principle of binder selection from a diverse antibody library is the linkage of phenotype and 
genotype. Each member of the library must be packaged in a way that allows its phenotypic (expressed) 
selection while retaining the encoding genetic information. The most widely used strategy to achieve this 
uses filamentous M13 bacteriophage as the packaging unit. Filamentous phage combines the robust display 
of antibody variants on individual phage particles with efficient packaging of the corresponding genetic 
information, and highly amplifiable replication in bacterial host cells87,88 (Fig. 1.5). Phage display libraries 
usually utilize Fab or scFv fragments (see Fig 1.4 and 1.5), as these can be adequately expressed and folded 
in prokaryotic host cells. The latter scFv fragments comprise the VH and VL domain joined by a suitable linker 
and are produced from a monocistronic vector, typically a so-called phagemid, which contains a phage origin 
of replication. Fab vectors differ in that a bicistronic vector is required for the separate expression of VHCH 
and VLCL chains, which then assemble into the Fab. The entire combinatorial library repertoire of VH and VL 
domains is sampled in a phagemid vector system89,90, which permits  the fusion of the scFv or Fab (via one 
chain) to a structural capsid protein of the bacteriophage, usually the major coat protein pVIII or the minor 
coat protein pIII91,92. 
Figure 1.5. Antibody Phage Display. 
Schematic overview of the phage display methodology as it was used in this thesis.  
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The helical pIII protein contains 406 residues and accumulates in the periplasm of the prokaryotic host 
cell93,94. After assembly of the phage particles, an average of four pIII copies are located at the tip of the 
phage. The N-terminus of pIII bind to the F-pili of E.coli and is thus indispensable for the infectivity of the 
phage95. Phages with scFv/Fab domains fused to each of their pIII proteins would therefore not be able to 
replicate. To solve this problem, a helper phage system is used where the helper phage contains the genetic 
information for native pIII, so that ultimately the assembled phages retain some native pIII for infectivity and 
display a single antibody-linked pIII molecule (on average)89. 
The resulting phage population can then be screened for binding to an immobilized antigen in a process 
referred to as ‘panning’ or ‘selection’ (Fig. 1.5). In this process, phages are incubated with immobilized 
antigen in several consecutive selection rounds, and only antigen-binding phages are retained and replicated. 
At the end of this process, antibodies expressed by single clones are screened for antigen binding, typically 
by enzyme-linked immunosorbent assay (ELISA) and sequenced, as further detailed throughout chapter 2.  
As an alternative to phage, many other display technologies have been developed, such as yeast display, 
ribosome display and mammalian display96-98. All of these technologies have their own unique advantages, 
but phage display remains the most versatile and most widely used method for selecting antibodies from in 
vitro combinatorial libraries. Importantly, display technologies have led to the development of a number of 
therapeutic antibodies. Among them, the anti-TNF-a antibody adalimumab (Humira) is the first fully human 
phage display-derived antibody to be approved for clinical use, and it is also the best-selling drug (by revenue) 
world-wide99. 
Besides their use as antagonists or agonists of therapeutically or otherwise relevant targets, antibodies can 
be engineered to deliver enhanced or novel effector functionality. For instance, antibodies can deliver toxic 
‘payloads’ to cancerous lesions100, or their unique antigen-binding properties can be employed to redirect T 
cell effector functions for the treatment of cancer, as will be discussed in the next section. 
 
 1.2 Cancer	Immunotherapy	1.2.1 Anti-tumor	immunity	
Cancer remains one of the leading causes of death worldwide and the second-leading cause of death in 
Switzerland, with an incidence of 120.7 cases per 100.000 inhabitants in 2018101. The underlying principle of 
the disease is the progressive transformation of normal cells into malignant cells, driven by a series of genetic 
and epigenetic alterations. Despite being an extremely heterogeneous disease, six original hallmarks have 
been defined that are common to most if not all human cancers: (i) self-sufficient proliferation, (ii) 
insensitivity to growth suppressors, (iii) evasion of apoptosis, (iv) replicative immortality, (v) sustained 
angiogenesis, and (vi) invasion and metastasis102. These common traits of cancer cells have later been 
extended to include (vii) reprogramming of cellular metabolism, and (viii) immune evasion103. Tremendous 
effort has been undertaken to correct or counterbalance any of these hallmark traits. In light of the extreme 
potency of the immune system and especially T cells to detect and eliminate aberrant cells, this section will 
focus on the concept of immune evasion and on strategies aiming to boost anti-tumor immunity. 
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Under physiological conditions, cells and tissues are subjected to constant immune surveillance and both the 
innate and the adaptive immune system contribute to the eradication of abnormal cells104. The accumulation 
of mutations by tumor cells leads to the expression of tumor antigens, which, if intracellular, can be 
processed and presented on the surface of MHC class I molecules and recognized by T cells as ‘foreign’. 
Additional antigens may be considered as tumor ‘associated’ if their expression levels or regulation deviate 
markedly from those same antigens found in healthy cells, leading to a differential cell presentation profile. 
Tumor antigens can thus be loosely classified into: (i) cell type-specific differentiation markers, (ii) tumor 
associated antigens such as cancer-testis antigens or onco-viral proteins, and  (iii) neo-antigens arising from 
mutated endogenous proteins which have been shown to lead to spontaneous T cell responses in patients105. 
Non-proteinaceous tumor antigen candidates such as aberrant glycosyl or glycolipid (or related) core 
structures on tumor cell glycoproteins or membranes also represent an additional class of tumor ‘signature’ 
molecules106-108.  
The mounting of an effective anti-tumor immune response, a process that has been referred to as the Cancer-
Immunity Cycle, requires a series of discrete cellular events109,110. Firstly, dendritic cells (DCs) must capture, 
process and present tumor antigens. At this stage, in order to promote immunity rather than tolerance to 
tumor antigens, DCs have to receive additional activation/maturation signals, such as proinflammatory 
cytokines111. Next, DCs have to process the captured antigens and present them on MHC class II molecules, 
or, via cross-presentation, on MHC class I11,112. These antigen-loaded DCs then must migrate to secondary 
lymphoid organs and initiate effector T cell responses by presenting tumor antigens along with adequate co-
stimulatory signals. Importantly, DCs lacking an immunogenic maturation signal will predominately induce 
tolerance by promoting the differentiation of regulatory T cells (Treg)113. Activated effector T cells 
subsequently need to migrate to the tumor tissue and infiltrate the tumor bed, where they must recognize 
and kill their cancer targets. Ultimately, the lysis of tumor cells releases additional tumor antigens, thereby 
further driving the cancer immunity cycle109,110. 
However, despite their presence in many solid tumors, such tumor infiltrating lymphocytes (TILs) are often 
dysfunctional and incapable of tumor eradication, in part because the tumors adapt by eliminating cells 
expressing T cell targets, a process that is referred to as ‘immune editing’114. Furthermore, the tumor 
microenvironment (TME) is often highly immunosuppressive, with several mechanisms contributing actively 
to prevent an effective anti-tumor T cell response. One common mechanism of immune evasion is the 
downregulation of MHC class I molecules by tumor cells to avoid recognition by T cells115. Alternatively, tumor 
cells may express inhibitory cell surface molecules, such as PD-L1 or PD-L2, which bind to PD-1 on the surface 
of activated T cells and promote T cell exhaustion or anergy116. Other mechanisms of immune evasion involve 
the secretion of immunosuppressive metabolic enzymes, such as indoleamine 2,3-dioxygenase (IDO) and 
arginase, which inhibit T cell function via amino acid deprivation117,118.  
Additionally, tumors often trigger the local accumulation of Treg cells and other suppressive immune cells, 
such as myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAFs), which release 
inhibitory factors such as transforming growth factor b (TGF-b)119,120. The tumor microenvironment also plays 
a crucial role in promoting local immunosuppression. For instance, endothelial cells in the tumor bed may 
downregulate adhesion molecules to prevent tumor homing by T cells, a mechanism that is, in part, mediated 
by vascular endothelial growth factor (VEGF)121. 
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1.2.2 Cancer	immunotherapy	
These inhibitory mechanisms, however, also present opportunities for therapeutic intervention and so a 
number of strategies have been developed to harness the potential of T cells to recognize and eliminate 
cancer cells, including, for example, therapeutic cancer vaccines, which aim to boost the cancer-immunity 
cycle110. Early vaccination attempts have mainly focused on shared tumor peptide antigens, such as the 
melanocyte differentiation antigen gp-100122 or the cancer-testis antigen MAGE-A3123. These trials have often 
shown only limited efficacy, in part due to a poor understanding of appropriate peptide delivery and limited 
DC activation/maturation109. With technological breakthroughs enabling the wide use of next-generation 
sequencing (NGS) to comprehensively map the ‘mutanome’, that is the entirety of somatic mutations in a 
given tumor sample, new and personalized vaccination strategies are currently being explored. Pre-clinical 
studies revealed that a substantial fraction of predicted neo-epitopes were immunogenic and could be 
employed successfully in synthetic RNA- or long peptide vaccines, eliciting productive CD4 and CD8 T cell 
responses124,125. Based on these results, a number of first-in-human clinical trials have attempted to 
manufacture personalized tumor vaccines on the basis of each melanoma patient’s individual mutational 
profile and predicted neo-epitope landscape126,127. Promising results, including indications of immunogenicity 
of the predicted neo-epitopes, and first clinical responses have now encouraged further investigations of 
personalized vaccines, especially in combination with other immunotherapeutic strategies, such as 
checkpoint blockade. 
Under physiological conditions, co-inhibitory signals, or immune checkpoints, play a key role in preventing 
autoimmunity and excessive tissue damage during T cell responses. Similarly, tumor cells commonly exploit 
and hijack these inhibitory ligands and receptors as a mechanism of immune resistance128,129. They therefore 
present an ideal opportunity for therapeutic intervention, and antagonistic antibodies blocking two of the 
key checkpoints, CTLA-4 and PD1, are now approved and marketed drugs. The CTLA-4 checkpoint is expressed 
early on activated T cells and acts as an antagonist of the co-stimulatory receptor CD28, both by 
outcompeting CD28 in binding its ligands B7.1 (CD80) and B7.2 (CD86) and by transmitting inhibitory 
signals130,131. Consequently, the amplitude of a T cell response is dampened and excessive T cell activation 
prevented132. This led to the rationale that blockade  of CTLA-4 action could boost endogenous anti-tumor 
immune responses133. In fact, ipilimumab, an antagonistic anti-CTLA-4 antibody, was the first therapeutic 
agent to mediate a survival benefit for patients with metastatic melanoma, and was approved by the US Food 
and Drug Administration (FDA) in 2010134. However, due to the unleashing of T cell effector functions, CTLA-
4 blockade is often accompanied by severe immune-mediated toxicities135. While CTLA-4 acts within the 
timeframe of T cell priming, other checkpoints regulate inflammatory responses in peripheral tissues. Key 
among these is PD1, which is upregulated by activated T cells and interacts with ligands such as PDL1 (also 
known as B7-H1), which in turn are induced in peripheral tissues by inflammatory cytokines, such as IFN-g136. 
As a consequence, T cell activity and tissue damage are controlled and autoimmunity is prevented137,138. The 
same mechanism comes into play in the tumor microenvironment, where tumor and stroma cells commonly 
express PDL1 to suppress T cell effector functions128. Like CTLA4, PD1 is also highly expressed on Treg cells, 
but here enhances their proliferation, which further contributes to immunosuppression139. In addition, 
chronic antigen exposure has been shown to induce persistent PD1 expression, rendering antigen-specific T 
cells exhausted or anergic140. Therefore, there is a strong rationale for therapeutic targeting of the PD1-PDL1 
axis, and eight blocking antibodies have been approved to date, targeting several tumor indications.  
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Another strategy to enhance anti-tumor immunity is the adoptive transfer of large numbers of anti-tumor T 
cells (adoptive cell therapy; ACT). It is widely accepted that TILs can recognize tumor antigens, especially neo-
antigens, and mediate productive immune responses, although those are frequently suppressed. Therefore, 
protocols have been developed to rapidly expand TILs from resected tumor material (up to 1011) and re-
infuse them into the patient in large numbers141. Additionally, the expanded lymphocytes can be selected for 
tumor recognition and effector functions; as a result of the expansion protocol, they become activated in 
vitro. Early studies have demonstrated that ACT using autologous TILs could induce tumor regression in 
patients with metastatic melanoma, but the infused cells were short-lived and did not persist in the 
patients142. This obstacle was in part overcome by the introduction of preparative lymphodepletion prior to 
ACT143. Since then, a number of studies have shown solid objective response rates of around 50 % to ACT 
with autologous TILs in melanoma patients141,143-145. Strikingly, a subset of patients displayed durable and 
long-term remission145. However, although TILs can also be expanded from other tumor types, only 
melanoma TILs show robust and consistent anti-tumor reactivity. A possible explanation for this 
phenomenon is the high rate of non-synonymous mutations in melanoma compared to other cancer types146. 
In fact, several studies have identified cancer-specific mutations in melanoma samples that were recognized 
by autologous TILs inducing complete cancer regression147,148. Current efforts therefore focus on the 
identification of neo-epitopes and neo-epitope-reactive TILs147,148. 
Given the often limited endogenous immune response to cancer (neo)antigens and the disappointing 
outcome of TIL-transfer in most cancer types, genetic engineering of autologous T cells represents an 
attractive alternative to elicit anti-tumor immunity.  1.2.3 T	cell	engineering	and	chimeric	antigen	receptors	
In order to redirect antigen specificity, T cells can be equipped with transgenic TCRs or with chimeric antigen 
receptors (CARs), synthetic immune receptors combining an extracellular recognition domain with 
intracellular signaling domains (Fig. 1.6). 
TCRs and CARs typically recognize fundamentally different antigens. TCRs recognize peptides derived from 
the intracellular proteome, which are presented on MHC molecules. A key requirement for T cell therapy 
with a transgenic TCR is therefore the expression of cognate antigenic peptides by tumor cells and their 
presentation on the tumor cell surface in the correct (cognate) MHC class I context recognized by the TCR. 
Once these requirements are met, TCRs are intrinsically highly sensitive and therefore represent attractive 
tools for redirecting T cell specificity. The first transgenic TCR tested in the clinic was directed against an HLA-
A2 restricted peptide derived from the melanocyte differentiation marker gp100149. Initial results were rather 
modest and so attempts have been undertaken to increase the affinity of the TCR for cancer targets, which 
is typically lower than the affinity of TCRs recognizing viral targets (low micromolar vs. nanomolar range)150. 
Trials using T cells equipped with affinity-engineered TCRs have indeed improved the clinical response rate, 
but have also led to substantial on-target off-tumor toxicities (including side effects such as vitiligo, due to 
the elimination of normal gp100-containing melanocytes)151. The fatal neuro- and cardiotoxicities observed 
with TCR-based therapies directed against the cancer-testis antigen MAGE-A3 further revealed the risks 
inherent with engineered transgenic TCRs152,153. Whilst native TCRs undergo stringent selection via thymic 
processes, engineered molecules may acquire undesirable activation threshold affinities for closely related 
native peptide antigens on healthy tissues, resulting in severe toxicities. This is exacerbated by the TCR having 
‘built in’ cross-reactive potential to many peptidic antigens154,152,155. Leveraging engineered TCRs for 
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therapeutic ACT therefore presents significant safety challenges, although an affinity-enhanced TCR 
recognizing the cancer-testis antigen NY-ESO-1 has recently shown clinical efficacy and is being evaluated in 
a late-stage clinical trial156. Other current efforts aim at developing neo-vasculature-specific TCR therapies 
with native (thymically ‘approved’) TCRs that would be expected to have higher natural affinities and more 
potent anti-tumor activities157,158. Conceptual disadvantages of TCR-based therapies are the restriction of any 
given TCR therapeutic to patients possessing the requisite cognate MHC haplotype. 
In contrast to TCRs, CARs recognize unprocessed cell surface antigens which thus enables MHC-independent 
tumor cell targeting159. Early CARs combined an antigen-binding domain, usually an scFv, with an intracellular 
signaling domain derived from the CD3z chain (Fig. 1.6). 
 
Figure 1.6. T cell engineering with transgenic TCRs vs. the various CAR generations. 
T cells can be equipped with transgenic T cell receptors (TCRs, left), or chimeric antigen receptors (CARs, right) to redirect antigen 
specificity. CAR constructs link an extracellular antigen recognition domain, usually a single-chain variable fragment (scFv), with 
intracellular signaling domains derived from the TCR/CD3 complex. 1st-generation CAR designs only contain a CD3z signaling domain, 
while 2nd- and 3rd-generation CARs encompass one or more additional co-stimulatory domains in addition to CD3z. VH, variable 
heavy; VL, variable light. Adapted from June, C. H. Science 359, 1361-1365 (2018)160. 
 
 
Since clinical trials with these first-generation CARs produced disappointing results, with rapid 
clearance/inactivation of the adoptively transferred cells 161,162, second-generation CARs were engineered to 
include an additional co-stimulatory domain derived from CD28, 4-1BB or OX40, with the intention of 
promoting the maintenance of T cell effector functions together with durable proliferation and expansion162-
164. Similarly, third-generation CAR designs include two or more consecutive co-stimulatory domains and aim 
to further refine and optimize these desirable properties160. Recently, fourth-generation CAR T cells, termed 
TRUCKs, have been engineered to express both a CAR and to secrete activating mediators, such as pro-
inflammatory cytokines165. A key attraction of the CAR paradigm is the independence from antigen 
presentation on MHC. This circumvents one of the most common mechanisms of immune evasion, namely, 
the downregulation of MHC-associated antigen presentation115, but also necessitates a requirement for 
suitable tumor cell surface bound targets. 
The potential of CAR-T cell therapy is best exemplified for the CD19 antigen, a B cell differentiation marker 
and part of the B cell co-receptor that is restricted to the B cell lineage166. CD19 represents a nearly ideal 
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target with its high expression levels in B cell malignancies and restriction to the B cell lineage, the loss of 
which is tolerable. Clinical trials with second-generation CARs directed against CD19 have shown tremendous 
success in the treatment of B cell leukemia with a majority of patients initially achieving apparent 
remission167-170. In the case of CD19, on-target off-tumor T cell activity is tolerable, since the resulting B cell 
aplasia can be treated with intravenous immunoglobulin170. However, the severe cytokine release syndrome 
(CRS) observed in some patients poses a challenge to the therapeutic administration of CAR-T cells and 
requires careful monitoring and management of immune-related toxicities167,171. Further, cerebral edema has 
been reported as an unexpected neurological complication possibly due to endothelial damage167,172. 
Beyond CD19, CAR-T cells directed against other B cell targets such as B cell maturation antigen (BCMA) or 
CD22 have shown potent anti-tumor activity in early clinical trials173,174. Targeting solid tumors, on the other 
hand, has proven more difficult, partly due to insufficient tissue penetration and a potentially 
immunosuppressive tumor microenvironment175. Early-phase trials involving CARs specific for mesothelin, 
carcinoembryonic antigen (CEA) and GD2 ganglioside have only generated minimal clinical responses160,176. 
Attempts to target ERBB2/HER2 or CEACAM5 have led to severe on-target off-tumor toxicities, highlighting 
another hurdle that is frequently encountered with target antigens being insufficiently restricted to tumor 
cells177,178. Many proposed cell surface markers currently under immunotherapeutic investigation are shared 
antigens that are also often expressed on normal healthy tissues to varying extents. Therefore, strategies to 
enhance tumor selectivity are a priority in the field, and some of them will be discussed in the next section, 
along with other considerations for the engineering of CARs. 1.2.4 Current	challenges	and	structural	considerations	for	CAR-T	cell	engineering	
The CAR constructs currently used in clinical trials have mostly been designed empirically, based on what is 
understood from TCR signaling and T cell activation. Despite their tremendous success in treating patients 
with B cell malignancies, a number of obstacles have thus far prevented the extension of CAR-T cell therapy 
to other tumor types. Some of these obstacles could be tackled by improving the molecular design strategies 
for CAR engineering. 
One of the clinical challenges emerging for CD19 CAR-T cell therapy is the development of resistance. 
Resistance mainly occurs through two distinct mechanisms: (i) downregulation or mutation of CD19, 
analogous to antigenic escape as a common mechanism of immune evasion179, and (ii) failure of the CAR-T 
cells to proliferate and persist in vivo180. Another major challenge for the treatment of solid tumors is the 
discrimination of tumor cells from normal cells, since many of the proposed targets are not exclusively 
expressed in the tumor tissue. In light of the fatal toxicities observed with some T cell-based therapies 
directed against non-exclusive tumor antigens, the choice of target antigen is of paramount importance177. 
Hence, molecules that are expressed during development, but are absent in normal healthy adult tissues, 
such as ROR1 and GD2, represent attractive candidates181,182.  
Another possibility, which can also be applied to prevent resistance, is the implementation of a ‘two-signal’ 
system, which, in analogy to co-stimulation during T cell activation, ensures that the T cell is only activated 
in the appropriate context. To achieve this, a dual-receptor strategy has been proposed, where the primary 
CD3z and the secondary CD28/4-1BB signaling domains are split between two separate CAR constructs 
recognizing two different antigens183-185. However, the signaling of the CD3z-bearing CAR might have to be 
tightly controlled in order to avoid activation in the presence of single-positive cells184. Alternatively, 
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transcriptional circuits based on a synthetic Notch (SynNotch) receptor system have been designed to 
achieve conditional expression of the CAR only in the presence of tumor cells186,187. A different variant of a 
‘two-signal’ system involves an inhibitory signaling receptor to mitigate T cell activation in the presence of 
normal cells188. For instance, an inhibitory secondary CAR has been designed by combining the endodomain 
of PD1 or CTLA4 with a recognition domain directed against PSMA, which inhibited T cell activation in the 
presence of PSMA-expressing cells188. Here, the choice of ligand to deliver the negative signal is a critical 
issue. 
Other tumor antigens are expressed at low density and therefore pose the problem of sensitivity rather than 
selectivity. While CD19 is estimated to be expressed in abundance, with around 10’000 copies per cell, 
alternative targets such as ROR1 are likely expressed two- to five-fold lower189. A study using an anti-CD20 
CAR suggested that ˜200 CD20 molecules per cell were the minimum threshold for lytic activity, whereas 
efficient cytokine production required around ten-fold higher antigen density190. These activation thresholds 
may differ from antigen to antigen, and additionally depend on T cell intrinsic factors, such as the 
involvement of co-receptors and endogenous TCR/CD3 clusters. The clustering of TCRs with multiple ITAM 
domains and co-receptors has evolved to ensure a high level of signal amplification upon physiological TCR 
signaling, which can respond to as few as ~10 target pMHC on the cell surface (e.g. NY-ESO1:HLA-A2)191,192. It 
remains to be seen whether CARs can be engineered to exploit or recapitulate this degree of sensitivity, or 
indeed, whether this is desirable from a targeting specificity perspective. In contrast to natural TCRs, the 
targeting scFvs of CARs often have relatively high affinities. For some targets, e.g. ROR1, it has been shown 
that the potency of CAR-T cells increases with increasing targeting affinity193. On the other hand, other studies 
have described an avidity threshold for both CARs and TCRs, above which T cell effector functions plateau or 
even decrease194,195. These observations are in line with the ‘serial triggering’ model, which suggests 
improved T cell activation upon serial engagement of multiple TCRs by the same peptide:MHC196.  
Another key aspect of T cell activation and cytotoxicity is the formation of an immunological synapse. The 
structure of the TCR – peptide:MHC interaction dictates the distance of T cell and APC, and is estimated to 
be around 15 nm189. This close interaction excludes the bulky membrane-located phosphatases CD45 and 
CD148 from the synapse, which otherwise attenuate T cell signaling197,198. A similarly close interaction may 
be necessary for efficient CAR signaling. The spatial distance between a CAR-T cell and its target is mainly 
influenced be the relative location of the target epitope and by the spacer domain between the scFv and the 
membrane. There are several reports of improved T cell activation when the same epitope is expressed closer 
to the membrane199-201. Moreover, it has been shown that the CAR spacer domain can be tailored for optimal 
CAR signaling depending on the epitope location193,202. 
In summary, the optimal binding properties of a targeting scFv towards a given target antigen cannot (yet) 
be reliably predicted or modelled. Even when a candidate scFv recognizes its target in solution, it may not 
necessarily confer potent T cell activation in the context of a surface-bound CAR. Therefore, the development 
of unbiased screening approaches to directly select scFvs on the basis of their ability to induce T cell activation 
may provide an efficient path for the development of new and improved CARs. Ideally, such screening 
platforms would not only sample large libraries of potential binders, but also include different linker/spacer 
designs to account for steric constraints imposed by the epitope location. Chapters 4 and 5 discuss these 
challenges in further detail, and present a high-throughput approach for the cell-based selection of binders 
with the desired functional properties.  
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1.2.5 Bispecific	antibodies	for	cancer	immunotherapy:	molecular	formats	
Redirecting T cell effector functions via CARs generally requires genetic engineering of autologous T cells for 
each patient. An alternative, yet analogous approach, has been developed using bispecific antibodies (biAbs) 
which simultaneously engage a tumor cell and a T cell, thereby redirecting T cell activity and stimulating a 
polyclonal T cell response203,204. Specifically, antibody-derived ‘engager’ molecules can physically link tumor 
cells via a cell-surface antigen, and T cells, usually via CD3 (Fig. 1.7). By this approach, MHC restriction can be 
bypassed and T cells are activated through TCR/CD3 complexes irrespective of individual TCR specificities. By 
bridging  tumor and T cell, the engager molecule creates an artificial immune synapse and induces the release 
of perforin and granzymes, ultimately leading to target cell lysis205 and tumor regression206. Importantly, T 
cell activation and killing via bispecific engagers can occur in the absence of formal co-stimulation207,208. It has 
been established that dual binding by both engager arms is required for synapse formation and target cell 
lysis209. In this way, bystander cells that do not express the chosen tumor-associated antigen, are spared. 
Furthermore, it has been shown that T cells activated with a bispecific T cell engager (BiTE) are capable of 
serial killing of multiple tumor cells providing the BiTE is present210. Hence, such T cell engaging bispecifics 
represent an attractive class of molecules for therapeutic development, especially given their potential as 
‘off-the-shelf’ soluble drugs. 
 
Figure 1.7. Bispecific T cell engagers redirect T cells to target malignant cells. 
T cell engaging bispecifics simultaneously bind a tumor-associated antigen, here CD19, and CD3 expressed by T cells. This cross-linking 
creates an immune synapse, leading to the secretion of lytic granules and ultimately to tumor cell lysis. A classical tandem BiTE is 
depicted as an exemplary molecule. TCR, T cell receptor; BiTE, bispecific T cell engager. 
 
 
To this end, over 100 different bispecific antibody formats with different structural and functional properties 
have been designed, with more than 20 being commercialized in the context of proprietary technology 
platforms211-213. Conceptually, these formats can be classified into (i) fragment-based; (ii) symmetric IgG-
based; and (iii) asymmetric IgG-based formats212 (Fig 1.8).  
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Figure 1.8. Overview of a selection of bispecific antibody formats. 
Bispecific antibody (biAb) formats can be categorized into fragment-based, asymmetric IgG-based and symmetric IgG-based. 
Exemplary platforms mentioned in the text are #2 bispecific T cell engager (BiTE), #10 rat-mouse hybrid TrioMab, #11 and #12 knobs-
into-holes technology, #23 dual variable domain (DVD)-Ig. Antibody domains are depicted as follows: orange, variable heavy (H) chain 
specificity 1; green, variable H chain specificity 2; blue, variable light (L) chain specificity 1; red, variable L chain specificity 2; grey, H 
chain constant region; white, L chain constant region; light grey , alternative L chain constant region; format #10: dark grey and black, 
rat L chain and immunoglobulin G2b (IgG2b) H chain; and white and light grey, mouse L chain and IgG2a H chain. cH common heavy; 
cL, common light; HLE, half-life extended; scDb, single-chain diabody; scFv, single-chain variable fragment; VHH, heavy chain-only 
variable domain. Figure adapted from Labrijn, A. F. Nat Rev Drug Discov 18, 585–608 (2019)212.  
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Fragment-based formats rely on the simple combination of antigen-binding domains, usually scFvs or Fabs, 
in the absence of a Fc region (Fig. 1.8). The most prominent example for this class of bispecifics are classical 
BiTEs which combine an anti-CD3 scFv with an scFv specific for a tumor-associated antigen, connected via a 
short peptide linker204 (Fig. 1.8). Blinatumomab, an anti-CD19 BiTE, is the first and currently only FDA-
approved T cell engager, demonstrating an impressive complete response rate of 43 % in a phase II/III trial 
for the treatment of relapsed/ refractory B cell acute lymphoblastic leukemia (ALL)214,215. BiTEs and other 
fragment-based bispecifics are often small (˜55 kDa for tandem scFv-based BiTEs) and lack an Fc domain, 
which, due to the lack of neonatal Fc receptor (FcRn)-mediated recycling, substantially decreases their 
plasma half-life203,216. Moreover, due to their deviation from the natural antibody structure, fragment-based 
bispecifics can have issues with expression yields, stability and aggregation, requiring challenges for 
downstream processing and formulation during manufacturing217. On the other hand, the modular design of 
such molecules is highly attractive as it permits the incorporation of additional domains for increased valency 
or additional functionality218.  
Bispecific formats retaining the native IgG architecture (biAbs) benefit from the unique stability and long half-
life of antibody molecules, but generating bispecific IgG comes with another challenge: the chain-association 
(pairing) issue. Theoretically, co-expression of two different heavy and light chains could yield 10 different 
molecules, of which only one would correspond to the desired HC/LC combination219. A number of strategies 
have been developed in order to circumvent this issue (Fig. 1.8). For instance, HC constant domains have 
been engineered for preferential heterodimerization220-222. Here, the “knobs-into-holes” technology has been 
pioneering, generating complementary structures between the two heterodimeric HCs, which were 
subsequently paired with common light chains222,223.  
Similarly, strategies have been designed to ensure correct heavy and light chain pairing224-226. An early 
solution to this problem was the combination of two HC/LC pairs with different species origin, i.e. rat and 
mouse225. More recently, orthogonal Fab interfaces have been designed to favor correct pairing224. 
Furthermore, purification strategies have been adapted to selectively enrich for the intended asymmetric 
molecule, for instance by modulating protein A binding of the two HCs225. Alternatively, the two specificities 
can be assembled on the protein level, for example by controlled Fab-arm exchange227,228. The resulting 
asymmetric formats closely resemble natural antibodies and are therefore usually restricted to functionally 
monovalent (1 + 1) targeting.  
Alternative design strategies bypass the chain-association issue by integrating both specificities in one HC/LC 
pair, i.e. by appending scFv or Fab fragments to a full antibody structure229 (Fig. 1.8). The resulting symmetric 
molecules still resemble natural IgG molecules, but differ in size and molecular architecture, which can lead 
to stability or solubility issues212. Formats with appended domains, such as the DVD-Ig, may nominally 
comprise bivalent antigen-binding domains, but due to the close proximity of the domains, it is not always 
apparent whether such designs translate into functional bivalency212,229.  
This plethora of bispecific antibody formats is reflected in the global clinical development arena, which 
currently encompasses over 85 bispecific antibody molecules, half of which are T cell redirecting antibodies 
for cancer therapy212. 
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1.2.6 Design	parameters	impacting	on	the	potency	of	soluble	T	cell	engagers	
The efficiency of simultaneous antigen engagement is critically impacted by a number of design parameters, 
such as binding strength (affinity/avidity), epitope location and format architecture. For instance, small 
fragment-based formats, such as BiTEs, have been shown to mediate more efficient linking of tumor and 
target cells, which is reflected by the ability of blinatumomab to induce cytotoxicity at much lower effector-
to-target ratios than a full-length biAb230. On a different note, Fc-deficient molecules such as blinatumomab 
are rapidly cleared from the circulation and therefore have to be administered by continuous infusion216. 
Despite increasing half-life, a native Fc part can also mediate unwanted binding to Fcg receptors on healthy 
cells. In the case of the CD3 x EpCAM bispecific catumaxomab, this behavior has led to severe T cell-mediated 
hepatotoxicity231. Moreover, the presence of a functional native Fc part seems to dampen therapeutic activity 
of CD3-engaging biAbs in vivo232. As a consequence, all CD3-targeting biAbs that are currently under clinical 
evaluation have engineered Fc domains, ideally abrogating FcgR and C1q interaction, but retaining FcRn 
binding233,234. Independent of the presence of an Fc domain, format architecture and relative paratope 
orientation have a key impact on simultaneous target binding and therapeutic activity229,235. 
Similarly, the choice of antigen-binding domain for both T cell targeting and tumor recognition is of 
paramount importance for the potency of T cell engager molecules. Most published T cell engagers utilize 
CD3e-binding units derived from the same murine antibody clones, often  a variant of OKT3236. Depending on 
the technology platform, this clone has usually been humanized, affinity matured and/or engineered to 
reduce immunogenicity212. While T cell engager variants with high CD3 affinity can induce more potent 
cytotoxicity in vitro, such molecules show unfavorable biodistribution and pharmacokinetics, since they can 
accumulate in T cell-dense tissues237,238. Generally, monovalent CD3-binding is favored over bivalent CD3 
engagement in order to balance tumor-specific T cell activation and tumor-independent ‘tonic’ activation 
mediated by CD3 crosslinking212,237,238. Besides T cell retargeting, natural killer (NK) cells are emerging as anti-
tumor effector cells that can be recruited by a bispecific activating mediator, usually via CD16A239,240.  
Efficient recognition of the tumor cell is critical for specificity and therapeutic activity and largely depends on 
the characteristics of the binding antibody domain and the molecular properties of the antigen itself. For 
some targets, such as CEA, CD33 and HER2, effective T cell engagement seems to depend on antigen 
expression levels241-243. Other targets, such as prostate-specific membrane antigen (PSMA) show no such 
obvious correlation244. Further complexity is provided by the affinity and binding kinetics of the tumor-
targeting entity. In this context, increasing the avidity by bivalent tumor binding has been shown to enhance 
potency and selectivity of T cell engagers242,245. The latter is especially important when the tumor-associated 
antigen is not truly tumor restricted, but expressed at lower levels on healthy tissues. A good example for 
such a case is HER2. Here, it has been suggested that utilizing a bivalent biAb with lower monovalent affinity 
for HER2 specifically redirects T cells to HER2-overexpressing tumor cells while sparing normal cells 
expressing HER2 at low density245. Besides expression levels, other properties of the antigen can impact on 
biAb activity, such as its mobility in the membrane246 and the size of its extracellular domain247. Targeting 
either a smaller antigen or a more membrane-proximal epitope has proven beneficial for efficient T cell 
engagement247,248. Presumably, bringing both cell types into close proximity allows optimal synapse 
formation and thus potent cytotoxic activity.  
In summary, while various molecular formats have been developed for soluble T cell engagers, defined rules 
for the design of effective molecules are lacking. At this point, targeting domains and molecular formats still 
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have to be validated empirically in order to identify an effective combination of tumor binding and T cell 
retargeting domains.  1.2.7 T	cell	engaging	bispecifics	in	clinical	development	
Following the encouraging results achieved with blinatumomab, a number of T cell engagers are currently 
being evaluated in the clinic, with the majority of molecules aiming to treat hematological malignancies. Most 
of these molecules are directed against a conserved set of well-validated targets, including CD19, CD29, 
CD33, CD38, CD123 and BCMA212. The bispecifics currently in the pipeline are however not redundant, since 
they utilize different molecular formats, which are likely to reveal differential safety and efficacy profiles.  
Clinical experience with blinatumomab has revealed a number of adverse events with T cell engagers directed 
against B cells. As expected, B cell aplasia accompanies a successful anti-leukemia response and some cases 
of acute cytokine release syndrome have been reported211. Although potentially life-threatening, this 
condition can often be managed with immune-suppressing interventions249. Further, neurotoxicity ranging 
from dizziness to convulsions and delirium has been observed in 10-20 % of the patients treated with 
blinatumomab203. In these cases, the very short half-life of this molecule has proven advantageous in 
mitigating severe side effects.  
Besides hematological malignancies, a number of biAbs directed against solid tumors are currently under 
clinical evaluation212. Again, the majority of these molecules target well-established antigens, such as HER2, 
epidermal growth factor receptor (EGFR) vIII, PSMA and epithelial cell adhesion molecule (EpCAM). However, 
the often immunosuppressive TME, irregular tumor vasculature and insufficient tumor penetration represent 
major hurdles for sufficient T cell recruitment and engagement. Another complication is the presence of low-
levels of these antigens in healthy tissues. On-target, off-tumor toxicities are therefore a major concern, 
especially since pre-clinical safety studies in rodents are often complicated by altered or absent cross-
reactivity of the lead candidate towards the equivalent murine antigens and/or effector T cells.   
Based on knowledge gained with blinatumomab and other clinical-stage bispecifics, multiple phase I and II 
trials are currently underway exploring combinations of T cell engaging bispecifics with other treatments, 
such as immune checkpoint inhibitors212. Alternatively, formats containing three or more specificities are 
being explored. For instance, trispecific NK cell engagers (TriKEs) combining CD133 x CD16 with an IL-15 cross-
linker are being tested in a phase I trial250. Another strategy aims to simultaneously engage CD3 and CD28 on 
T cells in addition to a tumor antigen in order to increase the potency of anti-tumor cytotoxicity251. The 
pending results from the host of ongoing clinical trials with T cell engaging bispecifics will undoubtedly 
contribute to our understanding of this class of molecules and their therapeutic potential. Finally, it is 
anticipated that conceptual and technical advances will continue to improve tumor targeting with bispecific 
antibody-based engager molecules in order to generate a wider therapeutic impact. 
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1.3 Tumor	endothelial	marker	1	and	the	tumor	microenvironment	1.3.1 The	tumor	microenvironment	
Solid tumors are complex organ-like structures, with several cell types contributing to the formation of a 
favorable tumor microenvironment (TME). In addition to cancer cells, fibroblasts and the extracellular matrix 
(ECM) they produce, blood vessels, lymphocytes and myeloid cells all contribute to the tumor tissue252. A 
critical step in the formation of tumors is the induction of neo-angiogenesis, that is, the sprouting of new 
blood vessels, to ensure a steady supply of nutrients and oxygen253. In contrast to physiological neo-
angiogenesis, the resulting tumor vasculature appears disorganized, with tortuous, dilated and collapsed 
capillaries254. Vascular immaturity and incomplete pericyte coverage and function leads to vessel instability 
and increased permeability255,256. Furthermore, the uncontrolled growth of cancer cells within a tissue can 
compress and collapse tumor vessels, causing inadequate perfusion257. Together, these vascular 
abnormalities lead to aberrant permeability and hypoxia in parts of the tumor tissue, which favors the 
selection of more aggressive tumor cells and impedes the anti-tumor capacity of immune cells254,257. 
Moreover, observations of tumor-specific immune cells co-existing with proliferating tumor cells has shaped 
the concept of immune privilege, a situation where the TME actively suppresses T cell activity. In fact, in many 
cancer types, (cytotoxic) T cells are excluded from the direct vicinity of cancer cells258, preventing any anti-
tumor cytotoxicity and strongly limiting the potential of immunotherapeutic intervention. Key cell types 
directing the exclusion of T cells are cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells 
(MDSCs) and tumor-associated macrophages (TAMs)259-261. For instance, reactive nitrogen species produced 
by MDSCs can post-translationally modify chemokines like CCL2, which in their modified form still attract 
monocytes, but not T cells262. In addition, the tumor vasculature also contributes by preventing T cell 
extravasation into the TME, while allowing other immune cells to migrate175. Mechanistic insights into this 
phenomenon came from studies comparing immune-infiltrated vs. immune-excluded tumors. Motz et al. 
described that immune-excluded tumors express the apoptosis signal FasL, leading to apoptosis of CD8+ T 
cells, but not Treg cells, which up-regulate the apoptosis inhibitor c-FLIP, leading to the selective exclusion of 
CD8 T cells from the TME263. 
There are many more mechanisms of immunosuppression by the TME. However, the examples above 
illustrate that the tumor stroma is a specialized tissue adapted to support the uncontrolled proliferation of 
cancer cells. Further, tumor neo-vasculature is structurally and functionally different from normal 
vasculature. Given their crucial role in supporting tumorigenesis, both the tumor stroma and the neo-
vasculature represent attractive targets for diagnosis and therapeutic intervention. Thus, many efforts have 
focused on identifying specific markers of tumor stroma and vasculature. 1.3.2 Tumor	endothelial	marker	1	(TEM1/	Endosialin/	CD248):	expression	pattern		
TEM1, also known as endosialin or CD248, is a transmembrane glycoprotein which was first described as a 
surface marker of human embryonic fibroblasts and tumor endothelium264,265. Later on, high-resolution 
analysis of a range of human cancers revealed that TEM1 is not expressed by endothelial cells, but rather by 
pericytes, myofibroblasts and smooth muscle cells within the tumor vasculature266-271. TEM1 is upregulated 
in various human cancer types including colorectal cancer265,272, breast cancer273,274 and malignant brain 
tumors, such as glioblastoma270,275. Unlike in carcinomas, where TEM1 expression is restricted to the 
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perivascular area, human sarcomas express TEM1 in both malignant and stromal cells. Indeed, 81 % of clinical 
sarcoma specimens were shown to be positive for TEM1, with all sarcoma subtypes being represented271,276. 
Today, TEM1/endosialin is considered to be restricted to activated cells of the mesenchymal lineage, both 
during embryonic development and malignant growth268,277,271,275. For instance, in lymphoid tissues, pericytes 
and fibroblasts were found to express TEM1 during tissue development, but not in the adult, except for 
situations of intense tissue remodeling278. Moreover, TEM1 expression was detected during wound healing, 
where TEM1+ stromal cells were shown to promote angiogenesis and re-epithelialization279. In healthy adults, 
TEM1 expression is largely undetectable except for tissues with active angiogenesis, i.e. regenerating wound 
tissue, the corpus luteum and the stromal compartment of the endometrium265,280,281. Moreover, one study 
reported TEM1 expression on a subset of human, but not murine naïve CD8+ T cells, where it had an anti-
proliferative effect282. Finally, TEM1 was detected on human mesenchymal stem cells in the bone marrow283. 
Besides cancer, TEM1 may play a role in fibrotic diseases, such as rheumatoid arthritis284, chronic kidney 
disease285, liver fibrosis286 and idiopathic pulmonary fibrosis287. In these conditions, TEM1 seems to contribute 
to pathogenic processes, since TEM1 knock-out (KO) mice developed less severe fibrotic phenotypes, for 
instance reduced synovial hyperplasia and inflammation in models of rheumatoid arthritis284. This unique 
expression pattern makes TEM1 an oncofetal protein with potential both as a biomarker and as a therapeutic 
target.  1.3.3 Structure	and	function	of	TEM1		
Structurally, TEM1 is a single-pass transmembrane protein of 757 amino acids with a predicted molecular 
mass of 80.9 kDa267,288. The large extracellular region consists of five separate domains, a c-type lectin domain 
followed by a sushi-like domain and three EGF repeats, and is separated from the membrane by a heavily O-
glycosylated sialomucin stalk288 (Fig. 1.9). The extensive post-translational glycosylation substantially 
increases the molecular weight from the predicted 80.9 kDa for the theoretical polypeptide to 165 kDa in the 
mature form264. Intracellularly, the short cytoplasmic domain contains a putative PDZ binding domain, which 
can act as adaptor molecule for the assembly of signaling complexes284,289. The N-terminal 360 residues bear 
sequence homology with thrombomodulin/CD141 (39 %) and the complement receptor C1qRp (33 %)288, 
which may give some indications regarding the biological function of TEM1, which to date has not been fully 
elucidated. 
 
Figure 1.9. Domain structure of human TEM1/endosialin/CD248. 
The extracellular domain (ECD) of TEM1 is composed of a c-type lectin domain (C-lec), a Sushi-like domain, and three epidermal 
growth factor (EGF) repeats. The ECD is extended from the membrane via a heavily O-glycosylated sialomucin stalk. TM, 
transmembrane domain; cyt, cytoplasmic domain. The N-terminal triangle represents the signal peptide. Figure adapted from 
Christian S. J Biol Chem, 276(10), 7408–7414 (2001)288. 
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However, its selective expression on pericytes and fibroblasts during active angiogenesis suggests a potential 
role in (tumor) angiogenesis. TEM1 KO animals develop normally, with no apparent defects in vascularization 
and wound healing290. However, while subcutaneous tumor growth was not affected by the lack of TEM1, 
orthotopically implanted tumors showed impaired tumor growth and reduced invasiveness in TEM1 KO 
mice290. These findings indicate that TEM1 might play a pro-tumorigenic role within an intact tumor 
microenvironment, possibly during tumor angiogenesis.  
In line with this hypothesis, an increase in TEM1 expression was observed under hypoxia, mediated by the 
transcription factor HIF-2a (hypoxia-inducible factor)291. Confirmed binding partners of TEM1 encompass 
components of the ECM, such as collagen type I and IV, as well as fibronectin292. Consequently, TEM1 
expression was shown to enhance cell adhesion to fibronectin and migration through matrigel292. In addition, 
TEM1 as well as CLEC14A and CD93, both expressed on endothelial cells, bind to Multimerin-2 (MMRN2), an 
endothelial selective ECM protein implicated in angiogenesis and tumor progression293. Recognizing distinct 
sites on MMRN2, CLEC14A and TEM1 can bind simultaneously at the interface between endothelium and 
pericytes and blocking of the CLEC14A – MMRN2 interaction had anti-angiogenic and anti-tumor effects293. 
These interactions indicate a role for TEM1 in the cross-talk between pericytes and endothelial cells, which 
communicate through the common basement membrane and via paracrine signaling to ensure the survival 
and maturation of blood vessels294.  
Platelet-derived growth factor receptor-b (PDGFR-b) signaling is crucial for the survival and proliferation of 
pericytes and is induced by PDGF-bb secreted by endothelial cells. In the absence of TEM1, the pro-
proliferative effect of PDGF-bb is attenuated, despite intact PDGFR-b expression and autophosphorylation295. 
TEM1 might therefore influence signaling components downstream of PDGFR-b295. However, although the 
proliferation of pericytes is essential for sprouting angiogenesis, loss of endosialin did not have any significant 
impact on pericyte recruitment and vessel sprouting in the developing murine retina296. 
In the context of tumor progression, TEM1 was found to promote spontaneous metastasis297. Similar to 
previous findings, Viski and colleagues found no structural differences in the tumor stroma of wild-type vs. 
TEM1 KO mice. However, TEM1-expressing pericytes actively promoted tumor cell intravasation in a cell 
contact-dependent manner. Furthermore, they described a correlation of upregulated TEM1 in primary 
human breast cancer samples with increased metastatic potential and poorer survival297. 
Together, these findings suggest that TEM1 plays a role in pericyte – endothelial cell interaction and vascular 
patterning. In cancer, TEM1 acts as a pro-tumorigenic factor of the TME, facilitating metastatic dissemination 
and possibly tumor angiogenesis. Although further investigations are required to decipher the complex role 
of TEM1 under physiological and pathological conditions, both its expression pattern and potential pro-
tumorigenic role make TEM1 an interesting target for therapeutic intervention. 1.3.4 TEM1	as	a	drug	target	
Based on the tumor-restricted expression pattern and frequency of TEM1 upregulation in the tumor stroma, 
a number of studies have started to explore TEM1 as a drug target in cancer. 
A humanized monoclonal antibody targeting TEM1, ontuxizumab (MORAb-004), was shown to target TEM1 
on pericytes, resulting in dysfunctional tumor microvasculature and impaired tumor growth298. Following 
these encouraging pre-clinical results, ontuxizumab has entered clinical evaluation. A first-in-human phase I 
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study in patients with treatment-refractory solid tumors revealed promising pharmacokinetics, preliminary 
anti-tumor activity and, importantly, a good safety profile299. Subsequently, a randomized, placebo-
controlled phase II study confirmed that ontuxizumab is well tolerated, but generated no objective response 
in chemo-refractory metastatic colorectal cancer300. Similarly, efficacy as a single-agent was low in metastatic 
melanoma patients301. Lastly, ontuxizumab was evaluated for the treatment of pediatric solid tumors and 
soft tissue sarcoma, but showed no enhanced activity over chemotherapy302,303.  
In order to increase the therapeutic effect of TEM1-targeting with monoclonal antibodies, antibody-drug 
conjugates (ADC) are being explored as an alternative strategy. This class of therapeutics is manufactured by 
conjugating the antibody with two to four highly potent small molecule toxins, often targeting microtubules, 
using a covalent linker that is stable in plasma but cleaved once internalized. An anti-TEM1 ADC using 
monomethyl auristatin E (MMAE) demonstrated high specificity and durable anti-tumor efficacy in a pre-
clinical model, as did another antibody conjugated to a duocarmycin derivative304,305.  
Besides ontuxizumab (MORAb-004), a fully human anti-TEM scFv binder, has been isolated from a human 
scFv library by yeast display and formatted as an scFv-Fc fusion protein306. The convenient human/murine 
cross-reactivity of this molecule, termed scFc78, has enabled bio-distribution studies evaluating both the 
specificity of the antibody and the feasibility of tumor imaging using TEM1 as a biomarker. These tumor 
imaging studies have revealed the potential of this molecule as a vascular tumor theranostic using radioactive 
conjugates, and as a tool for near-infrared imaging307,308. Moreover, scFc78 was used to further evaluate 
TEM1 expression in paraffin-embedded clinical sarcoma specimens, which confirmed TEM1 expression in 96 
% of human sarcomas309. This study also demonstrated the potential of immunotoxin-based therapy for 
sarcoma using the scFv fragment fused to a protein toxin309. 
Finally, a proof-of-principle study evaluated the potential of TEM1 as a target antigen for cancer 
immunotherapy310. Specifically, TEM1 cDNA was fused to a minimal fragment of tetanus toxoid in order to 
vaccinate immunocompetent mice.  Prophylactic vaccination elicited CD8+/CD4+ T cell responses and delayed 
tumor formation in different murine tumor models. Similarly, therapeutic vaccination led to reduced 
vascularity, increased tumor infiltration and T cell responses against TEM1 as well as other murine antigens, 
ultimately reducing the progression of established tumors. Importantly, physiological processes such as 
wound healing and reproduction were not impeded310. 
In summary, TEM1 is widely expressed during pathogenic neo-angiogenesis of various human cancers. 
Additionally, it represents an excellent tumor-associated antigen in human sarcoma, an often aggressive 
disease with limited therapeutic options. Furthermore, a number of pre-clinical and early clinical studies 
established the feasibility of therapeutic targeting of TEM1 without severe adverse effects. Therefore, TEM1 
represents an interesting new target for cancer therapy, in particular using novel immunotherapeutic 
paradigms such as CARs and bispecific T cell engagers. Exploring the potential of immunotherapeutic 
targeting of TEM1 will be the main focus of this work, as presented in detail in the next section. 
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Aims	and	Objectives	
This thesis originates at the interface of antibody discovery and cancer immunotherapy.  It aims to accomplish 
the following four main objectives: 
 Exploring	 and	 validating	 the	 functional	 utility	 of	 SpyCatcher/SpyTag	 covalent	fusion	tag	technology	for	de	novo	antibody	discovery.	
The production and purification of soluble recombinant antigen represents an early bottleneck in the 
isolation of antibody binders using in vitro library selection approaches such as phage display. Aiming to 
overcome this bottleneck and accelerate antibody discovery, chapter 2 presents the broad utility of the 
SpyCatcher/SpyTag covalent fusion system for the direct capture and immobilization of soluble antigens for 
phage display selection and screening procedures.  
De	novo	discovery	of	novel	fully	human	scFv	binders	targeting	TEM1.	
Building on the direct capture and immobilization technology described in chapter 2, chapter 3 focuses on 
the isolation and functional validation of novel fully human scFv binders targeting different epitopes on the 
extracellular domains of TEM1. The resulting diverse panel of scFv antibodies encompasses attractive 
candidates for the development of various therapeutic and diagnostic applications. Redirecting	human	T	cells	towards	TEM1-expressing	target	cells.	
Due to its upregulation in the stroma and vasculature of many solid tumors and relative absence in healthy 
adult tissues, TEM1 has been discussed as an interesting tumor-associated antigen. Although several studies 
have proposed TEM1 as a cancer biomarker and target for antibody-drug conjugates, no T cell redirecting 
therapies aiming at TEM1 have been published to date. Therefore, employing the novel anti-TEM1 scFv 
binders described in chapter 3, chapter 4 presents a proof-of-concept for the immunotherapeutic targeting 
of TEM1, using both soluble T cell engagers and CAR-T cells. Moreover, the development and validation of a 
new trivalent T cell engager format, termed ‘TriloBiTE’, is highlighted. Development	of	a	phenotypic	screening	platform	for	the	direct	 identification	of	functional	CARs	among	large	candidate	libraries.	
Both clinical efficacy and safety of CAR-T cell therapy strongly depend on the choice of targeting moiety for 
the synthetic immune receptor. In addition, clones that function as soluble antibodies do not always 
efficiently redirect T cells in the context of a CAR. Aiming to overcome this problem and bypass several labor-
intensive screening steps in the typical CAR discovery cascade, we are working towards a powerful 
phenotypic screening strategy to select functional scFv binders directly in the CAR format. Progress in this 
direction is the topic of chapter 5. 
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 Integrating	 SpyCatcher/SpyTag	covalent	 fusion	 technology	 into	phage	display	workflows	for	rapid	antibody	discovery.	
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 2.1 Abstract	
An early bottleneck in the rapid isolation of new antibody fragment binders using in vitro library approaches 
is the inertia encountered in acquiring and preparing soluble antigen fragments. In this report, we describe 
a simple, yet powerful strategy that exploits the properties of the SpyCatcher/SpyTag (SpyC/SpyT) covalent 
interaction to improve substantially the speed and efficiency in obtaining functional antibody clones of 
interest. We demonstrate that SpyC has broad utility as a protein-fusion tag partner in a eukaryotic 
expression/secretion context, retaining its functionality and permitting the direct, selective capture and 
immobilization of soluble antigen fusions using solid phase media coated with a synthetic modified SpyT 
peptide reagent. In addition, we show that the expressed SpyC-antigen format is highly compatible with 
downstream antibody phage display selection and screening procedures, requiring minimal post-expression 
handling with no sample modifications. To illustrate the potential of the approach, we have isolated several 
fully human germline scFvs that selectively recognize therapeutically relevant native cell surface tumor 
antigens in various in vitro cell-based assay contexts.  
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2.2 Introduction	
Over the past 20 years display technologies have become established as robust and powerful approaches for 
the in vitro isolation of protein and nucleic acid-based ligands with utility for both clinical and non-clinical 
applications311-313. However, despite considerable advances in library construction and binder enrichment 
strategies, certain aspects of display-based discovery technologies remain inefficient and potentially rate 
limiting. Among these is the need to generate recombinant, functionally immobilized antigens or antigen-
fragments to sustain the needs of multiple in vitro selection and screening activities. Usually, antigen material 
is provided chromatographically purified, often with oligo-histidine or IgG Fc affinity tags present.  In this 
format, it can be passively adsorbed directly to plastic well or tube surfaces, or biotinylated to permit 
essentially stable binding to streptavidin-coated matrices. The latter allows for significantly greater flexibility 
with regard to selection procedures and for this reason is generally favored.  
Biotinylation of antigens can be carried out using either chemical or enzyme-catalyzed approaches314,315, 
however these procedures often require antigen-specific optimization and, together with the requirement 
for purified protein, represent a significant inertia for rapid and multiple-throughput library selection 
projects. Approaches to circumvent this bottleneck have sought to exploit the native prokaryotic 
biotinylation apparatus, such that fusion of antigens to the biotin carboxyl carrier protein (BCCP) or to 
minimal biotin acceptor peptides (BAPs) have become established approaches for the in vivo production of 
naturally biotinylated recombinant molecules in E. coli316,317. Eukaryotic cells co-transfected with both BAP-
tagged antigens and bacterial biotin ligase (BirA), and supplied with exogenous biotin have likewise been 
shown to efficiently produce biotin-BAP-antigen fusions in both the cytosolic and secreted compartments318-
321.  
Despite its apparent attraction for display technology workflows, in vivo biotinylation is still subject to certain 
process drawbacks. Key among these are variable and inconsistent levels of biotinylation, inefficient 
biotinylation of proteins secreted to the media from bacterial hosts, and the hydrophobic character of biotin 
which could, in principle, lead to a reduction in the solubility of certain proteins and promote undesirable 
aggregation.   
Alternative possibilities for direct antigen production and capture are provided by the classical protein fusion 
tags such as glutathione S-transferase322, carbohydrate polymer-binding proteins323-325, and the Fc fragment 
of IgG326,327. However, although matrix-based purification (including bead capture) using these tag systems is 
well established, they each suffer from shortcomings and potential incompatibilities with library display and 
selection workflows. Common reported issues relate to the size of the tag itself (26 kDa for GST; 40 kDa for 
maltose binding protein, MBP; 50 kDa for dimerizing Fc) and to the aggregation of fusion proteins due to 
oxidation-induced oligomerization (GST)328. Similarly, certain engineered enzyme fusion tags, despite their 
potential for direct stable covalent capture via catalytic cycle trapping, are typically large (e.g. 34 kDa for 
Halotag7) which may explain why they have not been widely adopted for display technologies19-21.   
Decisions regarding the production of complex protein antigens can heavily influence the outcome of in vitro 
antibody and antibody-fragment discovery projects. Whereas reagent or ‘tool’ binders intended for use in 
denatured protein assays (e.g. immunoblots) can often be successfully isolated by using arrays of synthetic 
peptides, such molecules frequently fail to recognize native antigens on cells that generally present folded 
spatial or discontinuous surface epitopes rather than linear peptides. Reported strategies that seek to 
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produce antigens in a high-throughput generic manner often fail to replicate adequately the structural 
characteristics of many native antigens, often due to the absence of eukaryotic post-translational and/or 
redox modifications important for conformational folding and/or function329.  In this regard, we opted to 
investigate the recently reported SpyCatcher/SpyTag (SpyC/SpyT) ligand pair, which, in common with 
Halotag, results in an irreversible covalent bond between the interacting partners330,331. Unlike Halotag 
however, SpyC/SpyT is a ‘split’ protein system which, following association, is stabilized via the formation of 
an unusual side-chain amide bond. The reaction is reported as being rapid and insensitive to media, buffer 
composition, detergents, pH, temperature, and oxidation status, and with no requirement for metal ion 
addition331.  Additionally, the relatively small size of the SpyC domain (~12.5 kDa) could be considered 
advantageous for phage panning with a reduced likelihood of propagating tag-directed ‘background’ binders. 
Here we report the utility of SpyC/SpyT as a convenient and robust capture tool for the acceleration of 
antibody fragment discovery by phage display. 
 
 2.3 Results	2.3.1 Preliminary	 evaluation	 of	 E.	 coli	 for	 the	 production	 and	 secretion	 of	 mammalian	extracellular	protein	domains	fused	to	Spycatcher	
We initially sought to confirm that the CnaB2-derived SpyC domain could function as an effective C-terminal 
fusion partner under typical prokaryotic expression conditions and, importantly, that the desired fusions 
could be secreted to the media at levels sufficient to allow subsequent solid-phase capture and enrichment. 
To avoid potential steric interference between the upstream protein of interest and the SpyC tag, we chose 
to include the majority of the parental CnaB2 N-terminal amino acid sequence, and incorporated tandem 
epitope tags as an additional spacer moiety (pSTEVe6, Supplementary Fig. 2.1). For solid-phase 
immobilization, we synthesized a biotinylated minimal SpyT (bSpyT) peptide with an additional tetra-peptide 
‘linker’ extension and a C-terminal lysine-biotin to allow a pre-coating of streptavidin-coated beads or plate 
wells (Fig. 2.1a). 
As experimental test ‘antigens’ we first selected extracellular domain components (ECDs) of the human CD3 
complex assembled in a single chain format, and a series of corresponding anti-CD3 scFv antibody fragments. 
CD3-SpyC fusions, expressed and secreted by E. coli TG1 cells, could be captured specifically on bSpyT-loaded 
streptavidin coated beads and plate wells (Supplementary Fig. 2.1). Importantly, soluble CD3ed and CD3eg 
SpyC-fusions were bound by UCHT1, an anti-CD3 mAb known to interact with a non-conserved epitope found 
only in CD3 heterodimers and not in misfolded or monomeric CD3e (Supplementary Fig. 2.1)332,333. Similarly, 
the anti-CD3 scFv-SpyC fusions, expressed and captured on a bSpyT-coated surface, were shown to retain 
their expected T cell activating functionality (Supplementary Fig. 2.1).  
Collectively, these observations suggested that the direct capture and immobilization (dCI) of SpyC-protein 
fusions from clarified bacterial media is efficient and that fused antigens can retain their functional structure. 
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Figure 2.1. Production and functional evaluation of mammalian extracellular antigen-SpyCatcher fusions. 
(a) Schematic representation of the direct capture and immobilization (dCI) of SpyC-antigens via surface-bound bio-SpyT. (b, c) 
Mammalian cell expression and direct capture of representative SpyC-antigen fusions (see Table 2.1) on bSpyT-loaded magnetic 
beads. (b) Coomassie-stained SDS-PAGE (reducing). The insert-less pSTEVe49 vector cassette expresses the free HA-tagged SpyC (far 
right). (c) Anti-HA tag ECL Western staining of recombinant SpyC-antigens expressed in HEK culture supernatants (‘S’), and following 
selective covalent enrichment on SpyT beads (‘B’). Covalent immobilization to SpyT on the beads results in a shift to a higher MW 
corresponding to the mass of the peptide adduct. Samples were run on separate gels and interspersed with irrelevant samples, but 
were processed in parallel. Full-length gel and blot images can be found in Supplementary Figure 2.2. (d) ELISA illustrating functional 
recognition of selected immobilized dCI SpyC-antigens by cognate recombinant ligands. 
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Antigen ECD Key Architecture PTM MW/pI  Vector Expression Capture 
SpyC b; FBR; IgS - 12.5/4.6 e49 ü ü 
CD3ed b; IgC 2 N-gly (d) 21.5/4.6 e20 ü ü 
CD3ge b; IgC 2 N-gly (g) 22.7/5.0 e20 ü ü 
EpCAM a/b; Thy1 3 N-gly 27.3/5.6 e38 ü x 
    e49 ü ü 
TEM8 a/b; VWFA 3 N-gly 33.1/5.4 e38 ü x 
TEM8 (nSP/cD) a/b; VWFA 2 N-gly 23.3/5.3 e38 ü ü 
TEM1 (cD) a/b; CTL; Sus; EGFLc ~4 O-gly 37.6/4.6 e20 ü ü 
TEM1 (cD) * a/b; CTL; Sus; EGFLc ~9 O-gly 49.4/4.6 e20 ü ü 
TEM1 (nD) Mucin-like domain ~15 O-gly 14.0/7.2 e49 ü ü 
CEACAM1 b; IgV, IgC ~20 N-gly 31.8/4.7 e38 ü ü 
CEACAM5 (CEA) b; IgV, IgC ~28 N-gly 32.3/5.6 e38 ü ü 
CEACAM6 b; IgV, IgC ~12 N-gly 31.4/5.1 e38 ü ü 
CD70 b/coil ‡; TNF-L 2 N-gly 17.4/8.9 e38 ü (weak) ü (weak) 
    e49 ü ü 
Mesothelin a; ATR 3 N-gly 34.3/5.0 e38 ü ü 
ROR1 b/coil ‡; IgC; Krn; Frz 4 N-gly 42.5/5.4 e38 ü ü 
ROR2 b/coil ‡; IgC, Krn, Frz 3 N-gly 41.5/6.2 e38 x x 
TNFR2 b/coil; tnfr-cr 4 O-,2 N-gly 25.3/7.0 e38 ü ü 
CD19 b/coil; IgC 5 N-gly 29.8/7.2 e38 x x 
    e49 ü ü 
BCMA b/turn; tnfr-cr  5.9/7.6 e38 ü ü 
CTLA4 b; IgV 2 N-gly 13.5/4.6 e38 ü ü 
    e49 ü ü 
PD1 b; IgV 4 N-gly 16.3/8.8 e38 ü ü 
Tigit b; IgV 2 N-gly 13.2/4.8 e38 ü ü 
TIM3 b; IgV 1 O-,1 N-gly 20.2/6.6 e38 ü  ü 
TIM1 b; IgV; mucin stalk x O-,4 N-gly 29.1/7.0 e38 ü (Het) ü (Het) 
    e49 ü (Het) ü (Het) 
HER2-CTF611 N/A (peptide) 1 N-gly 4.7/4.4 e38 ü  ü 
PSMA a/b; PA; pM28 10 N-gly 79.5/6.4 e49 x x 
SIRPa b; IgV  12.9/8.0 e38 ü  ü 
SIRPa * b; IgV 2 N-gly 12.9/9.0 e38 ü  ü 
CD47 b; IgV 5 N-gly 13.5/5.4 e20 x x 
    e38 ü NT 
CD47 * b; IgV 6 N-gly 13.7/5.1 e20 ü ü 
FRa   25.1/8.3 e38 ü (weak) x 
LAG-3 b; IgV, IgC  46.1/9.5 e38 ü (weak) x 
EGFRvIII b; RLD; FL; GFR4 8 N-gly 38.3/6.5 e38 ü  ü 
Table 2.1. Antigen ECD fragments evaluated as SpyC fusions and selected physical characteristics. 
Unless otherwise indicated, the recombinant ECDs are human and terminate proximal to a TM domain/GPI anchor. 
Indicated potential post-translational modifications are derived from curated UniprotKB features and predictive O-glycosylation tools 
(NetOGlyc 4.0 Server).334 Fusions were assessed for both expression and bead-capture by SDS-PAGE and anti-HA tag ECL Western 
blotting. Domain folds and motifs: FBR, fibronectin binding repeat; IgS, Ig-superfamily; thy1, thyroglobulin-like type 1; IgV, Ig-like V-
type; IgC, Ig-like C2-type; VWFA, Von Willebrand factor type A; CTL, C-type lectin-like; Sus, Sushi; EGFLc, EGF-like calcium binding; 
ATR, ARM-type repeats; Krn, kringle; Frz, Frizzled; TNF-L, Tumor Necrosis Factor-like; tnfr-cr, TNFR cysteine rich repeats; PA, protease 
associated; pM28, peptidase M28; RLD, Receptor L-domain; FL, furin-like cysteine-rich; GFR4, growth factor receptor 4 domain. * 
murine sequence; ‡ prediction by PSIPRED v3.3; nSP, native signal peptide; cD, ECD truncation with C-terminal (membrane proximal) 
deletion; nD, ECD truncation with N-terminal (membrane distal) deletion; Het, expression and/or capture product appears very 
heterogeneous by SDS-PAGE; NT, not tested. 
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2.3.2 Pipeline	 production	 of	 SpyC-antigens	 for	 antibody	 phage	 display	 using	 a	 small-scale	mammalian	expression	system	
Following our validation studies in E. coli, we next constructed vector cassettes (pSTEVe20/38/49; 
Supplementary Fig. 2.1) appropriate for use in a mammalian transient expression system based on the 
HEK293-6E host cell line. We selected a diverse test panel of mammalian membrane protein ECD fragments 
representing established and prospective therapeutic target antigens for solid and hematological 
malignancies, and differing in size, charge and structural complexity (Table 2.1). Antigens were fused N- or C-
terminally to SpyC and targeted to the secretory pathway by appending to a common synthetic signal 
peptide. From SDS-PAGE and Western blotting of supernatants from 2 ml cultures we were able to show that 
30 of the 32 antigen fragments (93 %) could be expressed as fusions and secreted, and that of these, 26 (81 
%) could be directly captured from media supernatants on bSpyT-loaded magnetic beads for subsequent 
phage display experiments (Table 2.1, Fig. 2.1b, c, d and Supplementary Fig. 2.1). Encouragingly, a sub-panel 
of dCI SpyC-fused antigens were shown to retain specific recognition for their well-described physiologically 
relevant ligands (Fig. 2.1d), confirming that SpyC-fusions, expressed and secreted from mammalian host cell 
lines, can retain native structural characteristics.  2.3.3 dCI	 SpyC-fusion	 antigens	 represent	 suitable	 targets	 for	 scFv	 antibody	 discovery	 by	phage	display	
We next sought to evaluate how dCI SpyC-fusion antigens performed in scFv phage display experiments 
alongside a classical purified antigen. We therefore expressed an ECD fragment of human tumor endothelial 
marker 1 (TEM1, CD248, Endosialin; N-terminal mature 353 residues) in HEK cells and purified the protein by 
Ni-NTA chromatography. The protein was subsequently biotinylated enzymatically, quality-controlled by 
band-shift gel assay, and dialyzed into PBS prior to its immobilization onto streptavidin magnetic beads. In 
parallel, we produced SpyC fusions in HEK cell culture media for dCI using truncated h/mTEM1 ECDs (N-
terminal mature 353 and 460 residues respectively). Using large, fully human and essentially germline naïve 
scFv libraries (CHV101_DMk and CHV101_DMl), we applied two rounds of phage display selection against 
the three bead-immobilized antigens. An examination of selection metrics (Table 2.2) suggested strong 
enrichment for binders at round 2 using both antigen formats, resulting in significant ELISA-positive hit 
frequencies for both lambda and kappa libraries. Random sequencing of only modest numbers of re-arrayed 
hits (30 for the combined h/mTEM1-SpyC panel and 41 for the hTEM1-bio) revealed considerable clonal 
diversity within the h/mTEM1-SpyC panel with ~83 % of clones being represented by a unique sequence. This 
compares favorably with the number of ‘uniques’ identified from the hTEM1-bio sequencing (~90 %, data 
not shown). Interestingly, three of these clone sequences (Fig. 2.2) were also found to occur in the hTEM1-
bio panel, suggesting that the two antigen formats present shared or equivalent epitopes. Further, all hit 
clones emerging from the dCI TEM1-SpyC outputs also recognized the corresponding full length ECDs of 
human and mouse TEM1 (668 and 680 mature ECD residues respectively) that were produced in a rodent 
cell line (CHO) and purified via Ni-NTA chromatography. Importantly, the relative binding activities of these 
clones towards the human and murine TEM1-SpyC antigens appeared to be broadly conserved for the 
corresponding classically produced antigens (Fig. 2.2). Taken together, the data demonstrates that an 
arbitrary selection of diverse unique hit clones isolated by panning against SpyC-formatted TEM1 antigens 
can recognise TEM1 produced and purified using traditional procedures, implying that a substantial level of 
structural ‘equivalence’ is preserved between the SpyC-fusion and traditional antigen formats.  
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  hTEM1-bio  hTEM1-SpyC  mTEM1-SpyC 
 LIBRARY l k  l k  l k 
R1 
Input (phage; CFU) 7.4x1012 5.3x1012  7.4x1012 5.3x1012  7.4x1012 5.3x1012 
Output (CFU) 1.4x106 1.1x106  5.6x105 6.3x105  4.4x105 3.2x105 
R2 
Input (phage; CFU) 1.6x1011 1.2x1011  1.2x1011 1.4x1011  2.4x1011 1.9x1011 
Output (CFU) 2.3x109 1.7x109  3.0x109 2.6x109  5.3x109 4.1x109 
  Enrichment Factor* 7.6x104 6.8x104  3.3x105 1.6x105  3.7x105 3.6x105 
R2   ELISA hit rate (%)‡ 43 25  56 42  68 44 
Table 2.2. Panning metrics and hit-rates of phage display selections against TEM1. 
R1 and R2 input and output panning metrics illustrating respective library enrichments and primary ELISA hit-rates for both TEM1-
bio and TEM1-SpyC antigens. CFU, colony-forming units; * (R2 Output/Input)/(R1 output/input), ‡ signal threshold > 5x background. 
 
 
 
 
Figure 2.2. Phage display versus TEM1 antigen format. 
Raw ELISA profiling data for 30 randomly selected scFv hit clones isolated from the dCI h/mTEM1-SpyC antigen panning experiments. 
Bar length reflects the relative ELISA signal strengths for human and murine TEM1-SpyC and recombinant, CHO-cell derived and 
purified TEM1 full-length ECD antigens (L).  ELISAs were conducted separately and independently for the TEM1-SpyC and TEM1 (L) 
antigens. Identical clone sequences obtained from 21 randomly picked hTEM1-bio R2 ELISA hits are shaded. SpyC antigens were 
captured via dCI on prepared streptavidin-bSpyT plate well surfaces whereas purified recombinant TEM1 (L) was immobilized on 
plate wells by passive adsorption. 
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Importantly, very few enriched clones were found to recognize the SpyC domain (<5 % of screened clones 
isolated against h/mTEM1) indicating that, despite being of bacterial origin, the small SpyC domain does not 
appear to be excessively immuno-dominant when using naïve, native content antibody libraries. 
Supplementary Table 2.1 summarizes the frequencies of clones binding isolated SpyC in screened outputs 
from several SpyC-fusion phage panning experiments conducted without active SpyC deselection (i.e. 
subtraction). 
In addition to traditional plate-based ELISA screening, we also employed crude SpyC-antigen supernatants in 
bead-based multiplexed assays with the aim of acquiring higher information content for selection outputs. 
Fluorescently barcoded streptavidin bead multiplexes, pre-loaded with four to six distinct dCI SpyC antigens 
were used to screen phage display output clone supernatants for specific and/or cross-reactive antigen 
binding. By incorporating the dCI methodology into a ‘no wash’ direct read 384-well protocol on an iQue 
Screener Plus instrument (IntelliCyte), we were able to greatly accelerate primary output specificity screening 
(Supplementary Fig. 2.3). Furthermore, we were able to use this approach to successfully identify improved 
affinity matured clone sequences enriched against the same cognate dCI SpyC-antigen in a high-stringency 
phage display selection experiment (Supplementary Fig. 2.3).  2.3.4 Secreted	 SpyC-antigen	 fusions	 support	 the	 isolation	 of	 scFvs	 that	 recognize	 native	endogenous	cell	epitopes	and	have	downstream	functional	utility	
To investigate whether scFvs isolated against dCI SpyC-fusions could recognize endogenous cognate antigens 
on appropriate target cells, we reformatted three representative anti-TEM1 clones as scFv-Fc (IgG1) fusions 
alongside a previously described anti-TEM1 antibody, sc78335. All of the clones expressed well in our transient 
HEK293-6E system (100-200 mg/l) and, following purification by Protein A affinity chromatography, all 
antibodies were seen to stain HEK293T cells transfected with full-length hTEM1, as well as several cell lines 
previously established as positive for endogenous TEM1, but not lines negative for TEM1 (Fig. 2.3a). One 
clone, HS06, showed clear preference for recognition of the human A673 and SK-N-AS TEM1+ lines with 
significantly reduced binding to the 2H11 and TC1 TEM1+ murine lines.  During downstream characterization 
of HS06, we were also able to confirm that SpyC fusions have convenient and practical utility for affinity 
determination using surface plasmon resonance (SPR). The simple addition of free bSpyT peptide to crude 
HEK expression supernatant containing secreted hTEM1-SpyC, followed by rapid buffer exchange via spin 
column, allowed the efficient capture of the resultant covalent complex on a streptavidin-coupled Biacore 
chip. Rapid single-cycle kinetic binding data obtained for purified monovalent H06 scFv yielded a modest 
double-digit nanomolar affinity (Fig. 2.3b), characteristic of many antibody clones isolated from natural 
germline repertoires that have not undergone somatic hyper-mutation and clonal expansion. Encouragingly, 
reference KD data obtained using a commonly employed anti-Fc capture step to immobilize HS06 scFv-Fc as 
the ‘ligand’, a full-length (FL) recombinant hTEM1 ECD ‘analyte’, and multi-cycle kinetics, were shown to be 
comparable (Supplementary Fig. 2.4). To explore whether primary scFv hits arising from SpyC-fusion panning 
were suitable for subsequent entry into classical lead optimization experiments, we mutated the HS06 scFv 
by error-prone PCR to generate a library of ~109 variants and panned this library sequentially against both 
immobilized mTEM1-bio and hTEM1-bio in order to select for increased-affinity variants with h/mTEM1 
cross-reactivity. A strongly enriching clone (HS06mut) containing a single VH CDR3 amino acid substitution 
was recovered and its affinity determined using both hTEM1-SpyC and purified full-length hTEM1 ECD.  
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Figure 2.3. Characterization of anti-TEM1 clones isolated by dCI SpyC-antigen selection. 
(a) Binding of reformatted and purified scFv-Fc (hIgG1) clones (2 µg/ml) to human and murine cell lines. A673, human Ewing’s 
sarcoma; SK-N-AS, human neuroblastoma; 2H11, murine tumor vascular endothelium; TC1, murine lung adenocarcinoma; HEK293-
6E, human embryonic kidney; HT-1080, human fibrosarcoma; MDA-MB-231, human mammary carcinoma; MS1, murine pancreatic 
islet endothelium. Additionally, binding of anti-TEM1 scFv-Fc clones to HEK293T cells transiently transfected with native FL-hTEM1 
and an irrelevant surface protein (ahCD19:28z CAR) control is also shown. (b) SPR monovalent affinity determination of parental 
clone HS06 (left) and an affinity-matured variant, HS06mut (right). hTEM1-SpyC has been used as the immobilized ligand and 
monovalent HS06/HS06mut monovalent BiTE as the soluble analyte, with concentration ranges of 100, 50, 25, 12.5 and 0 nM for 
HS06, and 5, 2.5, 1.25, 0.625 and 0 nM for HS06mut. (c) Binding of HS06mut variant scFv-Fc (0.1 µg/ml) to endogenous human (A673) 
and murine (2H11) TEM1+ cell lines. 
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Remarkably, this single point mutation was shown not only to confer a ~70 to 80-fold improvement in raw 
KD towards human TEM1 in both formats (Fig. 2.3b and Supplementary Fig. 2.4), but also to possess 
appreciable cross-reactivity to mTEM1 (Fig. 2.3c). Taken together, our data validates TEM1-SpyC as a flexible 
reagent for the isolation and early characterization of functional anti-TEM1 molecules using highly 
streamlined dCI methodology. 
We subsequently sought to demonstrate that SpyC-fusion antigens would be suitable for more challenging 
discovery projects; for example, the isolation of scFvs intended to neutralize specific receptor-ligand 
interactions. To investigate this, we chose the murine signal regulatory protein alpha (SIRPa):CD47 
interaction as a test case. After confirming the correct folding and efficient capture of the mCD47 ECD SpyC-
fusion, we panned the libraries against bead-captured mCD47-SpyC and then screened the resultant binder 
clones by dCI competition ELISA to identify scFvs that specifically blocked the interaction between dCI 
mCD47-SpyC and an Fc-fused version of the CD47 ligand, SIRPa. Encouragingly, scFv clones with neutralizing 
activity could be readily isolated from the CHV101_DM libraries and, following reformatting to murine IgG2a, 
a representative candidate (MS115) was further characterized alongside two neutralizing rodent hybridoma 
mAbs336. Clone MS115 was shown to compete effectively with the binding of SIRPa for CD47-SpyC and to 
retain its neutralization activity using a His-tagged and purified mCD47 antigen sourced from a commercial 
vendor (Supplementary Fig. 2.5). Critically, MS115 recognized endogenous mCD47 present on a murine 
tumor cell line but did not stain the corresponding knock-out (Supplementary Fig. 2.5). Hence, dCI SpyC-
antigen selection and screening is compatible with the rapid isolation of target-selective neutralizing 
antibodies. 2.3.5 dCI	SpyC-antigens	are	suitable	targets	for	the	selection	of	functional	scFv	warheads	for	immunotherapy	applications	
Aside from classical antibody targeting applications, scFv ‘warheads’ have also demonstrated considerable 
utility in recruiting and re-directing the exquisitely potent killing functions of cytotoxic T cells towards tumor-
associated cell-surface targets. The two principle therapeutic paradigms, namely chimeric antigen receptors 
(CARs) and soluble bispecific ‘engagers’, both facilitate T cell-mediated killing by ‘bridging’ target and T 
effector cells followed by the transmission of activation signals from intracellular CD3 and co-receptor 
signaling components. We therefore sought to evaluate the utility of the dCI SpyC-antigen format for the 
rapid discovery of functional CAR scFv ‘warhead’ panels. To this end, we chose the mature ECD of human 
mesothelin as a relevant immunotherapeutic target337,338. Following panning of the CHV101_DM libraries 
against dCI mesothelin-SpyC, and the subsequent identification of binder clones in both dCI mesothelin-SpyC 
primary ELISA and secondary flow cytometry assays, six scFvs of interest were reformatted into a generic 2nd 
generation CAR comprising a CD28 spacer, transmembrane (TM) domain and cytosolic domain fused to CD3z 
immunoreceptor tyrosine-based activation motif (ITAM) signaling elements. The resultant CAR panel was 
transfected into an engineered Jurkat reporter cell line to assess CAR-mediated NFAT activation in response 
to target cell lines known to express endogenous cell surface mesothelin. All six clones were shown to trigger 
a strong induction of CD3 ITAM-mediated NFAT signaling in the presence of mesothelin-expressing H-226 
tumor cells (Fig. 2.4a). The magnitude of these signals compared favorably with those observed for a control 
CAR armed with the clinically validated murine anti-CD19 FMC63 scFv in the presence of CD19-expressing 
Raji cells, and with a published anti-mesothelin human scFv (P4)339,340.  
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Figure 2.4. Functional target cell engagement by anti-mesothelin scFvs isolated from dCI selection experiments. 
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(a) Induction of NFAT-driven expression of luciferase in Jurkat reporter cells transduced with anti-mesothelin CARs employing 
different scFv clones. Luciferase activity was measured after 24h of co-culture with mesothelin expressing target cells (H-226, AsPC-
1) or meso-negative Raji B cells. CD19 and P4 CARs are included as positive controls for CD19 and mesothelin respectively. NT, non-
transformed control. (b) Induction of NFAT-driven expression of luciferase in Jurkat reporter cells in the presence of H-226 (left), and 
AsPC-1 (right) target cells and soluble T cell engagers. Dashed lines represent baseline stimulation in the presence of engager 
molecule and HEK293-6E mesothelin-negative cells. (c) Mesothelin specific T cell engager constructed from clone HS201 redirects 
primary human CD8+ T cells to kill H-226 tumor target cells. Image-based acquisition of Cytotox Red fluorescence reports the extent 
and real-time kinetics of killing. Baseline killing was determined against irrelevant meso-negative A673 cells using 750 pM engager. 
(d) Time-dependent killing of H-226 cells in the presence of 2nM HS201 engager by primary human T cells (Pan-T purified; 14 days 
post isolation). Dead cell clusters emit red fluorescence. 
 
 
In the presence of AsPC-1 tumor cells, which are known to express lower levels of surface mesothelin, three 
of the six clones yielded substantially less NFAT reporter activation, probably reflecting the relatively modest 
monovalent affinities of these primary non-optimized scFv binders (data not shown).  
To explore further the potential of the anti-mesothelin clones originating from the SpyC dCI selections, we 
constructed soluble T cell engagers from two of the novel scFvs showing promising CAR signaling activity, 
together with P4. Unlike classical BiTEs which employ two monovalent scFvs linked in tandem203, our final 
molecules were bivalent for the anti-mesothelin warheads and monovalent for a humanized anti-CD3. Similar 
to the CAR format, the three resulting T cell engagers were shown to trigger potent NFAT-mediated activation 
of the Jurkat reporter line in a cell target and dose-dependent manner (Fig. 2.4b). Interestingly, while the 
HS201 and HS202 clone engagers displayed similar activation kinetics to the P4 benchmark clone against H-
226 meso-high cells, clear differences in sensitivity were evident against meso-moderate AsPC-1 cells, with 
the HS201 engager being the most discriminatory.  Extending the study to cell killing confirmed that this 
experimental T cell engager molecule could efficiently redirect primary human T cells to kill H-226 tumor cells 
in vitro in a time and concentration dependent manner (Fig. 2.4c, d). Collectively, the results indicate that 
our dCI procedure using small scale, SpyC-fusion supernatants can be employed successfully for the rapid 
and cost-effective isolation of functional scFv ‘warheads’ for a range of potential applications, including 
cancer immunotherapy. 
 
 2.4 Discussion	
In the current study, we sought to develop a minimal, cost-effective and generic solution to native 
mammalian cell-surface antigen production that could be easily integrated into a typical scFv antibody phage-
display discovery workflow. With this in mind, we decided to evaluate the reportedly robust and irreversibly 
associating SpyC/SpyT ligand pair in combination with a widely used human cell-line protein production host 
using modular episomal expression vector tools. 
To-date, the SpyC/SpyT interaction has been reported principally in the context of defined molecular 
assembly and imaging applications341-344,345. Following the elucidation of the original 2-component system, 
the inventors further engineered the SpyC module to function as an effective uncoupled peptide ligase for 
head-to-tail oligomerization of proteins of interest tagged with both SpyT and a partner peptide (SpyK) 
containing the corresponding reactive lysine346. However, to the best of our knowledge, the evaluation of 
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SpyC/SpyT as a practical tool for antibody phage display-based molecular discovery applications has so far 
not been reported. 
In this work, we synthesized chemically a SpyT peptide with a biotin handle to allow the controlled pre-
coating of immobilized streptavidin matrices with a high molar density of SpyT ligand to favor avid surface 
capture of SpyC-fusion proteins present in crude media supernatants. Although more cost-effective and 
efficient than expressing and purifying large stocks of recombinant biotinylated SpyC protein, a principle 
concern was that the use of the larger bacterial SpyC component for the antigen fusion partner would prove 
incompatible with efficient expression and/or secretion from cellular hosts. However, we observed that a 
codon-optimized SpyC sequence preceded by an immunoglobulin signal peptide was exported efficiently by 
HEK293-6E cells. Our subsequent findings confirm that the SpyC module tolerates fusion to many diverse 
mammalian cell-surface extracellular fragments/domains, and retains its functional integrity (as shown by 
efficient and selective capture on SpyT-surfaces) following its secretion by HEK293 cells in either an N- or C-
terminal fusion orientation (Fig. 2.1 and Table 2.1). By employing an optimized transient transfection protocol 
and a high-productivity HEK293 cell line, sufficient SpyC-antigen fusion material can be generated from small 
culture volumes to support multiple parallel and diverse discovery activities comprising several dCI selection 
and screening rounds. 
Interestingly, our broader observations demonstrate that even poorly expressing fusions can yield successful 
outcomes. For example, the secreted concentration of murine CD47-SpyC was estimated by ECL-Western 
analysis to be in the region of only 1 µg/ml and below our limit of detection for visible SDS-PAGE dye staining 
in crude expression media. However, SpyT-bead enrichment from 2 ml of media proved adequate for efficient 
and robust phage-display clone enrichment, mirroring the selection performance of SpyC-antigens 
expressing at far higher levels and allowing the isolation of functional clones (Supplementary Fig. 2.5). 
Collectively, our scFv phage display screening data gathered to-date suggests that the bacterial SpyC tag 
sequence is only modestly immunogenic as a fusion partner using our IgM/IgD-derived libraries — even in 
the absence of a typical solid-phase deselection step (Supplementary Table 2.1). Conveniently, SpyC has an 
additional advantage for display applications in that a single point mutation destroys its capability to form 
the covalent iso-peptide bond with SpyT331. Hence, purified SpyC(mut) can presumably be employed as an 
effective soluble library subtraction reagent or can be exploited in its fusion form as a soluble competitor 
during off-rate selections.  
In principle, we would anticipate that SpyC/SpyT dCI methodology could be readily integrated into any binder 
discovery platform that employs a solid-phase capture for enrichment, for example ribosome display, as well 
as phage display using non-immunoglobulin or synthetic library scaffolds. It could also be adapted for 
approaches that enrich for binders using flow cytometry-based sorting of particles, for example yeast, 
mammalian, bacterial and aptamer particle display technologies. For these cases, SpyC-antigen expression 
supernatants could be directly ‘charged’ with synthetic SpyT conjugates containing either biotin or 
appropriate bright dye adducts prior to incubation with library particles and sorting. Finally, the direct 
interfacing of dCI from small-scale cultures with automated magnetic bead handling would support 
applications requiring high-throughput scaling of selections347. 
In conclusion, we have extensively tested the practical utility of SpyC/SpyT and shown it to be an attractive 
and convenient tagging/immobilization tool for de novo antibody hit-discovery selection, screening and 
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characterization, circumventing the classical requirement for traditional antigen purification/processing. We 
have confirmed its general compatibility with i) mammalian soluble expression and secretion, and ii) the 
direct capture and immobilization of fusion antigens from crude cell media. The provision of covalent 
anchorage for antigen targets by SpyC/SpyT dCI, such that surface complexes can survive the prolonged 
incubations and extensive washing steps typically applied during stringent selection protocols, has permitted 
the successful isolation of several functional antibody candidates recognizing diverse therapeutic targets. 
 
 2.5 Materials	and	Methods	2.5.1 Molecular	biology,	protein	expression	and	phage	display	
Prokaryotic expression and secretion of SpyC-fusion proteins  
The nucleotide sequence of the CnaB2-derived SpyCatcher (SpyC) domain was synthesized (GeneArt, Thermo 
Fisher Scientific) with reference to the sequence of Genbank accession: JQ478411.1 (amino acids 28-136) 
and cloned into a pUC119-derived prokaryotic expression vector (pSTEVe16) containing a periplasmic 
secretion signal. The protein of interest was cloned N-terminal to the SpyC domain, separated by tandem 
myc/his or HA/his epitope tags. The amino acid sequences of the extracellular region of the human CD3e,d 
and g chains were obtained from UniProtKB (http://www.uniprot.org/)348 and assembled as single-chain 
heterodimers using a 28 amino acid flexible spacer. The amino acid sequences of anti-CD3 antibody variable 
domains were extracted from the following published patents: UCHT1 (US8519100), OKT3 (Blinatumomab; 
WO2005052004), Pasotuxizumab (WO2008119567A2), Solitomab (US8076459B2), Foralumab (US 
20060177896A1). A murine CD3-specific scFv was constructed from the sequenced 145-2C11 hamster 
mAb.349 Genes were synthesized in scFv format and cloned into pSTEVe16.  
E. coli TG1 cells (Lucigen, #60502) were electroporated with the relevant plasmids and grown overnight on 
agar prepared with 2TY medium supplemented with 2 % glucose and 100 µg/ml ampicillin (2TYAG).  Colonies 
were inoculated into 96-well plates containing 2TYAG and cultures were grown overnight at 30 oC. For protein 
expression, 4 µl of overnight culture was used to inoculate 170 µl Terrific Broth (TB) containing 0.1 % glucose 
and 100 µg/ml ampicillin. The cultures were grown in 96-well PP U-form microplates (Greiner, #650201) with 
shaking at 30 °C for 3-4 h until reaching an OD600 of 0.6. Protein expression was induced by adding 20 µl per 
well of 1 mM Isopropyl-β-D-thiogalactopyranoside (IPTG; Merck, #420322) to achieve a final concentration 
of 100 µM. Expression was allowed to continue for 16-18 h at 30 oC with shaking at 750 rpm, 70% humidity 
before harvesting of media for subsequent analysis. 
Eukaryotic protein expression and purification 
Extracellular domain (ECD) fragments of human and mouse membrane antigens were synthesized (GeneArt, 
Thermo Fisher Scientific) based on sequences and predicted topologies obtained from UniprotKB. Gene 
fragments were fused N- or C-terminally to vector-encoded SpyC housed in pTT-based mammalian episomal 
expression vectors.350 All vectors contained an identical semi-synthetic signal peptide (pSTEVe20/38/49 
constructs). Selected scFv candidates were typically either sub-cloned into a pTT-based vector containing a 
vector-encoded human IgG1 constant region to produce scFv-Fc fusion proteins, reformatted into modular 
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pTT-based IgG heavy and light chain vectors for co-transfection and production of assembled IgGs, or fused 
to anti-CD3 UCHT1 domains to generate secreted T cell engagers.  
Recombinant protein was produced using the mammalian HEK293-6E/pTT transient expression system 
(National Research Council of Canada; obtained under licence). HEK293-6E cells were grown in Freestyle F17 
medium (Thermo Fisher Scientific, #A13835) containing 4 mM GlutaMAX (Life Technologies, #35050061), 0.1 
% Pluronic® F-68 (Life Technologies, #24040032) and 25 μg/mL G418 (Life Technologies, #10131019) at 37 
°C, 5 % CO2 and 120 rpm. For transfection, the DNA was mixed with FectoPRO (Polyplus, #116-010) 
transfection reagent in F17 medium without supplements, according to the manufacturer’s instructions. 
After five days of protein expression, cultures were subjected to low speed centrifugation and the media 
collected. Samples could be used immediately for direct capture and immobilization (dCI) experiments or 
snap-frozen and stored at -80 °C until required.  
ScFv-Fc fusions and IgG molecules were purified from clarified expression media using a HiTrap™ MabSelect 
column (GE Healthcare, #11003494), followed by extensive dialysis against phosphate-buffered saline (PBS). 
His-tagged T cell engagers were purified by IMAC chromatography using a HisTrap™ Excel column (GE 
Healthcare, #17-3712-05). The peak monomer fractions were pooled and buffer-exchanged into PBS using a 
Superdex 200 Increase 10/300 GL preparatory grade column (GE Healthcare, #28-9909-44). The 6xhis-tagged 
variants of human or murine TEM1 ECD containing a C-terminal biotinylation sequence were purified using a 
HisTrap™ excel column followed by site-directed enzymatic biotinylation using purified BirA.351 Following 
confirmation of biotinylation by avidin gel shift assay,352 the proteins were buffer exchanged into PBS 
supplemented with 0.1% BSA and stored at -80 oC. 
Transient transfection of HEK293T cells with the FL-hTEM1 cDNA ORF (extracted from Genbank RefSeq 
NM_020404.3) and an irrelevant membrane-localised control ORF (anti-hCD19 2nd generation CAR construct) 
utilized the pTagGFP2-N CMV promotor vector (Evrogen, #FP192).  Briefly, HEK293T cells were detached and 
plated in 6-well plates at 106 cells/well in a volume of 4 ml. Recombinant plasmid DNA (4 µg) was combined 
with 400 ml serum-free DMEM and 6 ml Turbofect reagent (Life Technologies, #R0532), and incubated for 
20 min at RT before being added dropwise to the plated cells. Transfected cells were maintained at 37 oC, 5% 
CO2 under a humidified atmosphere for 48 h. 
Direct capture and immobilization (dCI) of secreted SpyC-fusion proteins for downstream library selections  
For solid-phase immobilization of SpyC-fused antigens, we synthesized a C-terminally biotinylated SpyT 
peptide (bSpyT) with a 4-amino acid ‘spacer’ extension (>90% purity; Protein and Peptide Chemistry facility, 
UNIL). Streptavidin-conjugated magnetic beads (80 µl; M-280 Dynabeads; Life Technologies, #11206D) were 
suspended in 1 ml of PBS containing 1 µM of bSpyT peptide and incubated overnight at 4 °C or 1 h at room 
temperature (RT) with gentle rotation. After 3x 1 ml wash steps in PBST (PBS + 0.1 % Tween-20) and 1x 1 ml 
wash step in PBS, the coated beads could be stored at 4 °C until required or incubated directly with 2 ml of 
SpyC-fusion expression supernatant for 2 h with gentle rotation at RT. The antigen-coated beads were 
washed 4x with PBST and 1x in PBS and generally used immediately for dCI evaluation and phage display 
experiments. 
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Selection of human germline scFvs by phage display using SpyC-fusion proteins 
All phage display selections were carried out using two large, fully human scFv libraries (CHV101_DMk and 
CHV101_DMl; SMD, unpublished) constructed from the peripheral blood of 120 healthy volunteer donors 
(Service de Transfusion, Epalinges, Switzerland). Briefly, IgD/IgM VH, and Vk/Vl domain repertoires were 
amplified from cDNA prepared from mRNA affinity-purified from enriched CD19+ cells, using a newly 
designed primer panel. Amplicons were pooled, purified and cloned sequentially (Vk/Vl followed by VH) into 
the gIII display cassette of a newly designed phagemid vector (pCHV101; SMD, unpublished). A bacterial 
library of ~2x1010 colonies was generated following electroporation into E. coli TG1 cells. Phage library rescue 
was performed according to standard published procedures and single-use phage aliquots were stored in a 
stabilization buffer at - 80 °C.  
Streptavidin magnetic beads pre-coated with bSpyT and coated with SpyC-antigens (or coated directly with 
purified and biotinylated h/mTEM1 ECD) were used as solid-phase targets for phage display selections. The 
scFv phage libraries were first blocked with PBST containing 2% skimmed milk, 1% BSA for 30 min at RT, and 
then incubated for 30 min with streptavidin beads coated only with SpyC domain to subtract (‘de-select’) 
non-specific or SpyC-specific binders. Subsequently, blocked and de-selected phage particles were 
transferred to tubes containing similarly blocked SpyC-antigen beads, and incubation was continued at RT 
for 1 h.  Non-binding phage were removed by 5x 1 ml washes with PBST followed by 1x 1 ml PBS. Typically, 
the stringency of selection was increased at the second round by transferring the 5x 1ml PBST washed beads 
into a Falcon tube containing 50 ml PBST and allowing lower affinity phage to passively dissociate over 20 
min prior to rapid magnetic capture and final washing with 1ml 1x PBS. Bound phage were eluted from the 
beads with 200 µl of 20 µg/ml trypsin (Sigma Aldrich, #T1426) in PBS for 30 min at 37 °C (stationary). Eluted 
phage were allowed to infect minimal medium-grown E. coli TG1 cells grown to an OD600 of 0.4-0.5 in 10 ml 
of 2TY medium supplemented with 2 % glucose (2TYG) for 1 h at 37 oC (stationary). The infected cells were 
collected by centrifugation at 4000 rpm (RT), re-suspended in 3 ml 2TYG, and plated on 2TYAG agar with 
incubation at 30 oC for 18-20 h. Colonies were scraped from plates and the cells stored frozen in 2TYG 
containing 15 % glycerol pending further rounds of phage rescue and selection. Phage rescue between 
rounds was performed according to standard protocols using M13KO7 helper phage (Life Technologies, 
#18311019) added at a MOI of 5:1. Secreted phage were collected and purified by two rounds of PEG/NaCl 
precipitation according to standard protocols, and stored as frozen, single-use aliquots in a stabilization 
buffer. 
Clones were cultured for primary screening by picking individual colonies into 2TYAG liquid medium, growing 
until turbid and then inoculating cells into supplemented TB medium for the induction of protein expression 
as described above. 
Affinity maturation of anti-TEM1 clone candidates 
Selected scFv clones were subjected to random mutagenesis across the whole scFv, using error-prone PCR 
with the Diversify PCR random mutagenesis kit (Takara, #630703). The scFv was amplified in one, two or 
three subsequent rounds of PCR with 25 cycles in the presence of 640 µM MnSO4 and 40 µM dGTP in order 
to generate variants with low, intermediate and high mutational load. Mutated scFv library DNA was cloned 
into pCHV101 and electroporated into E. coli TG1 cells to generate libraries of ~109 colonies. Phage particles 
displaying the mutagenized scFv libraries were rescued and PEG/NaCl-precipitated before being used in high-
stringency affinity maturation selections against either purified bio-TEM1 (‘classical’ approach) or TEM1-SpyC 
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(dCI approach). In order to enrich for high-affinity, cross-reactive binders towards both human and murine 
TEM1 ECD, the first round of selection was performed against bead-immobilized bio-hTEM1 and the second 
round against bio-mTEM1. Both rounds included competition (‘off-rate selection’) with 200 nM free 
unlabelled antigen and an extended high-volume washing step of 50 ml PBST (30 min for R1 and overnight 
for R2). For the dCI approach, employed using the SpyC-hTEM1(Dn) fusion target, R1 beads were loaded with 
HEK expression supernatant diluted 1:10 in PBS with stringent washing following phage binding (6x 1 ml PBST, 
2x 50 ml PBST (20 min), 1x 1 ml PBS). For R2, the expression supernatant was diluted further (1:50) and the 
stringency increased with an additional 2x 50 ml PBST (20 min) washes.  For all experiments, random colonies 
were picked from the R2 selection output and sequenced to assess clone integrity and diversity prior to the 
initiation of screening. 2.5.2 Biophysical	and	biochemical	protein	characterization	
SDS-PAGE and Western Blotting 
To elute bound protein, SpyC-antigen coated beads were re-suspended in 1x LDS buffer (NuPAGE; Life 
Technologies, #NP0007) with 10 % reducing agent (NuPAGE; Life Technologies, #NP0009) and boiled at 95 °C 
for 10 min. The beads were pelleted by centrifugation and the eluted protein fraction was separated on a 
Novex 4-12% Bis-Tris Gel (Life Technologies, #NP0321) for 38 min at 200 V. Separated protein fractions were 
visualized by Coomassie Blue staining (InstantBlue; Expedeon, #ISB1L) or transferred to nitrocellulose 
membranes (iBlot2; Thermo Fisher Scientific, #IB23001). After blocking with 5 % milk/ PBST, the membranes 
were incubated with an HRP-conjugated anti-HA tag antibody (Thermo Fisher Scientific, #PA1-29751), diluted 
1:1000 in PBS containing 1 % BSA. Membranes were washed four times in PBST and HA-tagged protein was 
detected with an enhanced chemi-luminescent (ECL) HRP substrate (Thermo Fisher Scientific, #34080), 
followed by image acquisition using a Fusion FX imaging system (Vilber). 
Surface plasmon resonance (SPR) 
SPR analysis was performed on a Biacore T200 instrument (GE Healthcare). Experiments involving TEM1-SpyC 
ligand immobilization used a Series S SA sensor chip (GE Healthcare, #BR-1005-31). Briefly, 1 ml of crude 
TEM1-SpyC expression media was incubated with 1 µM of bSpyT at RT for 2 h with gentle rotation. The 
resulting covalent TEM1-SpyC:bSpyT complex was separated from free bSpyT by buffer-exchange into 1x 
filtered Biacore running buffer (HBS-EP+; 0.01 M HEPES, 0.15 M NaCl, 0.05% Surfactant P20, 3mM EDTA, pH 
7.4; GE Healthcare, #BR-1006-69) using a spin column with a 10 KDa cut-off (Vivaspin 6; GE Healthcare, # 
28932296). The biotinylated TEM1-SpyC ligand complex was immobilized on the SA chip at a density of 150 
RU. For kinetic analysis, analytes were diluted into running buffer and injections/dissociations carried out at 
30 µl/min with data collected in Single Cycle Kinetics mode. For Fc-capture experiments, 10000 RU of 
AffiniPure Goat Anti-Human IgG (Jackson ImmunoResearch, #109-005-098) were immobilized on a CM5 
Series S sensor chip (GE Healthcare, #BR-1005-30) by amine coupling according to the manufacturer’s 
instructions. Anti-TEM1 scFv-Fc molecules were captured at a target density of 100 RU and analytes were 
injected and dissociated at 30 µl/min with data acquired in Multiple Cycle Kinetics mode. Surfaces were 
regenerated between cycles/experiments by injecting 10 mM glycine-HCl, pH 1.5 for 30 s. Corrections for 
bulk shift and refractive index changes were performed by subtracting the signal of a reference flow cell from 
the active cell. 
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2.5.3 Binder	characterization	and	screening	assays	
 Enzyme-linked immunosorbent assay (ELISA) 
For screening of scFv clones (and variant molecules) by dCI SpyC-antigen ELISA, wash steps were performed 
using 300 µl PBST dispensed from a BioTek 405 automatic plate washer. Nunc Maxisorp 96-well plates 
(Thermo Fisher Scientific, #442404) were coated with 100 µl of 10 µg/ml Neutravidin (Life Technologies, 
#31000) in PBS over-night at 4 oC, washed 3x with PBST and incubated with 100 µl of 1 µM bSpyT peptide in 
PBS for 1 h at RT with gentle agitation. After blocking in 5 % skimmed milk/PBST for 1 h, wells were washed 
3x with PBST and 100 µl SpyC-antigen expression supernatants (typically diluted 1:10 in PBST + 1 % BSA for 
mammalian expression, or blocking buffer for bacterial expression) were added to allow covalent capture by 
the bound bSpyT. Incubation was at RT for 1.5 h. Wells were washed 4x with PBST and 100 µl blocked scFv 
culture supernatants added. Wells were washed 4x with PBST and binders were detected using a primary 
recombinant anti-myc tag antibody (derived from parental mAb clone 9E10, in-house) and a horseradish 
peroxidase (HRP) conjugated goat anti-mouse IgG antibody (Sigma Aldrich, #A9917). The colorimetric read-
out was developed with TMB substrate reagent (Biolegend, #34029) and stabilized with 2N sulfuric acid. 
Absorbance was measured at 450 nm and 620 nm on a BioTek Synergy plate reader. ELISAs were performed 
in parallel against both cognate antigen-SpyC and non-fused SpyC in order to eliminate hits to the latter. 
CD3-SpyC single-chain heterodimers were detected using 1 µg/ml of a murine anti-hCD3 antibody (clone 
UCHT1, Thermo Fisher Scientific, #MA1-80044) followed by a HRP-conjugated anti-HA tag antibody (Thermo 
Fisher Scientific, #PA1-29751; diluted 1:5000), or with UCHT1-scFv displaying phage particles revealed using 
an M13 antibody HRP conjugate (Sigma Aldrich, cat. 27-9421-01). For evaluation of cognate ligand binding 
to captured SpyC-antigens, purified bivalent hFc(IgG1)-fusions (hCD27, hCD80, hCD155, hPD-L1) or his-
tagged monomer (hMuc16) were purchased from R&D Systems. Ligands were diluted to 2 µg/ml in PBST + 
1% BSA and incubated for 1 h at RT. After washing, bound Fc-fusions and bound Muc16 were detected with 
goat anti-human IgG Fc polyclonal HRP conjugate (Sino Biologicals, #SSA001; 1:5000 dilution) or anti-His tag 
HRP conjugate (Genscript, #A00612; 1:1000 dilution) using TMB as substrate. 
Multiplexed bead-based no-wash screening assay using SpyC-fusion proteins 
For screening of scFv clones by mix-and-read bead multiplex assay, SpyC-fused antigens in expression 
supernatants were covalently captured on fluorescently barcoded streptavidin-coated beads (Spherotech 
yellow beads, #SVFB-2552-6K) using the dCI protocol described above. The antigen-coated bulk bead 
populations were combined and blocked in assay buffer (PBS/2%BSA/0.1% PBST/2mM EDTA/0.02% sodium 
azide) for 30 min on ice. Multiplexed beads (10 µl) were added to wells of a 96-well plate, followed by an 
equal volume of scFv-containing E. coli TG1 expression supernatants diluted 1:5 or 1:10 in assay buffer. After 
incubating on ice for 30 min, bound scFvs were detected by subsequent addition of 10 µl of an iFluor647-
conjugated anti-his tag antibody (GenScript, #A01802-100) at a final dilution of 1:200 in assay buffer. 
Following a further 20 min incubation on ice, the sample plate was read directly on an Intellicyt iQue TM 
Screener PLUS instrument (10 s sampling; 1 µl/s). Bead populations displaying different immobilized SpyC-
antigens were resolved by their respective barcoding fluorescence intensity (FITC), and scFv binding to each 
population was assessed by iFluor647-mediated median fluorescence intensity (MFI). Data analysis was 
performed using Forecyt software (Intellicyt). 
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mCD47:mSIRPa competition ELISA screening 
96-well ELISA plates were coated as described above with Neutravidin, bSpyT and mCD47-SpyC. Alternatively, 
plates were coated directly with 0.5 µg/ml commercially available his-tagged mCD47 (Sino Biologicals, 
#57231-M08H-50). Pre-blocked scFv expression supernatants (100 µl) were added to each well immediately 
followed by 100 µl of diluted HEK expression supernatant containing recombinant mSIRPa-Fc (hIgG1) fusion 
produced by transient transfection. Appropriate dilutions of mCD47-SpyC and mSIRPa-Fc that yielded signals 
within the linear part of the response curve were determined previously by chequerboard ELISA titration.  
Following incubation for 1 h, the bound mSIRPa-Fc levels were determined by colorimetric detection with 
goat anti-human IgG Fc polyclonal HRP conjugate (Sino Biologicals, #SSA001; 1:5000 dilution) using TMB as 
substrate. Neutralizing scFv clones were reformatted as murine IgG2a and purified. Their mCD47:mSIRPa-
blocking activity was confirmed in ELISA titration experiments alongside commercially available benchmark 
rodent mAbs (kindly provided by Irving Weissman lab, Stanford). All competitors were titrated in a 3-fold 
dilution series starting at 2.5 µg/ml and mixed 1:1 v/v (200 µl final) with in-house produced mSIRPa-Fc HEK 
supernatant before addition to the plate. After 1 h of incubation, binding of mSIRPa-Fc to plate-bound 
mCD47 was revealed by goat anti-human IgG HRP-conjugated antibody (Sino Biologicals, #SSA001; 1:5000 
dilution) followed by the addition of TMB substrate for colorimetric detection. 2.5.4 Cell	assays	
Cell culture  
A-673 (ATCC CRL-1598), 2H11 (ATCC CRL-2163), MS1 (ATCC CRL-2279) and HT-1080 (ATCC CCL-121) cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with GlutaMAX and 10 % fetal 
bovine serum (FBS). SK-N-AS (ATCC CRL-2137) and TC1 (ATCC CRL-2934) cells were additionally supplemented 
with 0.1 mM non-essential amino acids (Gibco, Life Technologies, #11140050). HEK293T (ATCC CRL-11268) 
cells were cultured in DMEM, 10% FBS and 100 U/ml penicillin/streptomycin (Gibco, Life Technologies, 
#15140122). MDA-MB-231 (ATCC HTB-26), NCI-H226 (ATCC CRL-5826), AsPC-1 (ATCC CRL-1682), Raji (ATCC 
CCL-86), A-20 (ATCC TIB-208), A-20_CD47KO (kindly provided by Irving Weissman lab, Stanford) and Jurkat 
NFAT Lucia cells (Invivogen, #jktl-nfat) cells were cultured in RPMI-1640 Glutamax (Life Technologies, 
#61870010) containing 10% FBS. A-20 cells were additionally supplemented with 0.05 mM 2-b-
mercaptoethanol and Jurkat Lucia cells were maintained under selective pressure using 100 µg/ml zeocin 
(Invivogen, #ant-zn-1). All cells were maintained at 37°C, 5% CO2 in a humidified incubator and the absence 
of mycoplasma from all cell lines was confirmed by regular testing (GATC service). 
Peripheral blood mono-nucleated cells (PBMCs) were isolated from fresh buffy coats by density 
centrifugation using Lymphoprep (Axonlab, #1114545). T cells were subsequently extracted by magnetic 
separation using a human pan-T cell isolation kit (Miltenyi Biotec, #130-096-535) and stimulated with human 
T cell activator CD3/CD28 beads (Life Technologies, #11161D) and 50 RU IL-2 (Peprotech, #200-02-50UG) for 
5 days. After the removal of the beads, primary T cells were further expanded with IL-7 and IL-15 (Miltenyi 
Biotec, #130-095-367 and #130-095-765) for a further 5-10 days. 
Flow cytometry 
Adherent cells were detached using 10 mM EDTA, counted and resuspended in fresh, complete culture 
medium. All subsequent steps were performed on ice. For each sample, 0.5 x 106 cells were first blocked in 
FACS buffer (5 % FBS in PBS) and then incubated for 1 h with test antibody (typically 1-2 µg/ml) or expression 
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supernatant diluted in FACS buffer. After washing three times with FACS buffer, the following secondary 
antibodies were added: Alexa Fluor 647 AffiniPure Goat Anti-Human IgG (Jackson Immunoresearch, #109-
605-098, 1:200 dilution) or Alexa Fluor 647 anti-mouse IgG (Life Technologies, #A-21236, dilution 1:50). 
Secondary antibodies were incubated for 30 min and the cells were washed again three times. Immediately 
before data acquisition, dead cells were stained with 4ʹ,6-Diamidino-2-phenylindole (DAPI, 1:2000 dilution). 
Data was acquired using an LSR-II flow cytometer equipped with FACSDIVA software (BD Biosciences). Data 
analysis and plotting were carried out using FlowJo v10 (FlowJo LLC). 
Lentiviral transduction of Jurkat NFAT Lucia cells 
Sequences encoding human anti-mesothelin scFvs or an anti-CD19 scFv (FMC63; extracted from Sequence 2, 
patent US7446179) were linked to a spacer/hinge, transmembrane region and intracellular costimulatory 
domain derived from the hCD28 costimulatory domain, and to an intracellular hCD3z signaling domain. The 
resulting 2nd generation CAR cassettes were appended to an in-frame monomeric green fluorescent protein 
ORF (TagGFP2, Evrogen) and cloned into a modified pRRL lentiviral vector (Origin: Didier Trono lab, 
EPFL).  Virus was produced by transient transfection of HEK293T cells using pCMVR8.74 and pMD2.G 
plasmids for packaging (Origin: Didier Trono lab, EPFL) and Turbofect transfection reagent (Life Technologies, 
#R0532). Virus-containing supernatant was harvested after 48 h, concentrated by ultracentrifugation and 
added directly to 5 x 105 Jurkat NFAT Lucia cells. Transduced cells were expanded for 10-14 days before 
performing functional assays. 
Jurkat NFAT activation reporter cell assays 
For CAR and soluble engager assays designed to measure ITAM-mediated ‘Signal 1’ activation responses, 5 x 
104 target cells were seeded in 96-well plates and allowed to attach for 20 h. Subsequently, 105 Jurkat NFAT 
Lucia reporter cells were added to each well. For activation assays using T cell engager molecules, molecules 
were added in 3-fold serial dilutions, starting from 20 nM. Phorbol myristate acetate (PMA)/ionomycin was 
included as a positive response control. After 24 h of co-culture, the supernatants were collected and mixed 
with an equal volume of QUANTI-Luc luciferase substrate (Invivogen, #rep-qlc-1). Luminescence was 
measured immediately using a BioTec H1MFG Synergy plate reader. For functional analysis of anti-CD3 scFv-
SpyC fusions, TG1 E. coli expression supernatants were added to Neutravidin/bSpyT-coated 96-well Maxisorp 
plates and incubated for 2 h at RT to allow covalent capture of fusions. After washing (5x PBST, 2x PBS), Jurkat 
Lucia reporter cells were added and secreted luciferase determined as above. 
Primary T cell cytotoxicity assay 
Specific target cell killing was assessed using real-time kinetic cell imaging (Incucyte system, Essen 
Bioscience). Target and control cells (1.5 x 104) were seeded in 96-well plates prior to the start of the 
experiment. When approximately 30 % confluency was observed, soluble T cell engager molecules were 
added as 3-fold serial dilutions, starting from 20 nM. Positive control test wells were treated with 1 % Triton 
X-100. Primary human T cells prepared and expanded as described above were added to the plates (105 per 
well) to obtain an E:T ratio of approximately 5:1. Cytotox Red reagent (Essen Bioscience, #4632) was added 
to a final dilution of 1:4000, and resultant cell death was monitored as an increase in fluorescence over time. 
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2.6 Supplementary	Information	
 
Supplementary Figure 2.1. Production and functional evaluation of mammalian antigen-SpyC fusions. 
(a) Prokaryotic and eukaryotic expression vector cassettes used for the production of SpyC-fused proteins. SP, signal peptide; POI, 
protein of interest, ‡pSTEVe20 is an earlier variant of pSTEVe38 comprising the original non-codon optimized SpyC sequence and a 
histidine-tag; (b) The expression and secretion of single-chain hCD3 heterodimer-SpyC fusions in E. coli TG1 using vector pSTEVe16. 
Bead capture from culture supernatants is dependent on the presence of SpyT on the beads (Western blot detection of intact fusion 
protein via anti-HA tag ECL). (c) Secreted CD3-SpyC heterodimers were directly captured from bacterial media using plate wells pre-
coated with Neutravidin and bSpyT, and detected by anti-HA tag and UCHT1 (as both IgG and as a scFv-phage reagent. (d) 
Functionality of a panel of anti-CD3 scFv-SpyC fusions (parental IgG names retained) expressed and secreted from E. coli.  Fusions 
captured on Neutravidin/SpyT coated assay plates retain the functional ability to cross-link native human cell surface CD3 and 
stimulate NFAT-driven secretion of luciferase from a Jurkat NFAT reporter cell line. The anti-murine CD3 clone, 145-2C11, does not 
recognize hCD3 and was included as an additional negative control. NT, non-transformed; PMA, phorbol myristate acetate. 
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Supplementary Figure 2.2. Full Western Blot analysis of captured SpyC-antigens. 
(a) Full-sized anti-HA tag Western Blot image corresponding to Fig. 2.1c. Representative SpyC-antigens were expressed in HEK293-6E 
cells and directly captured from the expression supernatant (‘S’) onto bSpyT-loaded magnetic beads (‘B’). Covalent immobilization to 
SpyT on the beads results in a shift to a higher MW corresponding to the mass of the peptide adduct. (b) Additional SpyC-antigens 
that were captured and analyzed as described above. Samples were run on separate gels in the presence of additional undisclosed 
samples and controls, but were processed in parallel. Only relevant lanes of full-sized images are shown with their respective size 
marker. 
 
a
b
Supplemen ry Figu e S2
Full uncropped image of the Western Blot data shown in Figure 1c and Western Blot analysis of additional 
SpyC-antigens. (a) Full-sized anti-HA tag Western Blot image corresponding to Fig. 1c. Representative 
SpyC-antigens were expressed in HEK293-6E cells and directly captured from the expression supernatant 
(‘S’) onto bSpyT-loaded magnetic beads (‘B’). Covalent immobilization to SpyT on the beads results in a shift 
to a higher MW corresponding to the mass of the peptide adduct. (b) Additional SpyC-antigens that were 
captured and analyzed as described above. Samples were run on separate gels in the presence of additional 
undisclosed samples and controls, but were processed in parallel. Only relevant lanes of full-sized images 
are shown with their respective size marker.
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Supplementary Figure 2.3. Multiplexed bead-based primary screening of scFv clone supernatants from hTEM1(Dn) R2 selection 
outputs. 
(a) Barcoded streptavidin beads were pre-loaded with bSpyT prior to dCI of the respective antigens from HEK expression 
supernatants. The resulting 4-plex comprises (from top/brightest): hTEM1(Dn)-SpyC, mTEM1(Dn)-SpyC, SpyC-domain only, hEGFRvIII-
SpyC. Expanded panels: (i) irrelevant scFv supernatant (negative control); (ii) scFv specific for EGFRvIII (positive control); (iii) 
representative screening ‘hit’ (HS301) selective for hTEM1(Dn); (iv) binding profile of purified HS301 scFv-Fc towards endogenous 
TEM1+ (A673) and TEM1- cell lines (isotype staining control as grey curve). (b)  Bead-based multiplex MFI distribution plot of binders 
to SpyC-hTEM1(Dn) coated beads obtained following error-prone mutagenesis of the HS301 parental clone and two stringent dCI 
selection rounds against SpyC-hTEM1(Dn). Hit threshold was set at 5x background with no binding to mesothelin-SpyC or control 
SpyC coated beads. Multiple occurrences of enriched point-mutated variants of interest clustering at significantly higher MFI values 
than the parent are indicated.  MFI, median fluorescence intensity. 
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Supplem ntary Figur  3
Multiplexed, no-wash bead-based primary screening of bacterial scFv clone supernatants from dCI-se-
lected hTEM1(Δn) R2 selection outputs. (a) Barcoded streptavidin beads were pre-loaded with bSpyT 
prior to dCI of the respective antigens from HEK expression supernatants. The resulting 4-plex comprises 
(from top/brightest): hTEM1(Δn)-SpyC, mTEM1(Δn)-SpyC, SpyC-domain only, hEGFRvIII-SpyC. 
Expanded panels: (i) irrelevant scFv supernatant (negative control); (ii) scFv specific for EGFRvIII (posi-
tive control); (iii) representative screening ‘hit’ (HS301) selective for hTEM1(Δn); (iv) binding profile of 
purified HS301 scFv-Fc towar s endogenous TEM1+ (A673) and TEM1- cell lines (isotype staining c ntrol 
as grey curve). (b)  Bead-based multiplex MFI distribution plot of binders to SpyC-hTEM1(Δn) coated 
beads obtained following rror-prone mutagenesis of the HS301 parental clone nd two stringent dCI 
s lection rounds against SpyC-hTEM1(Δn). Hit threshold was set at 5x background with no binding to 
mesothelin-SpyC or control SpyC coated beads. Multiple occurrences of enriched point-mutated variants 
of interest clustering at significantly higher MFI values than the parent are indicated.  MFI, median 
fluorescence intensity.
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Supplementary Figure 2.4. SPR affinity measurement of clone HS06 and a matured variant HS06mut. 
SPR monovalent affinity determination of parental clone HS06 (left) and an affinity-matured variant, HS06mut (right), using 
HS06/HS06mut scFv-Fc as the immobilized ligand. Soluble hTEM1-FL analyte concentration ranges were 100, 50, 25, 12.5 and 0 nM 
for HS06, and 5, 2.5, 1.25, 0.625 and 0 nM for HS06mut. hTEM1-FL, full-length human TEM1 ECD (NS0 cells; R&D Systems, #7855-CD-
050). 
 
 
Supplementary Figure 2.5. Characterization of a mCD47-targeted neutralizing antibody Isolated by SpyC-fusion dCI phage display 
selection and screening. 
(a) Competitive blocking of the interaction between soluble mSIRPa-Fc and immobilized mCD47. Dashed lines: Commercial his-tag 
purified mCD47 coated by passive adsorption. Solid lines: mCD47-SpyC captured and immobilized directly from expression media on 
Neutravidin/bSpyT pre-coated wells. Reference/control antibodies: Black, 9E10 mIgG1 (isotype control); blue, MIAP301 rIgG2a 
(commercial neutralizing mAb); red, dCI mCD47-SpyC selected clone MS115 mIgG2a; gold, MIAP410 mIgG1 (commercial neutralizing 
mAb). (b) Specific recognition of endogenous mCD47 on murine B cell lymphoma cell line A-20 by clone MS115. Cell binding was 
assessed by flow cytometry in the scFv-Fc (hIgG1) format at 10- and 100-fold dilution of transient HEK expression supernatant. 
0 100 200 300 400 500
0
20
40
60
80
0 100 200 300 400 500
0
50
100
150
HS06_VH_CDR3
R
U
HS06mut_VH_CDR3
CASLTSYYGDPTGFDYW CASLISYYGDPTGFDYW
KD � 80 nM KD � 1 nM
time (sec)
Supplementary Figure S4
SPR monovalent affinity determination of parental clone HS06 (left) and an affinity-matured variant, 
HS06mut (right), using HS06/HS06mut scFv-Fc as the immobilized ligand. Soluble hTEM1-FL analyte 
concentration ranges were 100, 50, 25, 12.5 and 0 nM for HS06, and 5, 2.5, 1.25, 0.625 and 0 nM for 
HS06mut. hTEM1-FL, full-length human TEM1 ECD (NS0 cells; R&D Systems, #7855-CD-050).
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Screening 
Plate 
Target Antigen Library Round # Target 
binders 
% Hit 
Rate‡ 
# SpyC 
binders 
% SpyC 
binders* 
MP01 hTEM1-SpyC CHV101_DMl R2 49 55.7 1 4.5 
MP02 hTEM1-SpyC CHV101_DMk R2 37 42.0 1 4.8 
MP03 mTEM1-SpyC CHV101_DMl R2 60 68.2 1 2.3 
MP04 mTEM1-SpyC CHV101_DMk R2 39 44.3 0 0.0 
MP07 hMeso-SpyC CHV101_DMl/k R2 52 59.1 0 0.0 
MP37-40 hMeso-SpyC CHV101_DMk R2 175 11.9 0 0.0 
MP1914 spyC-hCD19 CHV101_DMl/k R2 23 6.3 4 1.1 
MP1915 spyC-hCD19 CHV101_DMl/k R3 40 10.9 11 3.0 
MP4701 mCD47-spyC CHV101_DMl R2 10 11.9 4 4.8 
MP4702 mCD47-spyC CHV101_DMk R2 1 1.2 1 1.2 
MP4703 mCD47-spyC CHV101_DMl/k R2 8 9.5 3 3.6 
Supplementary Figure 2.6. Hit rates and frequency of SpyC-binders in selected dCI discovery projects. 
Primary screening metrics illustrating respective primary ELISA hit-rates and frequencies of SpyC-reactive clones for selected scFv 
discovery projects using SpyC-antigens. Hit rates represent the frequency of clones binding to the respective SpyC-antigen in a 
primary screening. These hits were subsequently re-arrayed and screened for SpyC-reactive clones, the frequency of which is shown. 
Rd, selection round; ‡ signal threshold > 5x background. * signal threshold > 3x background.  
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 De	 novo	 discovery	 of	 a	 diverse	panel	 of	 fully	 human	 scFvs	 targeting	extracellular	regions	of	native	TEM1	
 
This chapter describes the de novo discovery of novel scFv binders to different extracellular regions of human 
TEM1. The resulting fully human antibodies represent ideal candidates for the development of various 
therapeutic and diagnostic applications focusing on TEM1 as a biomarker and/or drug target. 
 3.1 Introduction	
Tumor cell maintenance and growth requires support from surrounding cells which constitute the tumor 
stroma353,354. The stromal compartment represents a heterogeneous mixture of cells which interact and 
evolve with the tumor cells to form a favorable microenvironment. As part of this microenvironment, 
fibroblasts build and remodel the extracellular matrix (ECM) and contribute to tumor invasion355. Once solid 
tumors reach a diameter of 1-2 mm, the formation of supporting blood vessels is essential for ensuring the 
supply of oxygen and nutrients253. The sprouting of new vessels from existing vasculature is termed 
angiogenesis, a process that is not only critical for tumor development, but also for physiological and 
embryonic tissue growth, as well as for wound healing356,357. Multiple molecular and cellular adaptations are 
required for angiogenesis to take place. Fibroblasts secrete ECM proteins that constitute a structural scaffold 
for proliferating endothelial cells as well as tumor cells355. Surrounding the endothelial cells, pericytes 
additionally support and stabilize the sprouting vessels358. Tumor angiogenesis is however an erroneous 
process, resulting in a disorganized network of often unstable vessels with incomplete pericyte coverage that 
is clearly distinct from physiological vasculature254,256. In light of the critical role of the tumor 
microenvironment in supporting tumor progression, extensive efforts have been undertaken to identify 
specific markers of the tumor stromal and neoangiogenic cell compartments.  
Tumor Endothelial Marker 1 (TEM1), also called endosialin or CD248, was first discovered as a surface antigen 
present on tumor stromal cells as well as malignant cells of mesenchymal origin264. An independent study 
then identified the same protein as a marker of primary tumor endothelium265. Since then, extensive gene 
expression studies have confirmed TEM1/endosialin as a surface antigen upregulated within the tumor neo-
vasculature and stroma of various human carcinomas including, but not limited to, colorectal cancer272, 
breast cancer274, and invasive glioblastoma275. Moreover, malignant cells of mesenchymal origin, such as 
sarcoma271,276 and melanoma359,360, have been found to express TEM1 directly. More detailed 
characterization of the tumor stromal compartment has revealed TEM1 expression mainly on tumor-
associated pericytes and fibroblasts, with very low levels detected in healthy adult (micro)vasculature266. 
In contrast to the expression pattern of TEM1 under physiological and pathological conditions, the molecular 
function of the protein remains elusive. The observation that TEM1 knockout mice appear to develop 
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normally and display functional wound healing suggests that TEM1 is dispensable for angiogenesis during 
fetal development and wound healing. However, the lack of TEM1 within the tumor microenvironment 
greatly reduced tumor growth, invasion and metastasis in an orthotopic colorectal cancer model290, 
indicating that stromal TEM1 expression promotes tumor growth. Structural homology of the extracellular 
domain (ECD) with two receptor proteins, thrombomodulin and C1qRp (CD93), suggest that TEM1 might be 
a cell surface receptor and indeed, TEM1 was shown to bind to fibronectin and collagen types I and IV292. 
Responsible for this interaction is the N-terminal c-type lectin-like domain (CTLD), which is followed by a 
sushi-like domain and three EGF repeats. These three extracellular domains are separated from the 
membrane by a heavily O-glycosylated sialomucin stalk288. In light of the complexity of the TEM1 ECD and 
given the absence of structural information, it remains to be determined which region(s) are critical for any 
tumor-promoting role of the molecule. 
Given the high incidence of TEM1 expression within the tumor vasculature of many different tumor types as 
well as the majority of human sarcomas, TEM1 represents an attractive new target for the development of 
anti-cancer therapies271. Antibodies remain indispensable tools for targeted cancer therapies, and so a 
handful of antibodies targeting TEM1 have been developed. Among those, a humanized version of the 
monoclonal antibody used to originally identify TEM1, called ontuxizumab (MORAb-004), has been shown to 
decrease TEM1-levels on pericytes through antibody-mediated internalization, resulting in dysfunctional 
tumor microvasculature and impaired tumor growth298. Underlining a potential role for TEM1 in supporting 
neo-angiogenesis and promoting tumor growth, these findings have prompted the clinical investigation of 
MORAb-004 for the treatment of relapsed or refractory solid tumors300-302. The first fully human antibody 
against TEM1, termed scFv78306, has been investigated as a tool for solid tumor imaging and as an antibody-
drug-conjugate (ADC)308,309,335.  
Given the dual expression profile and cryptical biological function of TEM1, it is likely that multiple 
therapeutic approaches will be needed to explore the full potential of TEM1-targeting in cancer. Moreover, 
targeting strategies directed at disrupting stroma-modulating functions versus T cell mediated elimination of 
TEM1-positive cells, may require distinct and different molecular properties in the targeting antibody entity.  
Here we describe the generation of a panel of novel fully human scFv clones using phage display and our 
previously developed dCI methodology. The isolated clones are characterized as having different biophysical 
properties and as recognizing different epitopes of the TEM1 protein. These newly available scFv clones will 
critically contribute to the development of TEM1-directed anti-cancer therapies, particularly engineered 
immunotherapy approaches. 
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3.2 Results	3.2.1 De	novo	discovery	of	a	panel	of	fully	human	scFv	clones	recognizing	TEM1	using	phage	display	
As part of the validation of our newly developed dCI methodology (chapter 2), we first expressed the 
extracellular domain of human or murine TEM1 (N-terminal mature 353 and 460 amino acids, respectively) 
as SpyCatcher fusions using a mammalian HEK293-6E transient expression system. Capturing these fragments 
directly onto SpyT-coated streptavidin beads, they served as antigens for two rounds of phage display 
selection using large, fully human and essentially germline naïve scFv libraries (pCHV101_DMk and 
pCHV101_DMl)361. In this case both libraries, encompassing the respective lambda and kappa light chain 
repertoires were kept separate during phage display selection (Fig. 3.1a). All four selection branches showed 
strong enrichment for binders at round two (see Table 2.2) and ELISA screening of the selection outputs 
revealed high hit frequencies for both antigens and for both lambda and kappa libraries (Fig. 3.1b and Table 
2.2). After confirming that all hits also recognized the corresponding purified full length ECDs of h/mTEM1 
(mature 668 and 680 residues, respectively), unique hits were screened for human/murine cross-reactivity 
(Fig. 3.1c and d) and the strongest ELISA hits were sequenced. Sequence analysis revealed considerable clonal 
diversity (Fig. 3.1e and f) with ~83 % of clones representing a unique sequence (Table 3.1). Finally, the 15 
unique cross-reactive clones with the strongest binding signals were selected for downstream 
characterization.  
 
clone 
VH VL 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
1C1 GGTFSSYA IIPIFGTA ASLTSYYGDPTGFDY SSNIGSNT SNN AAWDDSLNALV 2.94 
1C10 GGTFSSYA IIPILGIA ARGYYYDSSGYYYNYYYGMDV SSNIGAGYD GNS QSFWV 2.94 
1F7 GYIFSGYY IDPNSGAT AREERFFAAPAFDY SSNIGDNY RNN AVWDDSLNGWV 2.94 
1H1 GYTFTRYG ISASNDNT ARDKCSSSDCFARAGHYYNGMDV KLGDKY QDS QAWDSGTDVV 2.94 
2B11 GFTFNTYT ISSSSTYI AKSIVGATHDAFDI QSISRW DAS QQYKNYSPT 2.94 
2B6 GYTFTSYY INPSGGST ARANDWLLGGALDY QSVSSSY GAS QQYGSSPRA 2.94 
2C6 GFTFDDYA ISWNSGSI AKDWNYGSGSYYNPYFDY QGISSW AAS QQANSFPLT 2.94 
2D11 GYTLTELS FDPEDGET ATAQRGWYGGGYYFDY QGISSW AAS QQANSFPPFT 2.94 
2G3 GFTFSSYG ISYDGSNK AKDQGYYDFWSGYLDY QSISSW KAS QQSYSTPQT 5.88 
2H11 GGTFSSYA IIPIFGTA ARVSGDGHPLNWFDP QSFTS EAS QQYNNYPIS 2.94 
3B6 GYTFTGYY INPNSGGT ARVRGSHPWFDP SSNIGINT STY ATWDDSLNGVV 8.82 
3C7 GFTFSYFA ISSGGGST ATVYYGSGEADY SSDIGGYNY EVT FSYAGSNNFI 2.94 
3D1 GYTFASYG INTYNDNT AREGYRGNDNYYYKYGMDV SSNIGAGYD GNS QSYDSSLSGSRVV 8.82 
3E5 GYTFTSYG IIPIFGTA ARDSSGYGGWFDP NIGSKS YDS QVWDSSSDHVV 2.94 
3E6 GYTFTSYY INPSGGST AREWFGGAHFDY SDINVGSYN YYSDSDK MIWPSNASGV 2.94 
3F11 GGTFSSYA IIPIFGTA AREDYGGNSRPLAFDI SSNIGSNT SNN FSYAGSNNFI 2.94 
3F2 GGTFSSYA IIPIFGTA ARDPIIYYYGMDV SSDVGGYNY DVS SSYTHTGALV 2.94 
3F4 GGTFxNYA INTNTGNP ARNPSYCSST    2.94 
4A1 GGSISSSNW IYHSGST ARGNWYFDL QSVSSSY DAS QHYGDSVYT 2.94 
4D4 GYTFSSYG VSPNTGNI ARDAERNGGFAEAWLDP QSIRSW EAS QQYNVYFRT 2.94 
4D8 GFTFSSYG ISSSGSTI ARGGGYSYGFDY QSISSY AAS QQSYSTPLT 2.94 
4E11 GYTFKNYG ISAYNGNI AR SGESNA DAS KxxYRNFLS 2.94 
Table 3.1. CDR amino acid sequences and frequencies of TEM1-ECD binders. 
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Figure 3.1. De novo discovery of a panel of fully human scFv clones using phage display. 
(a) Schematic representation of the phage display selection process for the discovery of scFv binders. (b) Heatmap representation of 
primary ELISA screenings of soluble scFv clones against plate-bound h/mTEM1-SpyC antigens. Phage display outputs of lambda (l) 
and kappa (k) light chain libraries were screened separately. (c, d) SpyC-ELISA screening of re-arrayed hits illustrating the high 
frequency of human/murine cross-reactive binders. Soluble scFvs selected against hTEM1 were screened for binding of mTEM1-SpyC 
(c) and vice versa (d). Green bars represent positive controls sc78 (c) or MORAb-004 (d). (e) Clonal diversity of cross-reactive TEM1-
binders. Each segment of the pie chart represents a unique clone sequence. Highlighted clones will be discussed below. (f) Heavy 
chain CDR3 length distribution among selected cross-reactive clones. 
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3.2.2 Functional	screening	of	anti-TEM1	scFv-Fc	candidates	
To facilitate functional testing and detection, these 15 clones were reformatted in scFv-Fc format by fusing 
the scFv to the constant domain of human IgG1 (Fig. 3.2a), and transiently expressed in HEK293-6E cells. With 
one exception, all clones expressed robustly in this system and showed concentration-dependent binding to 
biotinylated hTEM1 in an ELISA titration experiment (Fig. 3.2b).  
 
Figure 3.2. Functional screening of anti-TEM1 scFv-Fc candidates. 
(a) Schematic representation of an scFv-Fc fusion protein. (b) ELISA titration of anti-TEM1 scFv-Fc candidates (mammalian expression 
supernatants diluted 1:10) against plate-bound hTEM1 ECD. TEM1 coating density ranging from 0.1 to 100 nM. (c) The comparative 
mRNA expression of TEM1 was quantified by RT-qPCR. TEM1 mRNA levels were quantified based on the comparative threshold 
method and are presented relative to glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). A673, Ewing’s sarcoma; SK-N-AS, 
neuroblastoma; H2-226, mesothelioma; MDA-MB-231, mammary carcinoma; AsPC-1, pancreatic adenocarcinoma; HEK293, 
embryonic kidney epithelium; 2H11, murine tumor vascular endothelium; MS1, murine pancreatic islet endothelium; hECD, 
extracellular domains of human TEM1; hMuc, sialomucin stalk region of human TEM1.(d) Exemplary flow cytometry ranking 
experiment illustrating the differential binding of a panel of scFv-Fc clones to endogenous TEM1-expressing cell lines A673 and SK-N-
AS and to TEM1-negative HEK293-6E and MS1 cells. (e) Clones with higher or equivalent MFI binding signals compared to sc78-Fc 
were serially diluted and titrated against A673 cells. scFv-Fc concentrations ranging from 0.25 ng/ml to 2 µg/ml. CH2/3: hIgG1 heavy 
chain constant domain 2 or 3. MFI: median fluorescence intensity. PE: phycoerythrin. 
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Next, we aimed to identify scFv clones that would be able to specifically recognize native TEM1 on the cell 
surface. To this end, we incubated our candidate scFv-Fc clones with A673 Ewing’s sarcoma cells or 
endothelial 2H-11 cells, expressing endogenous human or murine TEM1, respectively. Similarly, we incubated 
the scFv-Fc panel with HEK293-6E and MS1 cells, which were confirmed to be negative for TEM1 (Fig. 3.2c). 
These flow cytometry-based functional screening experiments allowed us to eliminate certain false-positive 
clones that did not show any binding to native (human) TEM1 in the scFv-Fc format, and confirmed human-
murine cross-reactivity for the majority of the hTEM1 binders. Several iterations of such ranking experiments 
identified six top candidates, selected primarily by equal or higher binding signals compared to the current 
benchmark clone sc78 (Fig. 3.2d). Those lead candidates were then serially diluted and titrated against 
hTEM1-expressing A673 cells. In this way, we intended to gain insights into the relative functional binding 
affinities/avidities of these new scFv-Fc clones. Although all clones recognized A673 cells in a concentration-
dependent manner, three candidates, 1C1, 2B11 and 3B6, displayed higher apparent binding affinities and 
so were chosen for subsequent biophysical characterization alongside the published benchmark clone sc78 
(Fig. 3.2e). 3.2.3 Novel	anti-TEM1	candidates	display	favorable	biophysical	properties	and	span	a	wide	range	of	affinities	towards	hTEM1.	
One important metric for the characterization of antibodies is their monovalent affinity towards their 
cognate targets. We therefore determined the affinities of 1C1, 2B11 and 3B6 to the ECD of human TEM1 by 
surface plasmon resonance (SPR). Multiple-cycle kinetics data obtained for the purified binders in a simple 
monovalent bispecific T cell engager (BiTE) format revealed the following affinities: 22 nM for 1C1, 390 nM 
for 2B11 and 115 nM for 3B6 (Fig. 3.3a). These modest affinities are in line with our expectations for 
antibodies isolated from naïve natural germline repertoire libraries. Although higher than previously 
recorded, the monovalent affinity for 1C1 obtained in this experiment is comparable with the values obtained 
for the same clone using a different experimental set-up (68 nM and 80 nM, respectively; see chapter 2). The 
higher KD obtained with 1C1 BiTE may be caused by possible aggregates of this experimental format. 
Another parameter that is considered to impact on the developability and performance of scFv-based 
therapeutics is the stability of the scFv. Differential scanning fluorimetry (DSF) measurements revealed first 
thermal unfolding transitions occurring at 70.2 °C for 1C1, 75.0 °C for 2B11 and 64.9 °C for 3B6 (Fig. 3.3b). 
Encouragingly, the stability of our panel of novel TEM1-binders appeared comparable or superior to the 
current benchmark clone, sc78 (63.3 °C).  
Furthermore, in order to map the relative epitope locations targeted by our anti-TEM1 clones, we subjected 
them to a competition ELISA experiment, where each scFv competed with each scFv-Fc molecule for binding 
of immobilized hTEM1 ECD. Figure 3.3c shows that 1C1 competes with 2B11 for the binding of hTEM1, while 
2B11 only incompletely displaces 1C1, presumable due to the far lower affinity of the molecule. Thus, 1C1 
and 2B11 seem to be targeting an overlapping, but clearly distinct epitope, since in contrast to 1C1, 2B11 
binds mouse TEM1 very efficiently (compare Fig. 3.2d and Fig. 2.3a). 3B6 however binds to a distinct site on 
the TEM1 ECD. It is worth noting also that the benchmark clone sc78 binds to a different epitope close to the 
mucin stalk, which is absent in the ECD fragment used for our phage display selections306.  
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Figure 3.3. Biophysical and functional characterization of anti-TEM1 scFv clones. 
(a) SPR monovalent affinity determination of anti-TEM1 clones 1C1, 2B11 and 3B6. Biotinylated hTEM1 has been used as the 
immobilized ligand and monovalent anti-TEM1 bispecific T cell engagers (BiTE) as the soluble analyte, with concentration ranges of 0 
nM, 8 nM, 40 nM, 200 nM and 1 µM. (b) DSF measurement of the thermostability of anti-TEM1 scFv-Fc clones. Protein unfolding in 
response to temperature allows interaction and fluorescence of a hydrophobic reporter dye. ScFv melting temperatures are 
calculated using the derivative of the fluorescence signal. (c) ELISA competition of bacterial expressed scFv and purified scFv-Fc clones 
for binding of immobilized hTEM1 (0.5 µg/ml). A decrease in signal (anti-human Fc-HRP detection) indicates competition of the scFv. 
(d) SPR monovalent affinity determination of 1C1 and the affinity-matured variant 1C1m. mTEM1-SpyC has been immobilized on a 
streptavidin-chip and monovalent BiTEs have served as the soluble analyte. Analyte concentration ranges were 0 nM, 62.5 nM, 125 
nM, 250 nM and 500 nM for 1C1 and 0 nM, 1.25 nM, 2.5 nM, 5 nM and 10 nM for 1C1m. (e) IHC of the developing murine retina (P5) 
using 1C1m-Fc as a primary antibody. 1C1m staining (white) co-localizes with a subset of pericytes (stained against NG2; red). Cryo-
sections of Lewis lung carcinoma (f) and (g) MC38 colon carcinoma xenografts were stained with 1C1m-Fc (red) or anti-NG2 (white). 
Endothelial cells are stained in green (pecam) and nuclei are visualized with DAPI. 1C1m-Fc staining signal overlaps with TEM1 
expression on a subset of pericytes and fibroblasts within the tumor stromal compartment (f, g). IHC experiments were performed 
by Laureline Wetterwald, Tatiana Petrova lab, UNIL. 
time (s)
R
U
0 100 200 300 400 500
0
50
100
150
KD ≈ 22 nM
1C1
0 100 200 300 400 500
0
50
100
150
KD ≈ 390 nM
2B11
0 100 200 300 400 500
0
50
100
150
KD ≈ 115 nM
3B6
a
b
e
c
1C1-Fc 2B11-Fc 3B6-Fc
0.0
0.5
1.0
1.5
no
rm
al
iz
ed
 O
D
45
0
no scFv
1C1-scFv
2B11-scFv
3B6-scFv
0 200 400 600 800 1000
0
50
100
0 200 400 600 800 1000
0
50
100
150
time (s)
R
U
1C1 1C1m
KD ≈ 196 nM KD ≈ 6 nM
d
f g
Temperature 
D
er
iv
at
iv
e 
sc78-Fc 1C1-Fc 2B11-Fc 3B6-Fc
63.3°C 70.2°C 75.0°C 64.9°C
Pecam NG2
TEM1
developing retina (P5)
Pecam
Lewis lung carcinoma
PecaNG2 TEM1 DNA
MC38 colon carcinoma
PecaNG2 TEM1 DNA
De novo discovery of a diverse panel of fully human scFvs targeting extracellular regions of native TEM1 
 
 
62 
As described in chapter 2, all of the clones were able to stain several endogenous TEM1 expressing cell lines 
as well as HEK293T cells transfected with full-length TEM1, but not confirmed negative cell lines (Fig. 2.3a). 
These functional binding assays also revealed the significantly reduced binding of 1C1 to murine TEM1+ cells, 
which was further confirmed by SPR affinity measurements (KD = 196 nM; Fig. 3.3d). 3.2.4 Affinity	maturation	of	selected	candidates	
Given the relatively modest affinities of our panel of anti-TEM1 clones, we performed affinity maturation of 
the scFv by directed evolution. To this end, the whole scFv coding sequence was subjected to random 
mutagenesis using error-prone PCR. The resulting three mutant libraries were then either panned separately 
against hTEM1, or combined and panned consecutively against human and murine TEM1. In both cases, 
stringent washing conditions and intra-experimental competition were applied to select for high-affinity 
binders. Limited sequencing of the selection outcomes after two rounds of selection revealed a striking 
enrichment of a threonine to isoleucine mutation in the CDR3 loop of the heavy chain of 1C1 in the cross-
reactivity selection branch. While the single-clone libraries did not show any detectable enrichment at this 
rather limited depth of sequence analysis, this mutation was found in 40 % of the sequences in this condition 
and was therefore characterized in more depth.  
Strikingly, SPR affinity measurements revealed that this mutation significantly increased the affinity of 1C1 
to both human and murine TEM1, yielding a monovalent affinity of 1 nM towards hTEM1 (see Fig. 2.3b and 
Supplementary Fig. 2.4) and 6 nM towards mTEM1 (Fig. 3.2d).  Together, this single point mutation greatly 
improved the binding affinity (≈ 70 to 80-fold improvement) and restored cross-reactivity of 1C1, making this 
clone a promising candidate for further investigation. 3.2.5 Tissue	specificity	and	application	in	immunohistochemistry	(IHC)	
In order to further assess the specificity of 1C1m, we next sought to evaluate the specificity of this clone in 
staining TEM1-expressing cells within tissue sections. As a marker for neo-vasculature, TEM1 has been 
described to be expressed by a subset of pericytes in developing tissues266,268. Taking advantage of the 
restored human/murine cross-reactivity of 1C1m, we stained tissue sections of the developing murine retina. 
Encouragingly, staining signal originating from 1C1m-Fc co-localized with a proportion of neonatal pericytes, 
which were cross-stained for the pericyte marker NG2 (Fig. 3.3e). 
In the tumor setting, multiple cell types have been shown to express TEM1, such as pericytes and 
fibroblasts266,267,269,275,281. In line with this more diffuse expression pattern, 1C1m-Fc predominantly stained 
perivascular cells, but also stromal cells in sections of Lewis lung carcinoma (Fig. 3.3f) and MC38 colon 
carcinoma tissue (Fig. 3.3g). As was the case in the developing retina, 1C1m staining signal co-localized with 
pericyte marker NG2. Together, 1C1m clearly stained the expected TEM1-expressing cell types in developing 
and tumor tissue samples. 3.2.6 Targeting	a	membrane-proximal	epitope	of	hTEM1	
The extracellular domain of TEM1 is separated from the membrane by a large and heavily O-glycosylated 
mucin stalk domain288. To-date, most published antibodies targeting TEM1, including our panel of novel scFv 
binders, recognize the ECD or the junction of ECD and mucin stalk305,306,362. However, several studies have 
shown that targeting a more membrane-proximal epitope and thus decreasing the bridging distance between 
the membrane of the T cell and the target cell can improve T cell activation both by CARs200,201 and soluble 
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engager molecules247,248,363. With this in mind, we aimed to increase the diversity of our panel of TEM1 
antibodies by isolating scFv binders to the mucin stalk region of human TEM1. 
Using our previously developed dCI method361, we performed two rounds of phage display selection against 
a recombinant N-terminally truncated fragment of the hTEM1 ECD (TEM1(nΔ)), comprising only the 
sialomucin stalk domain (amino acids 547-683). To enrich for binders of native TEM1, this was followed by a 
third round of phage display against either endogenous TEM1 expressing A673 cells, or HEK293-6E cells 
transduced with full-length TEM1. In both cases, a negative selection step was performed using 
untransfected HEK293-6E cells, in order to subtract any irrelevant binders to the general cell surface. 
Selection outputs were collected after R2 (recombinant antigen) and R3 (cell panning), scFvs were expressed 
and screened for binding of recombinant TEM1(nΔ) protein using a multiplexed flow-cytometry based 
screening protocol (see Supplementary Fig. 2.3). Sequencing of primary hits revealed moderate diversity at 
R2 and a high degree of enrichment at R3, with one clone (7A6) representing 89.3% of all sequences (Fig. 
3.4a and b and Table 3.2). Unique binding clones were selected and screened for specific binding of native 
TEM1-expressing cell lines in scFv-Fc format (Fig. 3.4c and Supplementary Fig. 3.1). Clones that recognized 
both A673 and SK-N-AS cells, but that did not bind to cells described as negative for TEM1, were selected for 
in-depth characterization.  3.2.7 Functional	characterization	and	affinity	maturation	of	TEM1	mucin	stalk	binders	
In the first instance, selected scFv-Fc clones were titrated against TEM1+ (Fig. 3.4d and Supplementary Fig. 
3.1) cells to rank them according to their apparent functional binding affinity. In this ranking experiment, four 
clones stood out that were able to recognize endogenous TEM1 expressing cells at a higher dilution. These 
binders were purified by protein A affinity chromatography (see Supplementary Fig. 3.1) and re-assessed for 
concentration-dependent binding of TEM1+ cells. With the exception of clone 1G9, all of the mucin stalk 
binders recognized A673 cells with higher (1-2 log) apparent EC50 than the ECD binders 1C1 and sc78 (Fig. 
3.4e). 
Given the presumably very modest binding affinities of the TEM1(nΔ)-specific clones, we aimed to enrich for 
clone variants with improved affinity by random mutagenesis. To this end, the full panel of ten specific cell 
binders (clones 1G9, 2E1, 3A9, 3L7, 7I2, 7C10, 7G12, 7O22, 7A6 and 9G12) was mutagenized by error-prone 
PCR, as described previously. The resulting mutant clone libraries were pooled, phages were produced and 
the mutant library was incubated with bead-captured SpyC-TEM1(nΔ) for two consecutive rounds of phage 
display selection, applying stringent washing conditions. Subsequently, bacterial scFv clone supernatants 
were screened for binding of TEM1(nΔ) in a multiplexed flow cytometry-based screening assay. The median 
fluorescence intensity (MFI) of each binder was plotted and compared to binding signals obtained with 
parental scFv clones (see Supplementary Fig. 2.3). Two mutations were enriched among the strongest 
binders, both representing variants of the same parental clone, 7A6. These affinity-matured clone variants 
were thus selected and reformatted as scFv-Fc fusion molecules. Since one of these variants harbored the 
mutation in the heavy chain (CDR2 loop) and the second variant contained the mutation in the light chain 
FR3, these modified heavy and light chains were additionally combined to generate a ‘hybrid’ variant. 
All three variants expressed robustly in HEK293-6E cells and displayed uniform monomeric properties when 
analyzed by size-exclusion chromatography (Fig. 3.4f). As an indication for functional binding affinity, 7A6 
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and its three matured variants were titrated for binding of hTEM1+ A673 cells, alongside the ECD-specific 
clone 1C1m.  
 
Figure 3.4. Targeting the sialomucin stalk domain of hTEM1. 
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(a) Clonal diversity of anti-hTEM1(Dn) ELISA hits after two rounds of phage display selection against recombinant hTEM1(Dn) and 
after a third round of selection against TEM1+ A673 cells or HEK293-6E cells transfected with full-length hTEM1. Colored clones will 
be discussed further below. (b) Heavy chain CDR3 length distribution of hTEM1(Dn)-binders sequenced after R2 or R3. (c) Flow 
cytometry screening of unique scFv-Fc clones for binding of a panel of TEM1-positive and -negative cell lines. Mammalian scFv-Fc 
clone supernatants were incubated with the different cells at a 1/100 dilution and binding was revealed with anti-human Fc detection 
(Alexa647). HT-1080 cells might express a truncated isoform of TEM1. HT-1080: human fibrosarcoma, Raji: human B cell lymphoma. 
(d, e) Flow cytometry titration of serially diluted mammalian expression supernatants containing anti-hTEM1(Dn) scFv-Fc clones 
(estimated concentrations ranging from 20 ng/ml to 2 µg/ml) (d) or purified scFv-Fc protein (0.01 ng/ml – 2 µg/ml) (e) against A673 
cells. Binding has been revealed with Alexa647 and is displayed relative to background binding (secondary only). 1C1-Fc and sc78-Fc 
have been used as reference and positive control. (f) Analysis of protein homogeneity of purified affinity-matured 7A6 clone variants 
by size-exclusion chromatography. All variants show homogenous monomeric fractions. (g) Flow cytometry titration of purified 7A6-
Fc and affinity-matured variants (0.01 ng/ml – 2 µg/ml) against A673 cells. Binding has been revealed with anti-human Fc (Alexa647) 
detection and is expressed relative to background binding (secondary only). 
 
 
R2 VH VL 
% 
clone  CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
1A1 GFTFSSYA ISGSGGST AKAPGFDY SSNIGSNT SNN AAWDDSLNGPV 2.78 
3K1 GFTFSSYA ISGSGGST AKGGNSVFPTRY QSVTRKY GAS QQYGSSPRT 1.39 
6A7 GFTFDDYA ISWNSGSI AKGSYSDY QDISNY DAS QQYDNLPYT   1.39 
2C1 GFTFSSYA ISYDGSNK ARDPSMIVGFDL SSDIGSNT SNN AAWDDSLNGHYV 8.33 
5M15 GFTFSSYG IWYDGSNK ARGDYMDV SSDVGGYNY EVS SSYTSSSTVV 4.17 
1K1 GGTFSSYA IIPIFGTA ARGRYSSSWGYFDY NLGNKY QDN QAWDGSTPYV 1.39 
2H16 GYSFTNYW IYPGDSDT ARHGPRVEVFDAFHI QSLVYSDGNTY KVS MQGTHWPYT 2.78 
4H21 GYTFTSYG ISAYNGNT ARNVVVPALYYYGMDV QSLLHSNGYNY LGS MQSLQTPWT 2.78 
1A6 GYSFTNYW IYPGDSDT ARRYYDSSGYYSLSAFDI SSNIGNNY ENN GTWDSSLSAGV 6.94 
5C11 GFTFSSYG IWYDGSNK ARSNWFDP RSDIGSYNY EVN SSYTSSSTVV 26.39 
2F15 GFPFSGYP IDESGGRT ARVEVSGGYYRGFHP QSLLHSNGYNY LGS MQALQTPTT  4.17 
2E1 GYSFTSYW IYPGDSDT ARWGAQGAVAGSRDAFDI QSISSW KAS QQYNSYWT 1.39 
3B5 GYTFTSYY INPSGGST ASSGGATRASDAFDI SSNIGANYD GNN QSYDTDLRASV 23.61 
3I16 GYSFTSYW IYPGDSDT ATWGVGSSGYPIDP QSVLYSSNNKNY WAS QQYYSTPLT        8.33 
R3 
7G22 GFTFSSYA ISGSGGST AKAPGFDY SSNIGSNT SNN AAWDDSLNGPV 0.89 
7I2 GFTFDDYA ISWNSGSI AKVAAAGAFDY SSNIGSNY RNN AAWDDTLTGPV 1.79 
9I10 GFTFSSYW IKQDGSEK ARDQNWNYDY SSDVGGYDF EVS SSYSSSSTYV 2.68 
7G12 GYTFTGYY INPDNGGT ARGDLDH TGTVTTGHY DTS LLYDDGGRF 0.89 
7C12 GFTFSSYA ISYDGSNK ARGRSRAGYYYMDV ESVSDF RTS QQYDRYSWG 1.79 
7G14 GFTFSSYA ISYDGSNK ARGVGDSSGSYYFDY SSNIGSNT SNN AGWDDSLNGWV 0.89 
9G12 GYSFTNYW IYPGDSDT ARRYYDSSGYYSLSAFDI SSNIGNNY ENN GTWDSSLSAGV 0.89 
7O22 GYSFTSYW IYPGDSDT ARSDTGATAFDY QSLVHSNGNTY KVS MQGTHWPPYT 0.89 
7A6 GYTFTSYY INPSGGST ASSGGATRASDAFDI SSNIGANYD GNN QSYDTDLRASV 89.29 
Table 3.2. CDR amino acid sequences and frequencies of TEM1(Dn) binders. 
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However, although all variants stained A673 cells in a concentration-dependent manner, 7A6 and its mutants 
still only bound the cells at approximately 100-fold higher concentrations, compared to 1C1m (Fig. 3.4g). 
Collectively, these results show the de novo discovery of a diverse panel of TEM1-specific scFv clones, 
displaying different biophysical and functional properties and targeting different epitopes on both the ECDs 
and the sialomucin stalk region of TEM1. 
 
 3.3 Discussion	
In the present study, we have developed a diverse set of fully human and essentially germline TEM1-specific 
antibodies using our recently published dCI methodology361. Given the greatly reduced immunogenicity risk 
using fully human targeting scFvs364, these clones represent ideal candidates for the pre-clinical and clinical 
development of antibody-based therapeutic agents. Additionally, the murine cross-reactivity offers the 
potential for readily translatable pre-clinical testing in endogenous murine models. 
Given its exclusive expression within the tumor stroma and neo-vasculature, TEM1 represents an ideal 
biomarker for the detection and monitoring of cancerous lesions. In this context, the previously developed 
sc78 has been proposed as a tool for near-infrared (NIR) optical imaging. Pre-clinical evaluation of this 78Fc-
NIR tracer showed robust discrimination of TEM1-expressing tumor tissue from healthy organs and thus 
confirmed the suitability of TEM1 as a tumor biomarker308,335,365. With its high affinity towards human (1 nM) 
and murine (6 nM) TEM1, 1C1m compares well with clone sc78 (affinity towards hTEM1 reported as 5.6 
nM)306 and thus represents an additional promising candidate for both pre-clinical and clinical testing. To this 
end, we have established collaborations that aim to employ our lead candidate 1C1m as the targeting entity 
for radioimaging and radiotherapy of solid tumors. Encouragingly, Lu177-labeled 1C1m-Fc has been shown 
to selectively localize to TEM1+ tumor tissue in xenograft mouse models (Judith Delage and David Viertl, 
CHUV, unpublished). 
Besides tumor stromal cells, cancer cells of mesenchymal origin, notably sarcoma, have been found to 
express TEM1 directly276,309,366. Although a heterogeneous group of tumors, sarcomas often share an 
aggressive pathological behavior and resistance to chemotherapy, leaving surgery with or without radiation 
as the only therapeutic option. In light of the high prevalence of TEM1 expression across the different 
sarcoma subtypes, several studies have explored TEM1-targeted therapies as a new treatment strategy for 
human sarcoma. To our knowledge, all of these efforts have focused on the development of antibody-drug 
conjugates (ADC) directed against TEM1304,305,307,309. Conceptually, ADCs employ the exquisite target 
specificity of an antibody or antibody-derived targeting moiety for the local delivery of toxins to the tumor, 
thereby allowing higher local exposure of the tumor to the drug compared to systemic delivery. In this 
context, sc78 has been explored as an immunotoxin for the treatment of human sarcoma309,335. Similarly, 
other TEM1-specific antibodies have been conjugated with potent toxins to generate ADCs that have shown 
efficacy in pre-clinical osteosarcoma models271,304,305. In a preliminary line of investigation, one of our new 
clones, 1C1-Fc, has been conjugated to monomethyl auristatin-E, an antimitotic agent blocking the 
polymerization of tubulin, alongside sc78-Fc. Given its superior thermal stability and functional binding 
profile, 1C1 and its affinity-matured variant represent equally attractive candidates for ADC-type molecules. 
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As a prerequisite for investigating therapeutic efficacy, we have shown that both 1C1-Fc and sc78-Fc are 
internalized by hTEM-expressing cells and, further, that they exert specific cytotoxicity towards human TEM1+ 
cell lines (preliminary data not shown).  
Besides these more traditional antibody applications, scFvs can be utilized as targeting ‘warheads’ in 
engineered immunotherapy approaches, typically exemplified by CARs and T cell engaging bispecifics. Such 
therapies have been employed successfully for the treatment of hematological malignancies, mainly via CD19 
targeting160,168-171,180,214,215,367-369. However, the development of targeted immunotherapies directed against 
solid tumors have revealed a number of obstacles that have thus far hindered the clinical impact of these 
therapies. Key among these are the limited availability of adequately selective tumor-specific antigens, which 
together with physical and immunosuppressive barriers mediated by the solid tumor microenvironment, 
present significant challenges with regard to both tissue penetration and therapeutic efficacy160. The 
targeting of TEM1 aims to address both of these aspects. Firstly, TEM1, which as discussed above has a 
restricted/negligible expression profile in normal somatic tissues, has been shown to be strongly expressed 
with high incidence on the surface of sarcoma and osteosarcoma tumor cells, thus providing a sound 
therapeutic targeting rationale271,276,281,309. Secondly, the widespread association of TEM1 expression with 
neo-vasculature provides a conceptual mechanism for physically disrupting tumor integrity in the relative 
absence of stroma-mediated immunosuppression266-269,274,275,281,360.  This latter consideration offers the 
opportunity of general tumor targeting irrespective of the tissue of origin. Encouragingly, T cell responses 
directed against TEM1 have been shown to reduce tumor vascularity and control tumor progression in a DNA 
vaccination approach, underlining the potential of TEM1 as a target for cancer immunotherapy. Moreover, 
TEM1 vaccination did not affect physiological angiogenesis-dependent processes, such as wound healing310.  
Given their encouraging functional and biophysical properties and the low risk of immunogenicity, we 
anticipate that the isolated TEM1 scFv warhead domains may have significant potential for the development 
of tumor therapeutic targeting agents. While classical antibody applications, such as ADCs, generally require 
high affinity to achieve optimal selective efficacy, lower targeting affinities may be favorable for certain 
adoptive or engager-mediated T cell-based strategies, since a rapid dissociation would allow serial 
recognition of target antigen, and better recapitulate the weaker receptor/ligand interactions that drive T 
cell functional activation and killing370. Besides scFv affinity, epitope location plays a critical role for the 
efficacy of T cell engagement. Depending on the structure of the target antigen, recognition of more 
membrane-proximal epitopes has been found to facilitate T cell retargeting through bispecific engager 
molecules and CARs247,248,363. O’Shannessy and colleagues have previously identified an extensive panel of 
TEM1 domain-specific monoclonal antibodies with different molecular properties and human-murine cross-
reactivity patterns61. However, although these tools may help provide insights into the molecular function of 
the multi-domain protein TEM1, the fact that they were generated in rats may present a roadblock for any 
clinical development efforts, due to potential immunogenicity issues. 
Ultimately, the diverse panel of TEM1-specific scFvs presented here offers the opportunity to fine-tune 
antigen recognition and biophysical properties for different therapeutic applications. Therefore, in the next 
chapter, we describe the application of the isolated scFv clones as targeting ‘warheads’ for T cell engaging 
bi-specifics and CARs. 
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3.4 Materials	and	Methods	3.4.1 Protein	expression,	phage	display	and	primary	screening	
Recombinant eukaryotic and prokaryotic protein expression  
ECD fragments of human or murine TEM1 were synthesized (GeneArt, Thermo Fisher Scientific) and fused N-
terminally to SpyC in a pTT-based mammalian episomal expression vector (pSTEVe20). For phage display 
selections or bead capture analysis, SpyC-antigens were directly captured from the expression supernatant 
and immobilized on magnetic streptavidin beads (M-280 Dynabeads; Life Technologies #11206D) pre-coated 
with 1 µM biotinylated SpyT peptide. For prokaryotic expression of phage display selection outputs, 
individual E.coli TG1 colonies were picked into 2TY medium supplemented with 2% glucose and 100 µg/ml 
ampicillin (2TYAG) in round-bottom 96-well plates and grown overnight at 30 °C. The following day, the 
cultures were diluted into Terrific Broth (TB) containing 0.1% glucose and 100 µg/ml ampicillin and grown 
until reaching an OD600 of 0.6. Protein expression was induced by adding Isopropyl-b-D-
thiogalactopyranoside (IPTG; Merck #420322) to a final concentration of 100 µM and proteins were 
expressed overnight at 30 °C with shaking at 750 rpm. Selected scFv candidates were reformatted into a pTT 
expression vector containing the constant region of human IgG1 to produce scFv-Fc fusion proteins.  
Recombinant protein was produced using the HEK293-6E/pTT expression system and FectoPRO transfection 
protocol (Polyplus, #116-010), as described previously. ScFv-Fc fusions were purified from clarified 
expression media using a HiTrap™ MabSelect column (GE Healthcare, #11003494), followed by extensive 
dialysis against phosphate-buffered saline (PBS; Slide-A-Lyzer G2 dialysis cassettes; Life Technologies, 
#87731). 
Selection of naïve human scFvs using phage display 
Experimental details of phage display selections are described in chapter 2. Briefly, two fully human scFv 
libraries (pCHV101_DMk and pCHV101_DMl) were constructed from the IgD/IgM VH and Vk/Vl domain 
repertoires of 120 healthy donors. Variable regions were amplified, pooled, purified and cloned into the gIII 
display cassette of a proprietary phagemid vector (pCHV101) in VL – VH orientation. The resulting phage 
library was rescued using M13KO7 helper phage (Life Technologies, #18311019), pre-blocked with phosphate 
buffered saline (PBS) containing 0.1% Tween-20, 2% skimmed milk and 1% BSA and incubated with SpyC-
coated streptavidin beads to subtract non-specific or SpyC-specific binders. De-selected phage particles were 
subsequently transferred to tubes containing immobilized SpyC-antigens and incubated at RT for 1 h. 
Deviating from the protocol detailed in chapter 2, the stringency of washing was not increased at the second 
round of selection during the panning against h/mTEM1 ECD-fragments. Bound phage were eluted with 
trypsin, collected and allowed to infect E.coli TG1 cells, which were subsequently plated on 2TYAG agar for 
antibiotic selection of infected cells. Generally, two rounds of phage display were performed for each target 
selection. For the selection against the sialomucin stalk domain of hTEM1, a third round of phage display 
selection was performed using cellular targets. To this end, HEK293-6E cells were transfected with a pTAG-
CMV expression vector harboring the full-length hTEM1 cDNA ORF (extracted from Genbank RefSeq 
NM_020404.3), 48 h before the third round of phage selection. Transfections were performed using 
FectoPRO (Polyplus, #116-010), according to the supplier’s recommendations (see chapter 2 for details 
regarding the transfection and maintenance of HEK293-6E cells). On the day of the experiment, pre/selected 
phage populations were pre-blocked as described above and then incubated with 107 TEM1-negative 
HEK293-6E cells for 1 h at 4°C to eliminate any non-specific cell binders. Subsequently, the de-selected phage 
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libraries were transferred to tubes containing either TEM1+ A673 cells, or HEK293-6E cells transfected with 
full-length hTEM1 and incubated for 1 h at 4°C with gentle rotation. Non-specific phage were removed by 6 
x 1ml washes in PBST, followed by 1 x wash in PBS; each time gently collecting the cells by centrifugation 
(4min at 250 x g). Finally, bound phage were eluted with trypsin allowed to infect TG1 cells and finally stored 
frozen in 2TYG containing 15% glycerol, analogous to the standard phage display protocol.  
For primary screening, individual colonies were picked into 2TYAG liquid medium, grown until turbid and 
then diluted into TB medium supplemented with ampicillin for recombinant protein expression. 
Enzyme-linked immunosorbent assay (ELISA)  
Primary selection outputs were screened by dCI SpyC-antigen ELISA, as described previously. For ELISA 
titration experiments, Nunc Maxisorp 96-well plates (Thermo Fisher Scientific, #442404) were coated with 
10 μg/ml Neutravidin (Life Technologies, #31000) in PBS over-night at 4 °C, washed 3x in PBST and blocked 
with 300 µl 5% skimmed milk in PBST for 45 min at RT. After washing 3x with PBST, 100 µl biotinylated hTEM 
ECD (produced in-house, see chapter 2) was added to each well, in a 2-fold dilution series ranging from 100 
nM to 0.1 nM, diluted in PBS/1% BSA and incubated for 1 h at RT, followed by 3x PBST washes. Selected scFv-
Fc fusion molecules were diluted 1:10 in 1% BSA/ PBS and added to the plate at 100 µl per well. Incubation 
was at RT for 1 h and the well were washed 4x in PBST, before detection with goat anti-human IgG Fc 
polyclonal HRP conjugate (Sino Biologicals, #SSA001; 1:5000 dilution), using TMB as a substrate. All wash 
steps were performed by dispensing 300 µl PBST from a BioTek405 automatic plate washer. 
For assessing competition of scFv clones for binding of hTEM1, ELISA plates were first coated with Neutravidin 
overnight, then blocked as described above and subsequently incubated with 0.5 µg/ml biotinylated hTEM1 
ECD, diluted in 1% BSA/PBST for 1 h at RT. To set up the competition, scFv-Fc clones were diluted to 0.1 µg/ml 
and mixed 1:1 with cleared scFv containing TG1 expression supernatants pre-blocked with 5% skimmed 
milk/PBST. After 10 min of pre-incubation, the competition mixture was added to the washed (3x PBST) ELISA 
plate and allowed to interact with hTEM1 for 1.5 h at RT. The plate was washed 4x with PBST and bound scFv-
Fc were revealed as described above.  
Affinity maturation and multiplexed bead-based screening assays 
Selected scFv clones were subjected to random mutagenesis across the whole scFv, using error-prone PCR 
with the Diversify PCR random mutagenesis kit (Takara, #630703). The complete affinity maturation method 
for both TEM1 ECD-binders and scFvs specific for the sialomucin stalk of TEM1 (SpyC-hTEM1(Δn) is described 
in chapter 2. Similarly, the multiplexed bead-based no wash screening assay used to screen scFv clone 
outputs from the SpyC-hTEM1(Δn) primary selection and affinity maturation for specific binding of cognate 
SpyC-antigen has been described previously.  3.4.2 Biophysical	protein	characterization	
Surface Plasmone Resonance (SPR) 
SPR analysis was performed on a Biacore T200 instrument (GE Healthcare) and in 1x filtered Biacore running 
buffer (HBS-EP+; 0.01 M HEPES, 0.15 M NaCl, 0.05% Surfactant P20, 3 mM EDTA, pH 7.4; GE Healthcare, #BR-
1006-69). Experiments probing the monovalent affinities of anti-TEM1 scFv candidates used a Series S SA 
sensor chip (GE Healthcare, #BR-1005-31). To immobilize hTEM1, 1 µg/ml biotinylated hTEM1 were injected 
at 30 µl/min until reaching a target density of 150 RU, following the manufacturer’s instructions. For kinetic 
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analysis, monovalent scFv candidates fused in tandem to an anti-CD3 scFv were injected at 30 µl/min and 
data was acquired in Multiple Cycle Kinetics mode. Analytes were diluted to 8 nM, 40 nM, 200 nM and 1 µM 
in running buffer. The chip surface was regenerated between cycles by injecting 10 mM glycine-HCl, pH 1.5 
for 30 s. For kinetics analysis, the signal of a reference cell devoid of ligand was subtracted from the active 
cell to correct for bulk shift and refractive index changes. 
SPR experiments involving mTEM1-SpyC ligand were performed as described in chapter 2. Analyte 
concentration ranges were 0 nM, 62.5 nM, 125 nM, 250 nM and 500 nM for 1C1 and 0 nM, 1.25 nM, 2.5 nM, 
5 nM and 10 nM for 1C1m. 
Differential Scanning Fluorimetry (DSF) stability assay 
In order to compare the relative thermal stability of different scFv clones, a thermal shift assay was 
performed following the Protein Thermal Shift Assay protocol from Applied Biosystems (#4461146). 
Therefore, purified scFv-Fc fusion proteins were diluted to 5 µM with PBS and mixed with 5 µl Protein Thermal 
Shift Buffer and 2.5 µl 8x Protein Thermal Shift Dye. Each reaction was prepared in triplicate in a MicroAmp 
Fast Optical Reaction Plate (Lifetechnologies, #4346907) and sealed with MicroAmp Optical Adhesive Film 
(Lifetechnologies, #4360954). Melting curves were generated with a 7500 Fast RT-PCR machine (Applied 
Biosystems), starting at 25 °C and gradually increasing the temperature by 0.05 °C/s until reaching 99 °C. To 
obtain relative melting temperatures based on the transition point of the melting curve, the derivative of the 
fluorescence signal was calculated as a function of temperature. Data analysis was carried out using Applied 
Biosystems 7500 Fast RT-PCR software.  
Analytical size-exclusion chromatography (SEC) 
The integrity and homogeneity of protein candidates was assessed by SEC using an ÄKTApure 
chromatography system (GE Healthcare). To this end, 100 µl concentrated (≈1 mg/ml) protein sample was 
injected and separated over a Superdex 200 Increase 5/150 GL analytical grade column (GE Healthcare, 
#28990945) at a flow rate of 0.45 ml/min. PBS (0.01 M phosphate, 0.14 M NaCl, pH 7.4) was used as sample 
diluent and eluent.  
Analysis of proteins by SDS-PAGE 
For analyzing purified proteins by gel electrophoresis, typically 2 µg protein sample were mixed with 1x LDS 
buffer (NuPAGE; Life Technologies, #NP0007) with or without 10% reducing agent (NuPAGE; Life 
Technologies #NP0009) and heated at 70 °C for 10 min. To confirm protein expression, mammalian 
expression supernatants were mixed with LDS buffer and reducing agent and processed in the same way. 
Samples were collected by centrifugation and separated on a Novex 4-12% Bis-Tris gel (Life Technologies, 
#NP0321) for 38 min at 200 V. Separated protein bands were visualized by Coomassie Blue staining 
(InstantBlue; Expedeon, #ISB1L). 3.4.3 Cell	assays	and	functional	characterization	
Cell culture and flow cytometry 
All cell lines were obtained from the ATCC via LGC Standards. References and culture conditions, as well as a 
general protocol for flow cytometry are detailed in chapter 2. For flow cytometry based functional screening, 
mammalian expression supernatants containing scFv-Fc fusion proteins were diluted 1/10 in FACS buffer (5% 
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FBS in PBS) and added to 0.5x106 cells per sample. After washing three times in FACS buffer, PE-conjugated 
anti-human Fc secondary antibody (Biolegend, #409303) was added and incubated for 30 min on ice. For flow 
cytometry titration experiments, scFv-Fc molecules were serially diluted in FACS buffer, typically in a 
concentration range spanning 0.2 or 2 ng/ml to 2 µg/ml, before adding to the cells. In titration experiments, 
Alexa Fluor 647 AffiniPure Goat Anti-Human IgG was used as a secondary antibody (Jackson Immunoresearch, 
#109-605-098, 1:200 dilution). Data was acquired using an LSR-II flow cytometer equipped with FACSDIVA 
software (BD Biosciences). Data analysis and plotting were carried out using FlowJo v10 (FlowJo LLC).  
For high-throughput screenings of hTEM1(Dn)-binding clones, mammalian expression supernatants 
containing scFv-Fc protein were diluted 1/100 in FACS buffer and incubated with the blocked cells as 
described above. Any cell binding was revealed using an Alexa Fluor 647 AffiniPure Goat Anti-Human IgG 
secondary antibody (Jackson Immunoresearch, #109-605-098, 1:200 dilution). Wash steps after both primary 
and secondary antibody incubation were 3x 100 µl FACS buffer. Data for these experiments was acquired 
using an Intellicyt iQue TM Screener PLUS instrument (10 s sampling; 1 μl/s) and data analysis was performed 
using Forecyt software (Intellicyt).  
Quantifying mRNA expression by reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
For mRNA isolation, 107 cells were seeded into a T75 tissue culture flask and harvested with trypsin-EDTA 
after 24 h. Detached cells were collected by centrifugation (5 min at 250x g) and washed once in ice-cold PBS. 
The cell pellets were either snap-frozen on dry ice and stored at -80 °C or immediately processed for mRNA 
isolation. Cells were lysed by adding 600 µl buffer RLT and samples were homogenized by passing the lysate 
through an RNAse-free syringe with 20-gauge needle (Braun). Subsequently, mRNA was isolated by 
absorption of RNA longer than 200 bases to the silica-based membrane of microspin columns using the 
Qiagen RNeasy Mini kit (Qiagen, #74106), following the manufacturer’s instructions. Then, mRNA was 
reverse transcribed into cDNA using the Takara Primescript First Strand cDNA synthesis kit (Takara, #6110B). 
Briefly, 5 µM oligo dT primer were annealed with 1 µg total mRNA in a total volume of 10 µl containing dNTP 
(1 mM each), by incubating at 65 °C for 5 min. 20 units RNase inhibitor and 200 units PrimeScript reverse 
transcriptase were added to the annealed RNA/primer mixture and the reaction was allowed to take place 
for 1 h at 42 °C. The reaction was stopped by heating to 70 °C for 15 min and the samples were immediately 
cooled on ice before snap-freezing on dry ice for storage (at -80 °C) or analysis by qPCR. For TaqMan qPCR, 
approximately 50 ng cDNA were mixed with 10 µl TaqMan Fast Universal Master Mix (Applied Biosystems, 
#4352042) and 1 µl TaqMan probe in a total reaction volume of 20 µl. The following FAM-MGB-TaqMan 
probes were used to detect target and reference genes: hCD248 (#4331182_Hs00535586_s1), mCD248 
(#4331182_Mm00547485_s1), hGAPDH (#4331182_Hs02786624_g1) and mGAPDH 
((#4331182_Mm99999915_g1), all from ThermoFisher Scientific. Real-time PCR amplification of target and 
housekeeping genes was performed in a 7500 Fast RT-PCR machine (Applied Biosystems) and relative gene 
expression levels in different cell lines were analyzed by comparative threshold cycle (Ct) quantification. 
Expression levels are presented relative to GAPDH. 
Immunohistochemistry 
Retinas were collected from newborn pups at day 5, fixed in 4% paraformaldehyde (PFA) for 4 h at 4 °C and, 
after washing with PBS, blocked overnight at 4 °C with 5% donkey serum, 0.5% BSA, 0.3% Triton X-100, 0.1% 
sodium azide, in PBS. For tumor staining experiments, 5x 105 Lewis lung carcinoma (ATCC, #CRL-1642) or 
MC38 colon carcinoma (Kerafast, # ENH204-FP) cells were resuspended in PBS and injected subcutaneously 
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into the right flank of adult C57BL/6 mice. Once the tumors reached a volume of 1 cm3, the animals were 
perfused with 4% PFA, sacrificed and the tumors were collected and further fixed overnight in 4% PFA. 
Washed tumors were then incubated in 30% sucrose for 12 h before embedding in optimal cutting 
temperature (OCT) compound (Tissue-Tek, #4583) for frozen sectioning. 8 µm cryosections were prepared at 
the histology facility of UNIL and blocked as described above. For the staining, both retinas and tumor 
sections were incubated overnight at 4 °C with 5 µg/ml 1C1m-Fc, diluted in blocking buffer. The following 
day, the retinas were washed 5x 10 min and the tumor sections 3x 10 min with blocking buffer and then 
incubated with an Alexa Fluor 555-conjugated goat anti-human antibody (diluted 1:500 in blocking buffer; 
Invitrogen, #A21433) overnight at 4 °C. Wash steps were repeated and imaged were acquired using an 
upright Zeiss Axio Imager Z1 microscope. 
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3.5 Supplementary	Information	
 
Supplementary Figure 3.1. Expression and characterization of TEM1(Dn) binders. 
(a) Reducing SDS-PAGE of anti-TEM1(Dn) primary hits in scFv-Fc format. 6.5 µl crude expression supernatants were loaded and 
separated in a 4-12 % Bis-Tris gradient gel. Expected size for an intact scFv-Fc molecule is ~55 kDa. (b) Flow cytometry titration of 
serially diluted mammalian expression supernatants containing anti-hTEM1(Dn) scFv-Fc clones (estimated concentrations ranging 
from 20 ng/ml to 2 µg/ml) against hTEM1+ SK-N-AS cells. (c) Reducing and non-reducing SDS-PAGE of 2µg purified anti-TEM1(Dn) 
clones in scFv-Fc format. Expected molecular weight is ~55 kDa for reduced samples and ~110 kDa for intact dimers. (d) Analysis of 
protein homogeneity of purified hTEM1(Dn) scFv-Fc clones by size-exclusion chromatography. All variants show homogenous 
monomeric fractions. 
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 Novel	trivalent	T	cell	engagers	and	Chimeric	Antigen	Receptors	targeting	TEM1	for	cancer	immunotherapy	
 
The following chapter describes the design and validation of a versatile new bispecific T cell engager format, 
that we have termed TriloBiTE (Tri-lobed Bi-directional T cell Engager). Further, this study focuses on the 
application of our diverse panel of anti-TEM1 single-chain antibodies as targeting ‘warheads’ for soluble T 
cell engagers (TriloBiTEs) and chimeric antigen receptors (CARs). This chapter is based on an article that is 
currently under preparation. 
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4.1 Introduction	
It is a well-established concept that T cells are able to recognize malignant cells and participate in the control 
of tumor growth371. This observation has paved the road to cancer immunotherapy, aiming to harness the 
potential of the immune system to eliminate cancer cells. Under physiological conditions, T cells recognize 
unique, mutated (neo-) and aberrantly expressed peptides presented on major histocompatibility class 
(MHC) molecules through the T cell receptor (TCR). However, cancer cells often develop mechanisms to 
escape immune surveillance, for instance by downregulating the expression of MHC molecules112. Therefore, 
besides strategies to boost natural anti-tumor defense mechanisms141,143,372-375, several engineering 
approaches have been developed, equipping T cells with tumor-targeting capabilities that can bypass 
individual T cell receptor (TCR) specificities160,212,368,376. Thus, these approaches aim at recruiting and 
redirecting the cytotoxic potential of bulk T cell populations towards malignant cells, with the objective of 
overcoming (or overwhelming) immune tolerance and tumor-mediated suppression.  
In order to redirect the cytotoxic effector function of T cells, bispecific antibody-derived mediators have been 
developed comprising a tumor-targeting moiety fused to an anti-CD3 recognition domain for the engagement 
and activation of T cells203,204. The most advanced molecules of this class are the so-called bispecific T cell 
engagers (BiTEs)214. These soluble molecules are based on two distinct single-chain antibodies (scFvs) 
separated by an appropriate flexible linker. This approach allows the recruitment and activation of a broad 
polyclonal population of unstimulated T cells to the tumor cell surface irrespective of individual TCR 
specificities206,207. To date, a vast array of molecular formats have been developed for T cell engaging 
bispecifics, all of them conferring different binding geometries and molecular properties212,213. The choice of 
targeting geometry and affinity, as well as the binding epitope are of paramount importance for the efficacy 
of these bispecific mediators, and have to be optimized for each tumor-associated antigen212,213,248. 
Instead of using soluble mediators to recruit T cells to the tumor site, T cells can also be engineered to express 
synthetic tumor targeting receptors, termed chimeric antigen receptors (CARs). To redirect antigen 
specificity, a ligand-binding domain, typically a scFv, is linked to an intracellular signaling module that includes 
an assemblage of immunoreceptor tyrosine-based activation motifs (ITAMs), such as is found in the 
cytoplasmic tail of CD3ζ, which mediate T cell activation upon antigen recognition. In order to mimic co-
stimulation as it is provided by antigen presenting cells during T cell activation, the signaling endodomains of 
CD28, 4-1BB and/or OX40 are typically fused to CD3ζ, thereby attempting to achieve full physiological T cell 
activation163,164. CAR structural design has a major impact on the efficacy of adoptive T cell therapy in vivo, 
which in turn depends not only on efficient antigen recognition, but also on T cell expansion and 
persistence162,377. Antigen recognition is mainly driven by the affinity and specificity of the target-binding. 
Depending on the antigen density, CAR potency has been shown to improve with increasing scFv affinity or 
to be subjected to an avidity threshold, above which T cell function reaches a plateau or may even 
decrease193,194,196. Also, the spatial distance between the CAR T cell and the target cell plays a crucial role in 
T cell activation. Here, the factors determining optimal distance are epitope location and length/flexibility of 
the linker between CAR targeting domain and transmembrane domain199-202. Generally, however, few studies 
exist that have sought to comprehensively address the interplay between target epitope, scFv affinity and 
cellular bridging distance. Moreover, the proliferation and persistence of CAR T cells in vivo can be profoundly 
influenced by constitutive antigen-independent signaling. This phenomenon, termed tonic signaling, has 
been shown to drive early T cell exhaustion and limit T cell efficacy, and its extent is determined by the choice 
of co-stimulatory endodomain and by the specificity and biophysical properties of the targeting scFv378.  
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Altogether, the design of both T cell engaging bispecifics and CARs requires significant engineering efforts 
with a multitude of parameters to be optimized for each new target antigen. However, once in place, both T 
cell retargeting strategies have proven efficacious in numerous clinical trials167-171,180,214,215,367-369. Thus, both 
an anti-CD19xCD3 BiTE (blinatumomab/ Blincyto) and a CD19-targeting CAR (tisagenlecleucel/ Kymriah) have 
been recently approved for the treatment of severe relapsed B-cell malignancies. Following these pioneering 
approvals, there has emerged strong interest in the development of T cell retargeting therapies that have 
novel antigen specificities and that may prove efficacious in solid tumors. To this end, and in order to achieve 
maximum efficacy while limiting toxicity, it is of paramount importance to identify novel tumor-associated 
or tumor-specific antigens that facilitate the selective targeting of tumor tissue.  
The cell-surface antigen Tumor Endothelial Marker 1 (TEM1, Endosialin, CD248) is largely undetectable in 
normal tissues, but is selectively expressed in the stroma and neo-vasculature of many solid 
tumors264,266,267,270,271,275,288. More specifically, TEM1 expression has been detected on pericytes, endothelial 
precursor cells, fibroblasts and smooth muscle cells throughout the tumor vasculature266,269,379. Furthermore, 
TEM1 is expressed on tumor cells in a number of high-grade sarcomas276. Although its molecular function 
remains elusive, TEM1 is implicated in vascular cell adhesion and migration, angiogenesis and tumor 
progression292. Importantly, TEM1-/- mice show impaired tumor growth, invasiveness and metastasis, while 
exhibiting normal wound healing290. As a specific marker of tumor vasculature, TEM1 has emerged as an 
attractive target for cancer therapy266,271,275,304. Substantial therapeutic results can be achieved by targeting 
the supporting cells of the tumor vasculature, in part because these cells otherwise present a barrier that 
shields tumor cells from the immune system254,380. Moreover, as a vascular antigen, TEM1 should be relatively 
accessible to peripherally circulating drugs and T cells and may be expected to display lower mutational 
escape rates than more traditional antigens located directly on tumor cells381. Finally, since TEM1 is not 
restricted to a specific tissue of origin, any emerging therapies could be applied to a wide range of tumor 
types310. 
Therefore, the aim of this study is to explore the potential of TEM1 as a target for engineered cancer 
immunotherapy approaches using de novo discovered scFv antibodies. 
 
 4.2 Results	4.2.1 TriloBiTEs:	A	novel	trivalent	T	cell	engager	format.	
We initially sought to develop an intermediate-sized T cell engager molecule that would allow flexible mono- 
or bivalent antigen binding, yet have sufficient mass to resist direct renal elimination whilst still permitting 
efficient tissue penetration. Inspired by the use of the disulfide-stabilized interaction of LC and VH-CH1 as an 
heterodimerization scaffold proposed by Schoonjans, R. et al.382 , we C-terminally fused a scFv domain to 
both heavy (VH-CH1(IgG1)) and light chain (VL-Ck) of a humanized and chimeric anti-CD3 Fab (derived from 
the murine mAb clone UCHT1). In contrast to the previously published ‘tribody’ format382, which employs 
murine CH1 and Ck domains for dimerization, we utilized fully human Fab constant domain sequences. 
However, since the interaction between the isolated human CH1 and Ck domains alone is generally quite 
weak, and would require significant co-operative stabilization via the interface generated by the appended 
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UCHT1 VH and Vk domains to maintain structural integrity57, we aimed to further stabilize the human CH1-
Ck Fab interface. Previously, structural exploration of the CH1-CK interface has revealed a relative absence 
of buried hydrophobic packing interactions at the N-terminal region of the interface. To address this, 
stabilizing mutations have been introduced in this region using phage display383. Guided by this study, we 
have inserted the S64E and S66V mutations into the human CH1 (IgG1) domain and the S69L and T71S 
mutations into the human Ck domain of the chimeric UCHT1 Fab (Fig. 4.1a). The resulting T cell engager 
molecule, which we term “TriloBiTE” (tB), now allows the modular combination of a stabilized anti-CD3 Fab 
with one or two antigen-targeting scFvs, separated from each chain of the Fab by carefully considered flexible 
(Gly/Ser-rich) linkers (Fig. 4.1a).  4.2.2 TriloBiTEs	specifically	redirect	human	T	cells	to	target	relevant	cancer	cells.	
As a proof-of-concept, we first engineered a bivalent CD19-specific TriloBiTE by fusing the clinically validated 
murine anti-CD19 scFv clone FMC63 to both chains of the anti-CD3 arm384. Transient expression from 
recombinant HEK293-6E cells yielded robust protein quantities (≈ 20 mg/l; Fig. 4.1b) with the purified 
material comprising predominantly homogeneous heterodimeric monomer (Fig. 4.1c). TCR signaling via CD3z 
activates a number of molecular pathways, such as the induction of the calcium-calmodulin-dependent 
phosphatase calcineurin, which dephosphorylates members of the nuclear factor of activated T cells (NFAT) 
family. The NFAT transcription factors then migrate to the nucleus and induce a number of genes involved in 
cytokine production, T cell proliferation and survival32. Since NFAT signaling depends on the strength and 
duration of T cell activation385, reporter systems have been developed that couple NFAT signaling with the 
expression of a reporter gene in order to probe and compare T cell engagement via the TCR/CD3 
complex386,387. We thus employed a Jurkat reporter cell line expressing luciferase under the control of an 
NFAT-driven promoter to assess T cell activation by the aCD19-tB. Encouragingly, our proof-of-concept 
aCD19-tB molecule induced NFAT-signaling in a concentration-dependent manner and specifically in the 
presence of CD19+ Raji cells, while no luciferase signal was detected in the presence of irrelevant cells (Fig. 
4.1d). We next sought to assess the potential of the TriloBiTE engagers to redirect the effector function of 
primary T cells. In a co-culture set-up, the aCD19-tB was able to specifically activate a polyclonal population 
of primary human CD8+ T cells, which in turn lysed CD19+ Raji cells, but spared CD19-negative HEK293 cells 
(Fig. 4.1e). Moreover, T cells activated with the TriloBiTE secreted relevant effector cytokines with the 
magnitude of the cytokine response being dependent on the TriloBiTE concentration (Fig. 4.1f).  4.2.3 TriloBiTEs	induce	potent	cytotoxicity	of	human	T	cells	towards	mesothelin-expressing	human	cancer	cells.	
Having validated our TriloBiTE T cell engager format with the well-characterized anti-CD19 ‘warhead’ FMC63, 
we next aimed to test the TriloBiTE format with more experimental scFv clones isolated in-house from de 
novo phage display using our dCI-technology (see chapter 2). We therefore reformatted two novel scFv 
clones specific for human mesothelin (meso) in the bivalent TriloBiTE format, alongside a published 
benchmark clone, hP4340. After confirming that the resulting aMeso-tBs were able to engage T cells via CD3 
(see Fig. 2.4b, c), we assessed the potential of these molecules in redirecting primary human T cells. All three 
molecules induced target-specific cytotoxicity (see Fig. 4.1g and Fig. 2.4c, d) and effector cytokine production 
(Fig. 4.1h), directed exclusively against mesothelin-expressing tumor cells, indicating that our aMeso-tBs 
efficiently activated a polyclonal pool of primary human T cells in an antigen-dependent manner.  
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Figure 4.1. TriloBiTEs specifically redirect human T cells to target relevant cancer cells. 
(a) Schematic representation of the TriloBiTE format. A tumor-antigen specific scFv is fused to both heavy and light chain of a chimeric 
humanized anti-CD3 Fab UCHT1. The human CH1 – Ck interface serves as the heterodimerization scaffold and has been reinforced 
by stabilizing mutations, shown in bold stick representation. The structural representation has been generated with PyMOL molecular 
graphics software (Schrödinger) based on PDB entry 1HZH. (b) Reducing and non-reducing SDS-PAGE of various TriloBiTEs (1 µg 
loaded). Expected molecular weight is ~55 kDa for reduced tB and ~110 kDa for non-reduced protein. (c) Analytical size-exclusion 
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chromatography of purified TriloBiTE variants in PBS (pH 7.4) following a single freeze-thaw cycle. (d) Jurkat-NFAT reporter assay 
showing target- and concentration-dependent induction of luciferase activity by the aCD19-tB (0.01 pM – 0.5 nM) at an E:T ratio of 
5:1. (e) Specific killing of CD19+ target cells by purified human CD8+ T cells in response to stimulation with aCD19-tB (0.01 pM – 0.5 
nM). Cell death was assessed using a caspase 3/7-cleavable fluorescent dye after 4 h of co-culture at an E:T ratio of 5:1. (f) 
Quantification of effector cytokines secreted by human CD8+ T cells activated with aCD19-tB (0.01 pM – 0.5 nM) in the presence of 
CD19+ Raji cells (E:T 5:1). (g) Specific cytotoxicity of human CD8+ T cells redirected against meso-expressing H-226 mesothelioma cells 
(solid lines) by different aMeso-tB variants (1 pM – 20 nM). Cell death was observed by time-lapse fluorescence microscopy and 
analyzed after 6 h of co-culture. Meso- A673 cells (dashed lines) were not killed in response to tB treatment. E:T ratio 5:1. (h) 
Quantification of effector cytokines secreted by TriloBiTE-activated primary CD8+ T cells. T cells have been co-cultured with meso+ H-
226 cells (5:1) and different aMeso-tB (1 pM – 20 nM) for 24 h. (i) Anti-meso clone 40O3 redirects primary human CD8+ T cells to kill 
meso+ H-226 target cells in TriloBiTE format. Image-based acquisition of Cytotox Red fluorescence reports the real-time kinetics of 
killing. Baseline killing was determined against irrelevant meso-negative A673 cells using 750 pM tB. The anti-meso clones utilized 
here were isolated by Johan Abram, L-AbCore. They correspond to the following clones presented in chapter 2: 38B7, HS201; 40O3, 
HS202; hP4, P4. 
 
Interestingly, both cell killing and cytokine secretion were induced at different concentrations depending on 
the targeting scFv, possibly reflecting differences in affinity and/or epitope location. Regarding the kinetics 
of tB-mediated T cell killing, we found that T cells are activated very rapidly, leading to detectable target cell 
lysis after only 2 h of stimulation and reaching complete lysis after 12 h (see Fig. 4.1i and Fig. 2.4c, d). These 
encouraging results then prompted us to investigate the potential of our newly developed anti-TEM1 scFvs 
as targeting moieties for T cell engagers in the TriloBiTE format. 4.2.4 Design	and	functional	characterization	of	TEM1-specific	TriloBiTEs.	
We first generated TEM1-specific TriloBiTEs by fusing each clone in our panel of anti-TEM1 scFvs to both 
chains of the TriloBiTE cassette, generating bivalent engager molecules. Recombinant expression in HEK293-
6E cells followed by affinity chromatography again yielded good protein quantities (≈ 20 mg/l) of the 
expected size (≈ 110 kDa; Fig. 4.2a). Analyses of protein homogeneity of the purified material by analytical 
SEC revealed >95 % monomeric species for the clones 1C1, 1C1m, 3B6 and 7G22, but both sc78-tB and 2B11-
tB showed a significant proportion of higher molecular mass oligomers and/or aggregated species in the basic 
non-optimized PBS buffer (Fig. 4.2b). Since these clones represent early-stage experimental molecules, it is 
probable that optimization of expression and purification methodology, together with extended 
buffer/excipient screening would result in significant improvements in monomeric yield and quality. In order 
to assess the thermostability of this anti-TEM1 TriloBiTE (aTEM1-tB) panel, we subjected the purified 
molecules to a Differential Scanning Fluorimetry (DSF) stability assay. Encouragingly, the DSF measurements 
revealed melting transitional temperatures comparable to those obtained in the scFv-Fc fusion format:  
62.6 °C for sc78-tB, 71.4 °C for 1C1-tB, 64.9 °C for 1C1m-tB, 75.2 °C for 2B11-tB, 57.9 °C for 3B6-tB and 70.1 
°C for 7G22-tB (compare Fig. 4.2c with the scFv-Fc data shown in Fig. 3.3b).  
Extending our investigations to a more functional characterization of the aTEM1-tB panel, we next probed 
whether all clones were able to recognize cognate target cells. Importantly, all aTEM1-tB variants specifically 
bound to endogenous TEM1-expressing A673 cells, as well as to Jurkat cells, which express human CD3 (Fig. 
4.2d). Since all TriloBiTEs use the same anti-CD3 clone (UCHT1), binding to Jurkat cells was very consistent 
between the clones, while binding signals on A673 cells varied slightly, in line with the different affinities 
towards TEM1. Most TriloBiTEs displayed negligible binding to irrelevant HEK293-6E cells, with the exception 
of sc78-tB and 7G22-tB (Fig. 4.2d).  
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Figure 4.2. Biophysical and functional characterization of anti-TEM1 TriloBiTEs. 
(a) SDS-PAGE of anti-TEM1 scFv clones reformatted as TriloBiTEs (1 µg loaded). The expected protein structure and molecular weight 
for reduced and non-reduced engager molecules is shown in the schematic on the right. (b) Analytical size-exclusion chromatography 
of aTEM1-tB variants in PBS (pH 7.4), following a single freeze-thaw cycle. (c) ScFv thermostability of purified aTEM1-tBs was 
determined by differential scanning fluorimetry. Melting temperatures were calculated based on the minima of the derivative of 
fluorescence as a function of temperature for the first unfolding transition. (d) Binding of purified aTEM1-tB variants (1 µg/ml) to 
hTEM1+ A673 Ewing’s sarcoma cells, hCD3+ Jurkat cells and hTEM1-/hCD3- HEK293-6E cells. Cell binding was detected using an Alexa 
Fluor 647-conjugated anti-hFab antibody. (e) Cross-linking of primary human T cells and relevant target cells by TriloBiTEs. TEM1+ 
A673 cells and CD19+ Raji cells were stained with DiD and incubated with CellTrace Violet-stained human T cells in the presence of 
different TriloBiTEs (5 nM). Double-positive events were quantified by flow cytometry. FMC63 targets human CD19. Statistical 
significance was assessed using student’s t test.  
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This residual binding signal might be due to insufficient blocking of the inherently “sticky” cell surface for this 
suspension-adapted cell line, or it may be caused by a transient or culture-context expression of a truncated 
isoform of TEM1 on HEK cells, consistent with published observations from other investigators306. 
Interestingly, unlike the other clones in our study which recognize epitopes within the TEM1 multi-domain 
region situated distal from the membrane, both sc78 and 7G22 clones recognize epitopes that either overlap 
with, or reside within the upstream membrane-proximal mucin stalk region, consistent with binding to one 
or more truncated or splice variants. Confirming the dual functionality of the aTEM1-tB panel, these results 
led us to investigate whether TriloBiTE molecules could sterically engage both targets simultaneously, 
thereby bridging T cells and tumor cells. We therefore labeled target cells (A673 or Raji) and Jurkat cells with 
different fluorochromes and then incubated this cell mixture with 1 µg/ml TriloBiTE. Quantifying double-
positive events by FACS, we found that aTEM1-tBs significantly increased the frequency of A673 – Jurkat 
hetero-doublets, but did not induce doublets between Raji and Jurkat cells. The opposite was observed with 
the CD19-tB, suggesting that TriloBiTEs can specifically cross-link T cells and relevant target cells (Fig. 4.2e). 
Taken together, the aTEM1-tBs appear to possess not only promising expression and biophysical properties, 
but also the desired functionality, recognizing and cross-linking TEM1+ tumor cells and human T cells. 4.2.5 TEM1	TriloBiTEs	mediate	specific	cytotoxicity	of	primary	human	T	cells	against	TEM1+	target	cells.	
Following the initial validation of TriloBiTEs as a new molecular engager format, we next aimed to test the 
potential of our original panel of TEM1 ECD binders to engage and activate primary human T cells in the 
TriloBiTE format. As an early marker of T cell activation, we first measured expression of CD69 and CD25 in 
primary human T cells that were co-cultured overnight with TEM1+/CD19- A673 cells or TEM1-/CD19+ Raji 
cells in the presence of 5 nM TriloBiTE. All TriloBiTE clones clearly activated both CD8+ and CD4+ T cells, 
upregulating the early expression markers CD69 and CD25, although activation with 2B11-tB was quite weak 
(Fig. 4.3a). In contrast to the other TriloBiTEs, the previously published anti-TEM1 clone sc78306, which led to 
the strongest upregulation of activation markers of any of the aTEM1-tBs, also up-regulated these markers 
in the presence of TEM1-negative Raji cells. A possible explanation for this apparent nonspecific activation 
of T cells is the presence of oligomeric/aggregated species in the sc78-tB preparation (see Fig. 4.2b) and the 
high tB concentrations (5 nM) used in this experiment. Similarly, the CD19-tB stimulated strong activation 
marker up-regulation in the presence of cognate Raji target cells, and also to a significant extent in the 
presence of A673 cells (Fig. 4.3a).  
A crucial effector function of activated T cells is the production of pro-inflammatory cytokines. Encouragingly, 
with the exception of 2B11-tB, all aTEM1-tB molecules induced the secretion of IFN-g by primary human T 
cells, when co-cultured with relevant endogenous TEM1-expressing cells. 1C1m-tB induced the highest levels 
of effector cytokines, alongside sc78-tB, a trend that is consistent with the higher molecular affinity of these 
clones (Fig. 4.3b). In line with these findings, the same aTEM1-tBs also redirected human T cells to kill 
relevant target cells. Interestingly, 1C1 and the affinity-matured variant 1C1m were able to mobilize T cell 
killing at a significantly lower concentration than the other clones, including sc78 (Fig. 4.3c). Given the 
superior apparent killing activation potential of 1C1m-tB, we subjected this clone to a head-to-head kinetic 
comparison with the benchmark clone sc78. In a time-lapse microscopy-based killing assay, both clones 
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specifically and rapidly redirected primary human T cells to lyse relevant target cells, with complete lysis 
reached after 12 h for both lines (Fig. 4.3d, e).  
 
Figure 4.3. TEM1 TriloBiTEs mediate specific cytotoxicity of primary human T cells against TEM1+ target cells. 
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(a) aTEM1-tBs specifically activate both CD8+ and CD4+ T cells in the presence of TEM1-expressing A673 cells. Upregulation of early 
activation markers CD69 and CD25 was measured by flow cytometry after 16 h of co-culture (E:T ratio 1:1). Expression of CD69/CD25 
by CD8+ T cells co-cultured with Raji cells is shown as a control. (b) IFN-g secretion by primary human T cells activated with aTEM1-
tB variants (1 nM) in the presence of different target cell lines: A673 (hTEM1+), SK-N-AS (hTEM1+), AsPC-1 (hTEM1-). Cytokine 
concentration in the supernatant was measured after 24 h of co-culture. (c) Anti-TEM1 clones redirect primary human T cells to kill 
TEM1-expressing A673 cells in TriloBiTE format. TriloBiTEs were added at 1 nM or 0.1 nM and LDH activity was measured after 24 h 
as a reporter of lysed cells. Specific cell killing was calculated as a percentage of complete lysis achieved with 1 % Triton-X 100. (d) 
Real-time kinetics of cell killing by primary T cells activated with 0.6 nM or 60 pM TriloBiTE. Image-based acquisition of Cytotox Red 
signal indicates lysis of TEM1+ A673 cells (closed symbols and connected lines), while TEM1-negative AsPC-1 cells (open symbols) are 
spared. (e) Time-dependent killing of TEM1-positive A673 cells by primary human T cells in the presence of 0.6 nM 1C1m-tB. Clusters 
of dead cells emit red fluorescence. (f) Induction of effector cytokine production in human pan-T cells with increasing concentrations 
of anti-TEM1 tB. Cytokine levels in the supernatant were measured after 24 h of co-culture with TEM1+ A673 cells. T cells used in a-c 
were derived from a different donor than in d-f. E:T ratio was 5:1 unless indicated differently. 
 
 
Although the data suggests that sc78-tB induces a steeper kill curve and is more potent at the higher dose, 
1C1m-tB was able to efficiently mediate complete lysis of TEM1-expressing target cells at a ten-times lower 
molecular concentration than sc78-tB. Furthermore, neither of these molecules activated T cells in the 
presence of irrelevant cells, thereby sparing them from T cell mediated cytotoxicity (Fig. 4.3d, e). Finally, T 
cells activated with both sc78-tB and 1C1m-tB secreted effector cytokines in response to TriloBiTE dose (Fig. 
4.3f). Interestingly, stimulation with sc78-tB achieved higher levels of cytokine production overall, but 1C1m-
tB induced measurable dose-dependent IFN-g secretion at far lower concentrations (Fig. 4.3f). Therefore, at 
least for in vitro functional assays that directly score cell killing, cytokine production levels alone can only be 
considered indicative of T cell activation, and not as a predictor for end-point tB-mediated killing outcome. 
Follow-on studies that examine post-killing T cell exhaustion/proliferation may be more informative in 
understanding the relationship between tB-induced cytokine levels, immunotherapeutic safety, and optimal 
post-killing T cell fate. Nevertheless, these results clearly suggest that our novel de novo isolated panel of 
anti-TEM1 scFvs can serve as ‘warheads’ for T cell engager molecules, specifically redirecting T cells to kill 
TEM1+ target cells. To our knowledge, this is the first demonstration that a T cell engager paradigm may have 
application for the targeting of TEM1+ tumor cells.  Clone 1C1m especially, with its improved affinity over the 
parental 1C1 and tight coupling of functional T cell activation to the presence of TEM1 target, represents an 
exciting candidate for the development of a TriloBiTE-based T cell engager.  4.2.6 The	 TriloBiTE	 format	 allows	 fine-tuning	 of	 avidity	 and	 affinity	 in	 order	 to	 achieve	optimal	selectivity	and	functionality.	
A key design feature of our TriloBiTE format is its modular design. By C-terminally fusing an antigen-specific 
scFv domain to the CH1 or Ck domain of the anti-CD3 Fab, bi- or trivalent engager molecules can be created 
(Fig. 4.4a). In this way, target binding can be modulated in order to achieve optimal selectivity and T cell 
engagement. Depending on the density of the target antigen on the cell surface, monovalent binding may be 
sufficient, or bivalent antigen recognition may be required for optimal T cell retargeting. Another critical 
parameter impacting on target cell recognition is the affinity of the targeting scFv. Several studies have 
established the concept that increasing the targeting affinity improves the potency of bispecific T cell 
engagers in most cases388. In order to achieve strong and specific antigen binding, bivalent targeting using 
two low-affinity targeting moieties represents an intriguing alternative to high-affinity monovalent targeting. 
This approach thus relies on avidity stabilization (and/or rapid rebinding) rather than raw affinity, a strategy 
that has recently been applied successfully to achieve tumor-selectivity with targets that are expressed at 
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low levels in normal tissues245. With the modest-affinity 1C1 parent and its high-affinity 1C1m variant, 
differing by a sole VH CDR3 residue, at hand, we decided to illustrate the interplay of affinity and avidity in 
the context of soluble T cell engagers. To do so, we expressed mono- and bivalent TriloBiTE variants of both 
1C1 and 1C1m (Fig. 4.4a) and employed them as cytotoxic mediators in a co-culture assay. Unsurprisingly, 
the bivalent 1C1m-engager induced specific cytotoxicity at the lowest concentrations and mediated the 
highest potency of cell killing, while the low-affinity monovalent variant barely achieved T cell activation (Fig. 
4.4b). The bivalent low-affinity TriloBiTE (1C1-tB) performed equivalently to the high-affinity monovalent 
variant, thus illustrating the requirement for avid binding to drive killing. As avidity-based binding is sensitive 
to target density, 1C1-tB may demonstrate improved discrimination between target-rich tumor and residual 
levels of TEM1 that may be present in healthy tissues and some reported cell subsets265,283,287. 
In summary, the combination of the modular TriloBiTE format and our diverse panel of TEM1-specific scFvs 
provides a unique opportunity to fine-tune affinity and avidity in order to achieve an optimal balance 
between antigen target selectivity, functional T cell activation and killing, and minimization of potential (on-
target) off-tumor autoimmunity. 4.2.7 Specific	targeting	of	the	sialomucin	stalk	domain	of	TEM1	may	facilitate	optimal	T	cell	engagement.	
As discussed in the previous chapter, targeting more membrane-proximal epitopes may improve T cell 
engagement by soluble mediators247,248,363. We therefore aimed to develop novel scFv clones targeting the 
membrane-proximal sialomucin domain of TEM1. In chapter 5, I describe an alternative phage library output 
screening approach for the direct selection and identification of phenotypically functional CAR-active scFv 
warheads. Using this method, we have identified a promising TEM1(Dn)-specific scFv clone, 7G22, which we 
subsequently tested for functional activity in CAR and TriloBiTE format. Strikingly, the 7G22-tB induced a 
more pronounced cytotoxic T cell response than both 1C1m- and sc78-tB, while sparing irrelevant TEM1-
negative cells (Fig. 4.4c, e). Similarly, T cells stimulated with 7G22-tB secreted higher levels of effector 
cytokines in the presence of TEM1+ A673 or SK-N-AS cells, when compared to 1C1m-tB (Fig. 4.4d). In contrast, 
other clones isolated against the TEM1(Dn) domain (see chapter 3, especially Fig. 3.4) failed to redirect T cell 
effector functions towards TEM1-expressing target cells (Supplementary Fig. 4.1). 
Albeit still preliminary, these results suggest that epitope location may indeed be a relevant parameter for 
the engineering of immunotherapies directed against TEM1. This is especially true in light of the presumably 
modest affinity of the non-affinity matured clone 7G22. However, a deeper investigation of the activation 
kinetics and, importantly, the in vivo efficacy of 1C1m-tB and 7G22-tB will be required to dissect the impact 
of affinity, avidity and epitope location on the potency of a TEM1-directed TriloBiTE.  
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Figure 4.4. Target affinity and epitope location play a key role for the potency of anti-TEM1 TriloBiTEs. 
(a) The modular design of the TriloBiTE allows the production of mono- or bivalent variants. Mono- and bivalent TriloBiTEs have been 
generated using 1C1 or the high-affinity variant 1C1m as the tumor-targeting moiety. Surface plasmon resonance (SPR) curves and 
SEC profiles are shown for illustrative purpose. (b) Comparison of high- and low-affinity mono- and bivalent 1C1-tB variants (7 pM – 
5 nM) as mediators of cytotoxic T cell activity. Lysis of target cells (A673) by polyclonal human T cells was quantified based on LDH 
released from dead cells. Cell killing is expressed as a fraction of maximal lysis achieved with 1 % Triton-X 100. (c) Real-time kinetics 
of cell killing by pan-T cells redirected by different aTEM1-tBs (5 nM) over the course of 24 h (E:T ratio 5:1). Increased detection of 
Cytotox Red fluorescence indicates lysis of TEM1+ A673 cells (filled symbols), while TEM1- AsPC-1 cells (open symbols) are spared. (d) 
Quantification of effector cytokines secreted by polyclonal human T cells stimulated with 1C1m- or 7G22-tB in the presence of TEM-
expressing A673 or SK-N-AS cells, or in the presence of irrelevant AsPC-1 cells. Cytokines were quantified after 24 h of co-culture (E:T 
ratio 5:1). IFN-g and TNF-a secretion was quantified after stimulation with 1 nM tB and IL-2 was measured after activation with 10 
nM tB. (e) LDH-release assay comparing the tB-mediated lytic activity of human T cells towards the TEM1+ cell lines A673 and SK-N-
AS and the TEM1- cell line AsPC-1. T cells and target cells were co-cultured with 1 nM TriloBiTE for 24 h (E:T ratio 5:1) before measuring 
LDH activity in the supernatant.  
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4.2.8 1C1m-tB	prevents	the	outgrowth	of	A673	tumors	in	vivo	
In light of the promising in vitro results achieved with 1C1m- and 7G22-tB in particular, we next sought to 
investigate the potential of TEM1-specific TriloBiTEs to redirect T cell activity in vivo. Initially, we aimed to 
establish the experimental conditions and feasibility of T cell retargeting using aTEM1-tBs in vivo. In order to 
gain insights into the appropriate dosing schedule, we first assessed the serum clearance of TriloBiTE 
molecules. To this end, female NOD/SCID/IL-2Rg KO (NSG) mice were injected i.v. with 1 mg/kg 1C1-tB. Blood 
samples were taken at baseline as well as after 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h and 1 week 
(Fig. 4.5b). Subsequently, TriloBiTE serum levels were analyzed by ELISA and concentrations were calculated 
using a standard curve (Fig. 4.5a, b). Peak serum concentration of 4.604 µg/ml was reached after 60 min and 
baseline was reached after 48 h (Fig. 4.5b). However, over 90 % of the material was cleared after 24 h, and 
so we reasoned that a daily dosing regimen may be appropriate to maintain TriloBiTE levels in an initial proof-
of-concept study. 
As a pilot study, we next aimed to assess the potential of our lead candidate 1C1m-tB to redirect primary 
human T cells in an A673 xenograft model. Therefore, 106 A673 cells were implanted s.c. into the right flank 
of female NSG mice, either alone or mixed with 107 purified and expanded primary human pan-T cells. One 
hour after tumor implantation, the mice received 1 mg/kg 1C1m-tB or PBS vehicle control, administered i.v. 
into the tail vein. The TriloBiTE dose was repeated 24 h and 48 h after tumor implantation. Subsequently, the 
outgrowth of s.c. tumors was followed for 45 days, or until animals had to be sacrificed for ethical reasons. 
Encouragingly, neither the injection of human T cells, nor the administration of 1C1m-tB had an impact on 
body weight and no apparent toxicities were observed over the course of the experiment (Fig. 4.5c). As 
expected, the A673 cells rapidly formed tumors in the untreated animals (Fig. 4.5d). The administration of 
human T cells together with the tumor cells substantially delayed tumor outgrowth, but all animals eventually 
developed tumors (Fig. 4.5e). In contrast, the treatment with 1C1m-tB prevented tumor establishment, or 
significantly suppressed tumor formation, compared to the T cells only group (Fig. 4.5f-h). In fact, five out of 
ten animals never developed any tumor, indicating that all tumor cells were eradicated initially (Fig. 4.5g, h). 
Other animals only developed flat, scar-like lesions, which never grew to a three-dimensional tumor mass.  
Albeit preliminary, the results from this pilot study suggest that 1C1m-tB is active in vivo, redirecting human 
T cells to kill TEM1-expressing target cells. However, several parameters will need to be assessed in 
subsequent studies before drawing any definite conclusions. First, the requirement of TEM1 engagement for 
T cell activation will have to be confirmed either using a TEM1-negative tumor model or an inert knock-down 
TriloBiTE. The latter approach would also exclude any tonic impact of the anti-CD3 arm alone. In addition, it 
should be tested whether the observed anti-tumor effect of the 1C1m-tB is T cell dependent. Finally, the full 
potential of T cell redirecting therapy using aTEM1-tBs will require validation in tumor regression models, 
administrating both T cells and TriloBiTE systemically after tumor establishment. Ultimately, these studies 
will reveal the therapeutic potential of TEM1-targeting via soluble T cell engagers. 
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Figure 4.5. 1C1m-tB prevents A673 tumor formation in an A673 xenograft pilot study. 
(a, b) Serum clearance of 1C1-tB was analyzed in a pilot PK study. After administration of 1 mg/kg 1C1-tB, serum was collected at 
different time points and TriloBiTE concentrations in the serum were measured by ELISA (b). Serum concentrations were calculated 
using a standard curve (a). Serum from two animals was pooled for each time point. The following parameters were calculated: cmax 
= 4.604 µg/ml at tmax = 1 h; AUC = 8859. (c-h) The potential of 1C1m-tB to induce the lysis of A673 cells by primary human T cells was 
assessed in a s.c. xenograft model. 106 A673 Ewing’s sarcoma cells were implanted s.c. into the right flank of 10 week-old female NSG 
mice, either alone or admixed with 107 purified human pan-T cells. 1 h, 24 h, and 48 h after tumor implantation, mice received 1 
mg/kg 1C1m-tB in 100 µl PBS, or PBS only, administered i.v. (c) No apparent toxicities were observed upon TriloBiTE administration, 
and body weight remained comparable between the groups throughout the study. (d-f) Tumor volume was measured three times a 
week until the end of the study (day 45) or until tumors reached ~1000 mm3. Each line represents an individual animal. Arrows 
indicate the time of tB administration. (g) Mean tumor growth in the three experimental groups. The mean and SD of each treatment 
group are plotted. Statistical significance (multiple paired t-test) between the “T cells only” and “1C1m-tB” treatment groups was 
reached at day 15 (P value = 0.016916) and maintained until the end of the study (P value = 0.000045 on day 45). (h) Tumor volume 
was compared at end point: day 45 for “T cells only” and “1C1m-tB” treatment groups and day 22-29 for the untreated group. 
Statistical significance was assessed with a paired two-tailed t-test. P value (untreated vs. 1C1m-tB) <0.0001; P value (T cells only vs. 
1C1m-tB) = 0.0002. n = 10 animals per group.  
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4.2.9 Selected	anti-TEM1	scFvs	show	potential	as	targeting	‘warheads’	for	CAR-T	cells.	
The therapeutic potential of classical paradigm soluble T cell engager molecules (e.g. blinatumumab) can be 
limited by their rapid clearance from the circulation and by the need for continuous infusion administration 
in order to maintain steady state systemic drug levels within, typically, narrow therapeutic safety windows367. 
An alternative strategy of redirecting autologous T cells to the tumor tissue focuses on the genetic 
modification of T cells to combine the antigen-binding domain of an antibody or other targeting moiety with 
intracellular co-stimulatory and T-cell activation domains. These chimeric antigen receptor (CAR)-modified T 
cells have shown great promise in various clinical trials, particularly those targeting B-cell malignancies via 
lineage specific antigens such as CD19, which to-date comprise the only approved CAR-T cell therapeutic 
treatments167-171,180,369.  
We therefore sought to evaluate the utility of our new panel of TEM1-specific scFvs as targeting moieties for 
CARs. Our anti-TEM1 scFv clones were thus embedded in a modular second-generation CAR construct 
comprising a CD28 spacer, transmembrane (TM) domain and cytosolic domain fused to CD3ζ 
immunoreceptor tyrosine-based activation motif (ITAM) signaling elements and an in frame monomeric GFP 
reporter. As a first indication of the activating potential of these novel CARs, Jurkat NFAT-reporter cells 
engineered to express the fluorescent protein mCherry under the control of an NFAT-driven promoter were 
virally transduced with the resulting CAR panel. Again, the clinically validated anti-CD19 FMC63 scFv and the 
published anti-TEM1 clone sc78 were included as controls. Among all anti-TEM1 clones, only 1C1m and 7G22 
triggered a differential induction of CD3z-driven NFAT signaling in response to TEM1-expressing target cells, 
compared to irrelevant control cells (Fig. 4.6a). None of the other aTEM1-CARs, including sc78, induced 
TEM1-specific mCherry responses. The apparent inactivity of sc78 in this human CAR scaffold is surprising 
and cannot easily be attributed to, for example, the use of an inappropriate fixed scFv-TM CD28 extracellular 
spacer length, as 1C1m and 7G22 recognize TEM1 epitopes both more distal from, and more proximal to, the 
TM domain than sc78.  
Following on from these initial results, we next transduced primary human T cells with lentiviral constructs 
containing the 1C1m- and 7G22-CARs. In contrast to the Jurkat reporter cells, where high transduction 
efficiencies were achieved for most clones (84.6 % for 1C1m-CAR), far fewer primary T cells expressed the 
CAR-constructs after lentiviral delivery. Reduced transduction efficiencies are commonly observed in primary 
T cells, but 7G22-CAR expressed especially poorly, with only 10.2 % of T cells displaying measurable GFP 
signals, as compared to the ~35-40 % transduction efficiency observed with the other clones (Fig. 4.6b). 1C1m 
and 7G22 CAR-T cells were able to recognize their cognate target antigen fragments, with the high affinity 
1C1m-CAR cells showing a strong GFP-correlated diagonal shift in response to biotinylated TEM1 ECD. In the 
case of 7G22, a weak diagonal shift is evident in the minor GFP-positive population in response to expression 
supernatants containing the mucin stalk TEM1(Dn)-SpyC fragment, consistent with weak GFP expression 
levels and the expected weaker affinity of this primary naïve clone. As expected, the sc78-CAR did not 
recognize the biotinylated TEM1 fragment bound by 1C1m as its epitope resides in a region of TEM1 not 
present in either of the ECD fragments used in our de novo discovery campaigns. Extending to functional 
investigation of theses CAR clones, we next sought to measure and compare the expression of early T cell 
activation markers in response to cognate target cells. Both 1C1m and 7G22-CAR-T cells upregulated CD69 
and CD25 expression markers upon stimulation with TEM1+ A673 cells, with the magnitude of expression by 
1C1m-CAR-T cells reaching levels comparable with FMC63-CAR-T cells co-cultured with CD19+ Raji cells (Fig. 
4.6c).  
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Figure 4.6. Functionality of anti-TEM1 scFvs as targeting moieties for CAR-T cells. 
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(a) Jurkat NFAT-reporter cells transduced with 2nd generation aTEM1-CARs express mCherry in response to stimulation with cognate 
target cells: A673 (TEM1+) for anti-TEM1 CARs and Raji (CD19+) for the anti-CD19 CAR FMC63. CAR-transduced Jurkat reporters were 
equally co-cultured with irrelevant HEK293-6E cells as a negative control. CAR expression was tracked via GFP. 2nd generation CAR 
constructs comprise a targeting scFv, followed by hCD28-derived hinge and transmembrane region, intracellular CD3z and an in-
frame eGFP. (b) CAR-expression and antigen binding by primary human T cells transduced with selected CAR constructs. Binding of 
cognate biotinylated recombinant antigen (sc78: mTEM1(ECD); 1C1m: hTEM1(ECD); 7G22: TEM1(Dn)-SpyC-bioSpyT was visualized 
with APC-conjugated streptavidin. The anti-CD19 CAR FMC63 was treated as a negative control for non-specific binding of bio-
hTEM1(ECD). (c, d) Expression of early activation markers CD69 and CD25 by TEM1-CAR-T cells in the presence of endogenous TEM1-
expressing A673 cells (c) or TEM1-negative AsPC-1 cells (d). CD69/CD25 expression was quantified by flow cytometry after 16 h of 
co-culture. (e) Real-time kinetics of target cell killing (TEM1+ A673 cells) by aTEM1-CAR-T cells over the course of 48 h. Cell killing was 
quantified based on the image-based acquisition of Cytotox Red signal. (f) Lysis of TEM1+ A673 target cells by T cells equipped with 
aTEM1-CARs and added at different effector-to-target (E:T) cell ratios. Cell killing was quantified by measuring LDH activity after 24 
h of co-culture and normalized to complete lysis with detergent. TEM1-independent killing of TEM1- AsPC-1 cells at the highest E:T 
ratio (10:1) and cytotoxicity of anti-CD19 CAR-T cells (clone FMC63) towards CD19- A673 cells were assessed as negative controls. 
CAR-T cells and target cells were co-cultured in an E:T ratio of 5:1, unless indicated differently.  
 
 
Importantly, CD69/CD25 expression observed in the presence of irrelevant target cells remained low (Fig. 
4.6d). Of note, sc78 again did not seem to induce significant activation of CD3z-ITAM signaling (Fig. 4.6c, d). 
Consistent with the observed 1C1m and 7G22-CAR-T cell marker activation, both CAR-T cells specifically lysed 
TEM1-expressing tumor cells, while sparing TEM1-negative cells (Fig. 4.6e, f). Maximum lysis was completed 
after 24 h of co-culture (Fig. 4.6e) and increasing the effector-to-target (E:T) cell ratio improved TEM1-
mediated cytotoxicity for both clones, although 1C1m-CAR-T cells killed a significant proportion of target cells 
at E:T ratios as low as 2.5:1 (Fig. 4.6f). Neither of the two clones mediated unspecific killing at higher E:T 
ratios, in contrast to the clinically employed FMC63.  
Taken together, our collated data show that TEM1 may be an amenable target for both soluble T cell engager 
and CAR-engineered immunotherapeutic strategies. Further, our studies suggest that not all anti-TEM1 scFvs 
perform equally in this regard, with a scFv constructed from the previously reported sc78 molecule having 
significant shortcomings in both formats.  In contrast, our novel early lead candidates 1C1m and 7G22, which 
recognize distinctly different epitopes of TEM1, both demonstrate convincing and interesting levels of 
functional and selective target activity. Although both of these scFvs in the CAR format show similar potency 
and specificity in in vitro killing assays, roughly three-times fewer primary T cells seemed to express the 7G22-
CAR compared to 1C1m-CAR-T cells. Hence follow-on studies aimed at balancing expression levels would be   
desirable in order to balance CAR expression levels for a true comparative assessment of efficacy. Additional 
explorations may also take into consideration the influence of membrane spacer length and biophysical 
properties, parameters that have been shown to impact on CAR potency189,199,200,202. In summary therefore, 
these fully human scFv clones clearly merit further investigation in the context of T cell targeting of TEM1 
expressing tumors.  
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4.3 Discussion	
In the current study, our objective was to engineer a novel T cell engaging bispecific targeting TEM1. With 
this in mind, we designed and constructed a heterodimeric T cell engager format, termed TriloBiTE (tB), 
combining the flexible mono- or bivalent binding of target cells with simultaneous T cell engagement via the 
activating CD3 complex. For proof-of-concept we first confirmed that soluble TriloBiTEs could be produced 
and purified, and could kill target cells expressing the established engager and CAR targets CD19 and 
mesothelin. For the former, we utilized an existing, clinically approved scFv derived from the reverse 
engineering of a murine mAb, and for the latter, we exploited a published benchmark human scFv clinical 
development candidate alongside a panel of novel molecules obtained via de novo discovery activities within 
our lab.  
To our knowledge, this study represents the first attempt to explore the potential of TEM1 as a target for bi-
specific engager-based anti-tumor therapy. Our diverse panel of anti-TEM1 single-chain antibodies provides 
the unique opportunity of comparing clones with different affinities, epitopes and presumably different 
binding geometries in order to identify those ‘warheads’ that are most suitable for effective binding and cell 
bridging/T cell activation.  
Our results clearly show that soluble T cell engagers can redirect human T cells to target tumor cells via TEM1. 
Although a more in depth and systematic comparative study would be required to better illuminate the 
impact of different biophysical properties on the efficacy of T cell engagement, our data indicates that two 
key determinants for effective TEM1-targeting are binding affinity and epitope location.  
In direct comparison, the two clones with the highest monovalent affinity towards TEM1, our affinity-
matured clone 1C1m and the previously described clone sc78306 clearly outperform the remaining clones in 
terms of T cell activation and cytotoxic potential (Fig. 4.3). In line with this observation, others have reported 
previously that the potency of bispecific molecules increases with increasing targeting affinity, especially for 
targets with low cell-surface abundance388. As an example of bispecific mediators directed against very low-
density antigens, ImmTACs, which recognize peptide-MHC, require TCR affinities in the pM range389. 
Furthermore, we have shown that bivalent antigen binding can to some extent compensate for lower 
monovalent affinities (Fig. 4.4), underlining the importance of tight antigen binding especially for soluble T 
cell engagers which cannot benefit from the extreme ‘synaptic’ avidities conferred by multiple cell-mediated 
stabilizing and re-binding interactions.  
As a class, bi-specific engagers acting via CD3 are extraordinarily potent, typically with narrow therapeutic 
windows. Hence, safety and the avoidance/minimization of background toxicity are of key concern when 
advancing these molecules towards the clinic. Here, the nature of the target antigen can play a crucial role. 
While engager molecules directed against proteins with very specific/restricted expression patterns may 
benefit from increased functional affinity, generally, many solid tumor-associated antigen targets require 
molecules able to adequately discriminate between antigen expression in tumor and normal tissue. In this 
case, lower-affinity scFvs can be employed in a bivalent engager format in order to increase tumor-selectivity 
and mitigate on-target off-tumor adverse effects245. Since TEM1 is relatively poorly explored as a therapeutic 
target, thorough pre-clinical investigations will be required of any potential T cell engager candidate in order 
to demonstrate desired levels of in vivo anti-tumor efficacy, and also to assess the scope and severity of any 
off-tumor toxicity.  
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Besides the high-affinity clone 1C1m, another clone, 7G22, has also shown strong potential to redirect T cells 
to TEM1-expressing targets, both as a soluble TriloBiTE and as a CAR. As a clone isolated directly from an 
IgM/D-derived naïve library, the affinity of 7G22 is expected to be rather modest. This clone has been 
selected against a truncated version of human TEM1, comprising only the heavily glycosylated membrane-
proximal sialomucin stalk domain (TEM1(Dn)). Targeting a more membrane-proximal epitope has been 
shown to improve the potency of both soluble T cell engagers247,248,363 and CARs200,201 directed against protein 
antigens of considerable size. This phenomenon can be explained by considering the “kinetic segregation” 
model of T cell activation. The close apposition of the two membranes excludes the bulky ECD of the 
phosphatase CD45 from the immune synapse, thereby allowing the stable phosphorylation of the TCR 
complex370. Given the relatively large size of the multidomain TEM1 ECD, this may explain the fact that 7G22 
induced stronger T cell activation than the other TriloBiTE variants (Fig. 4.4) Future studies will aim to explore 
the potential of clone 7G22 in more depth.  
Although our aTEM1-tBs clearly redirect the cytotoxic potential of primary human T cells, other T cell 
functions are stimulated less efficiently. It has been established that different cellular responses are triggered 
at different thresholds of T cell activation, with the onset of cytolytic activity requiring less TCR signaling than 
the release of cytokines390,391. Moreover, IFN-g secretion occurs at a lower threshold than IL-2 release, which 
is consistent with our data392. The fact that our lead TriloBiTE candidates require relatively high 
concentrations to induce the release of IL-2 may reflect a general characteristic of the tB format which, unlike 
classical ‘back-to-back’ scFv BiTEs contains a structural ‘spacer’ moiety (the CH1/Ck domains) with additional 
flexible GS linker sequences connecting the scFvs. However, as this format is structurally analogous to the 
highly potent ImmTAC engager paradigm (which employs the Ca/Cb TCR constant domains as a ‘spacer’)389, 
a clear explanation for the observed weaker cytokine induction is not immediately apparent, particularly for 
the aTEM1-tBs.  
Besides tumor targeting affinity and epitope distance from the membrane, three other aspects have been 
shown to impact strongly on the potency and performance of bispecific T cell engagers (recently reviewed 
by Ellerman, D.)393. Firstly, the accessible copy number of the tumor-associated cell-surface antigen; 
secondly, the affinity and specific epitope recognized by the anti-CD3 binder; and finally, the molecular 
format and targeting geometry of the engager molecule. Low target copy number of tumor-specific antigens 
can be addressed with increased targeting affinity (e.g. ImmTacs)389. However, many tumor-associated 
targets are characterized by elevated expression levels, and so copy number may be less of an issue. Different 
activating anti-CD3 clones, notably OKT3, are available and could be tested in the TriloBiTE format in place 
of UCHT1. Similarly, the length and composition of intra-molecular linkers and, in the case of CARs, 
transmembrane domains, can be modified to enhance T cell functional effector functions. Conversely, in light 
of the extreme potency of T cell-based therapies and the risk of severe adverse effects, induction of clear 
target-specific cytotoxicity whilst avoiding excessive cytokine release may even prove therapeutically 
advantageous. 
Since the use of fully human targeting scFvs greatly reduces the risk of immunogenicity in the clinical 
setting364, our novel single-chain antibodies, which have been isolated from a fully human antibody library 
with minimal somatic V-gene mutations, represent ideal candidates for clinical development. Although a 
certain interest has emerged in exploiting TEM1 as a cancer target, it remains to be determined how to best 
target TEM1 for therapeutic effect. Several pre-clinical studies have highlighted the therapeutic potential of 
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antibody-drug-conjugates (ADCs) directed against TEM1304,305,307,309, but to date, no study has been published 
attempting the immunotherapeutic targeting of TEM1. As our studies suggests, aTEM1-tBs and CARs both 
show promise in vitro and preliminary results suggest promising in vivo activity of 1C1m-tB, but any 
therapeutic advantage of one strategy over the other remains to be elucidated. Generally, CAR-T cells are 
thought to be more potent than bispecific engagers at redirecting T cells394. Currently, approved clinical CAR 
therapies and most late stage clinical trials come with large associated manufacturing and treatment costs 
due to the generation of personalized engineered cell products. Soluble, “off-the shelf” T cell engager 
biologics may have cost and operational advantages in this regard. To overcome this economic hurdle, several 
strategies to generate generic allogeneic engineered CAR-T cells are currently being explored in the clinic395-
397. Furthermore, the therapeutic efficacy of both CAR-T cells and soluble T cell engagers can be limited by 
toxicological side effects and by the persistence of tumor-directed T cells171. For soluble mediators, the dosing 
regimen has to be adapted according to the pharmacokinetic properties of each engager format in order to 
achieve sustained T cell activation. While formats with molecular weights below the glomerular filtration 
rate, such as the classical BiTE format, are rapidly cleared from the circulation and thus require administration 
by continuous infusion398, medium-sized formats, such as the TriloBiTE, seek to balance the potential 
advantages of increased half-life (reduced frequency dosing) with clearance properties that are still favorable 
in the event of unexpected severe adverse events.  
It is widely acknowledged that the potency and safety of any antibody-based therapeutic agent relies heavily 
on the performance and properties of the targeting fragment moiety. Although traditional selection and 
hybridoma campaigns have generated a plethora of powerful antibodies, the development of functional 
therapeutics based on these antibodies is often laborious and requires many engineering and screening 
iterations. Frequently, simple antigen binding criteria do not correlate with the desired functionality in the 
therapeutic format of choice and many clones have to be tested before finding a promising candidate. 
Therefore, in the next chapter we describe and develop an approach for the de novo discovery of novel CARs 
using phenotypic reporter-based screening.  
 
 4.4 Materials	and	Methods	4.4.1 Recombinant	protein	expression,	purification	and	characterization	
Recombinant protein expression and purification 
To generate the TriloBiTE construct, heavy and light chain of the humanized and chimeric anti-CD3 clone 
UCHT1 were synthesized in Fab format (GeneArt, Thermo Fisher Scientific). Stabilizing mutations have been 
introduced into the human CH1-CK interface383. Both heavy and light chain of the resulting chimeric molecule 
were separately cloned into a pTT-based mammalian episomal expression vector. Both constructs contained 
modular cloning sites (NcoI/SalI) to accommodate scFv clones, which were C-terminally fused to the CH1 or 
CK domain of UCHT1 via a flexible (GS)-linker: GGGGSGGGSGGGS for CK and DKTHTGGGGSGGGGS for CH1. 
The sequence of the anti-CD19 scFv (FMC63) was extracted from Sequence 2, patent US7446179. 
Recombinant protein was produced using the HEK293-6E/pTT expression system and FectoPRO transfection 
protocol (Polyplus, #116-010), as described previously. TriloBiTEs were purified from clarified expression 
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media by immobilized metal ion affinity chromatography (IMAC) using a HisTrap excel column (GE 
Healthcase, #17371205) at a flow-rate of 1 ml/min. The column was equilibrated with 50 mM Tris, 0.5 M 
NaCl, 10 mM imidazole, pH 7.5 and protein was eluted with 50 mM Tris, 0.5 M NaCl, 300 mM imidazole, pH 
7.4 in 1 ml fractions. Monomeric peak fractions were immediately separated by preparative size-exclusion 
chromatography using a Superdex 200 Increase 10/300 GL column (GE Healthcare, #28990944) at a flow-rate 
of 0.75 ml/min. PBS (0.01 M phosphate, 0.14 M NaCl, pH 7.4) was used as sample diluent and eluent. All 
chromatography experiments were run on an ÄKTApure chromatography system (GE Healthcare). 
Biophysical protein characterization 
Purified protein samples were typically quality controlled by SDS-PAGE, loading 2 µg per sample on a Novex 
4-12% Bis-Tris gel (Life Technologies, #NP0321) under reducing/non-reducing conditions. Additionally, the 
homogeneity of purified TriloBiTEs was assessed and controlled by analytical size-exclusion chromatography 
using a Superdex 200 Increase 5/150 GL analytical grade column (GE Healthcare, #28990945). ScFv stability 
in the TriloBiTE format was confirmed by differential scanning fluorimetry following the Protein Thermal Shift 
Assay protocol from Applied Biosystems (#4461146). All three methods are described in detail in chapter 3.  4.4.2 T	cell	assays	
Cell culture 
All cell lines were purchased from the ATCC via LGC Standards. References and general culture conditions 
can be found in chapter 2.  
Purification of primary human T cells 
For the isolation of primary T cells, peripheral blood mono-nucleated cells (PBMCs) were isolated from fresh 
buffy coats obtained from healthy volunteer donors (Service de transfusion, Epalinges, Switzerland). PBMCs 
were seperated by density centrifugation using Lymphoprep (Axonlab, #1114545). Pan-T cells were 
subsequently extracted by magnetic separation using a human pan-T cell isolation kit (Miltenyi Biotec, #130-
096-535) and stimulated with human T cell activator CD3/CD28 beads (Life Technologies, #11161D) and 50 
RU IL-2 (Peprotech, #200-02-50UG) for 5 days. After the removal of the beads, primary T cells were further 
expanded with IL-7 and IL-15 (Miltenyi Biotec, #130-095-367 and #130-095-765) for a further 5 – 10 days. 
Manufacturing of CAR-T cells 
For the manufacturing of CAR-T cells, sequences encoding human anti-mesothelin or anti-TEM1 scFv 
(developed in-house) or anti-CD19 (FMC63; sequence extracted from patent US7446179) were fused to a 
spacer/hinge transmembrane region and intracellular costimulatory domain derived from hCD28, followed 
by an intracellular hCD3z signaling domain. The resulting 2nd generation CAR cassettes were cloned in-frame 
to a monomeric green fluorescent protein ORF (TagGFP2, Evrogen) into a modified pRRL lentiviral vector 
(originally developed by Didier Trono, EPFL). Lentivirus was produced by transient transfection of HEK293T 
cells using pCMVR8.74 and pMD2.G plasmids for packaging (origin: Didier Trono lab, EPFL) and Turbofect 
transfection reagent (Life Technologies, #R0532). Virus-containing supernatant was harvested after 48 h, 
concentrated by ultracentrifugation and 100 µl were added directly to 5 x 106 Jurkat-NFAT reporter cells or 
primary human T cells pre-plated in 48-well plates on the previous day. Primary T cells were transduced the 
day after isolation. All transduced cells were expanded for 10 – 14 days before performing functional assays. 
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Jurkat NFAT activation reporter cell assays 
In order to measure anti-CD19 TriloBiTE-mediated NFAT activation responses, 105 Raji target cells were 
seeded in 96-well U-bottom plates. Subsequently, 105 Jurkat NFAT-Lucia reporter cells (Invivogen), were 
added to each well. Purified TriloBiTEs (diluted in PBS) were added in 3-fold serial dilution, starting from 1 
nM. Phorbol myristate acetate (PMA)/ionomycin was included as a positive response control. After 24 h of 
co-culture, the supernatants were collected and mixed with an equal volume of QUANTI-Luc luciferase 
substrate (Invivogen, #rep-qlc-1). Luminescence was measured immediately using a BioTec H1MFG Synergy 
plate reader.  
For the assessment of CAR-induced ITAM-signaling, Jurkat-NFAT-mCherry reporter cells (kindly provided by 
Melita Irving, Lausanne) were transduced with CAR-GFP constructs as described above. 10-14 days after 
transduction, 106 transduced Jurkat reporters were seeded in 24-well plates together with 106 target cells. 
After 24 h of co-culture, Jurkat-NFAT-mCherry cells were harvested by pipetting, washed in FACS buffer (5% 
FBS, PBS) and analyzed for GFP and mCherry expression by flow cytometry.  
Primary T cell cytotoxicity assays 
Target cell killing mediated by the CD19-tB was assessed using a Caspase 3/7 flow cytometry assay 
(Lifetechnologies, # C10427). Specifically, 105 target cells and 0.5x106 primary human CD8+ T cells (isolated 
using a human CD8 T cell isolation kit; Miltenyi Biotec, #130-096-495) were mixed in 96-well assay plates. 
CD19-TriloBiTEs were added in 3-fold serial dilution starting at 5 nM. Additionally, cells in control wells were 
lysed with 20% ethanol. After 4 h of incubation, the supernatant was removed and the cells were 
resuspended in 20 µl Caspase 3/7 solution (previously diluted 1:1000 in FACS buffer, as recommended by the 
manufacturer). Cells were incubated with the caspase dye for 30 min at 37 °C and the sample plate was read 
directly on an Intellicyt iQue TM Screener PLUS instrument (10 s sampling; 1 μl/s).  
For the assessment of specific target cell killing using real-time kinetic cell imaging, 2x104 adherent target 
cells were seeded in 96-well flat-bottom plates and allowed to attach for ~20 h. When approximately 30 % 
confluency was observed, soluble TriloBiTEs were added as 3-fold serial dilutions, typically starting from 5 
nM. Positive control wells were lysed using 1 % Triton X-100. 1.25x106 purified and expanded primary human 
T cells were added to the plate to reach an E:T ratio of around 5:1. Transduced and expanded CAR-T cells 
(prepared as described above) were equally added at 1.25x106 cells/well, in this case omitting the soluble 
engager molecules. Cytotox Red reagent (Essen Bioscience, #4632) was added to a final dilution of 1:4000, 
and resultant cell death was monitored as an increase in fluorescence over time.  
Alternatively, specific target cell killing was assessed by measuring LDH release with the CytoTox 96 kit from 
Promega (#G1780), following the manufacturer’s instructions. Target cells, (CAR-)T cells and TriloBiTEs were 
prepared as described above and the assay was incubated for 24 h at 37 °C. Control wells were lysed using 
10 % Triton X-100. Subsequently, 50 µl clarified culture supernatant was mixed with 50 µl CytoTox 96 Reagent 
and incubated at RT for 30 min (protected from light). The reaction was stopped by adding 50 µl stop solution 
and LDH activity was quantified colorimetrically, measuring absorbance at 490 nm on a BioTec H1MFG 
Synergy plate reader. Background signal was subtracted from all samples and corrected cell killing 
(spontaneous release by targets and effectors subtracted) were calculated as a percentage of maximum lysis. 
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Quantification of effector cytokines 
Supernatants of co-cultures set up as described above were tested for the presence of T cell-secreted effector 
cytokines. Cytokines were either quantified by sandwich ELISA (human IFN-g or IL-2 ELISA MAX Standard kits, 
Biolegend #430102 and #431801) or by cytokine bead array (MultiCyt QBeads customized Human 3-Plex (IFN-
g, IL-2, TNF-a), Bucher Biotec #90603).  Both assays were performed according to the manufacturer’s 
instructions. In both cases, standard curves were prepared to quantify secreted cytokines. ELISA-based assays 
were read out on a BioTec H1MFG Synergy plate reader using TMB as a substrate for the HRP-conjugated 
secondary antibody. Plates for the MultiCyt bead array were analyzed on an Intellicyt iQue TM Screener PLUS 
instrument (10 s sampling; 1 μl/s). 
Flow cytometry assays 
To test TriloBiTEs for binding of TEM1+ or CD3+ target cells, adherent cells were detached using 10 mM EDTA 
and 0.5x106 pre-blocked cells were resuspended in 100 µl purified TriloBiTE (diluted to 1 µg/ml in 5% FBS, 
PBS). After 45 min of incubation on ice, the wells were washed 3x with FACS buffer. 50 µl Alexa Fluor 647-
conjugated goat anti-human Fab antibody (Jackson ImmunoResearch, #109-605-097) was added for 30 min 
on ice to detect binding TriloBiTEs. Then, the samples were washed again 3x with FACS buffer. 
In order to assess simultaneous antigen binding by TriloBiTEs, A673 and Raji cells were stained with Vibrant 
DiD lipophilic cell dye (Lifetechnologies, #V22887; final dilution 1:1000) for 5 min at 37 °C. Unbound dye was 
removed by washing 3x with serum-free RPMI. Primary T cells (prepared and expanded as described above) 
were stained with CellTrace Violet (Lifetechnologies, #C34557; final dilution 5 µM), incubating the cells for 
20 min at 37 °C and quenching excess dye with complete RPMI. 105 stained tumor cells were subsequently 
mixed with 105 stained T cells in a V-bottom 96-well plate. TriloBiTEs were added at a final concentration of 
1 µg/ml and the assay was incubated for 1 h at RT. Following incubation, the cells were washed carefully with 
150 µl FACS buffer per well and then fixed in 2 % PFA for 20 min on ice. The fixed cells were carefully washed 
3x with FACS buffer before data acquisition.  
For measuring early T cell activation, 0.5x106 A673 or Raji target cells were seeded into 24-well plates. 
Subsequently, 0.5x106 purified and expanded (CAR-)T cells were added the wells. When measuring TriloBiTE-
mediated T cell activation, purified tB protein was added to a final concentration of 5 nM. After 16-18 h of 
co-culture, the stimulated T cells were recovered and washed once in FACS buffer. Cells were blocked with 
FACS buffer for 20 min on ice and incubated with the following staining mix: APC anti-hCD8 (Biolegend 
#344722), BV785 anti-hCD4 (Biolegend #317441), Alexa Fluor 700 anti-hCD69 (Biolegend #310922), PE anti-
hCD25 (Biolegend #302606). After 30 min of incubation on ice, the cells were washed again three times.  
Antigen binding by CAR-T cells was assessed by incubating 0.5x106 CAR-T cells with 1 µg/ml bio-hTEM1 
(produced in-house, see chapter 2) and APC-conjugated streptavidin (1:2000; Biolegend #405207), both 
diluted and mixed in FACS buffer. Mammalian expression supernatant containing TEM1(Dn)-SpyC fusion 
protein was mixed with 1 μM of bio-SpyT at RT for 2 h with gentle rotation. The resulting covalent TEM1-
SpyC:bSpyT complex was separated from free bSpyT by buffer-exchange into PBS using a spin column with a 
10 KDa cut-off (Vivaspin 6; GE Healthcare, # 28932296).The resulting biotinylayed SpyT-SpyC-antigen 
complex was used as the staining antigen for 7G22-CAR-T cells. The cells were incubated with the staining 
mix for 30 min on ice and subsequently washed three times with FACS buffer. Immediately before data 
acquisition, dead cells were stained with 4ʹ,6-Diamidino-2-phenylindole (DAPI, 1:2000 dilution). Data was 
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acquired using an LSR-II flow cytometer equipped with FACSDIVA software (BD Biosciences). Data analysis 
and plotting were carried out using FlowJo v10 (FlowJo LLC). 4.4.3 In	vivo	experiments	
To gain insights into the pharmacokinetics of TriloBiTE molecules, 1 mg/kg 1C1-tB was injected into the tail 
vein of 10 8-week-old female NSG mice. The TriloBiTE was purified and prepared as described above and 
injected in a total volume of 100 µl, in PBS. Blood was collected by tail vein puncture at two time points per 
animal, resulting in 10 different duplicate time points (10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h and 1 
week after TriloBiTE injection). In addition, prior to TriloBiTE administration, a sample was taken from the 
facial vein of each animal. Serum was obtained by centrifugation and stored at -80 °C.  
For the PK ELISA, Nunc maxisorb plates were pre-coated with neutravidin, blocked, and coated with 0.5 µg/ml 
biotinylated hTEM1-ECD protein, according to the standard ELISA protocol described in chapter 2. A TriloBiTE 
standard curve was prepared by 2-fold dilution of purified 1C1-tB in 2 % pooled murine serum (baseline)/ 
PBST/ 1 % BSA, starting at 10 µg/ml. Serum samples from duplicate animals were pooled and diluted 1/50 in 
1 % BSA/ PBST. Both samples and standard curve were added to the coated ELISA plate and incubated for 1 
h at RT. TriloBiTEs were detected using an HRP-conjugated anti-human Fab antibody (Jackson 
ImmunoResearch, #209-035-097; 1:10000). ELISA plates were read on a BioTec H1MFG Synergy plate reader 
using TMB as a substrate. 1C1-tB serum concentrations were calculated based on the obtained standard 
curve. 
For the A673 xenograft pilot, 30 female NSG mice (10-weeks old) were implanted with 106 A673 cells s.c. on 
the right flank. 10 out of the 30 animals received only A673 cells and 20 mice received the tumor cells mixed 
with 107 primary human T cells. Human pan-T cells were isolated from a fresh buffy coat and expanded using 
CD3/CD28 beads as described previously. One hour after tumor implantation, 10 of the T cell-implanted mice 
received 1 mg/kg 1C1m-tB in 100 µl PBS into the tail vein. Control groups (n=10) received 100 µl PBS. The i.v. 
dosing of 1C1m-tB or PBS vehicle control was repeated 24 h and 48 h after tumor implantation. Subsequently, 
mice were monitored three times a week and tumors were measured using calipers for a total of 45 days, or 
until the tumor volume approached ~1000 mm3. NSG mice were bred and housed in a specific and 
opportunistic pathogen-free environment. All animal experimentation was performed in accordance to the 
guidelines of the Swiss Federal Veterinary Office and approved by the Cantonal Veterinary Office under the 
license number 2797.1.   
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4.5 Supplementary	information	
 
Supplementary Figure 4.1. Functional testing of anti-TEM1(Dn) clones in TriloBiTE format. 
(a) SDS-PAGE of crude HEK293-6E expression supernatants containing aTEM1(Dn)-tBs (6.5 µl loaded). (b, c) Binding of aTEM1(Dn)-
tBs to hTEM1-expressing A673 cells (b) or hCD3+ Jurkat cells (c). TriloBiTE protein concentrations were estimated based on relative 
expression levels (a). The percentage of stained cells was calculated based on gating on supernatants from non-transduced (NT) 
controls. (d) Jurkat NFAT-Lucia reporter cell assay revealing the activation potential of unpurified aTEM1(Dn)-tBs (estimated 
concentration ~25 nM) in the presence of TEM1+/meso- A673 cells or TEM1-/meso+ H-226 cells (E:T ratio 5:1). Expression supernatants 
containing aMeso-tB (~25 nM; 6B11 and hP4) served as positive controls. (e) Jurkat NFAT-Lucia activation assay using purified 
aTEM1(Dn)-tBs (0.01 – 100 nM) and TEM1+ A673 cells (E:T ratio 5:1). (f) Cytotoxicity assay assessing the potential of purified 7A6-tB 
and its affinity-matured variants (0.001 – 10 nM) to redirect primary human pan-T cells towards TEM1+ A673 cells (E:T ratio 5:1). Lysis 
of target cells was quantified based on LDH in the supernatant after 24 h of co-culture and is represented relative to maximum cell 
lysis achieved with 1 % Triton-X100. Open symbols represent LDH release by TEM1- AsPC-1 cells in the presence of 10 nM tB.
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 Development	 of	 a	 phenotypic	reporter-based	 screening	 platform	 for	 the	rapid	 de	 novo	 discovery	 of	 Chimeric	 Antigen	Receptors	(‘CAR-Factory’).	
 
The following chapter describes investigations into the feasibility of developing a practical phenotypic 
screening method for the direct de novo discovery of functional Chimeric Antigen Receptors (CARs) from 
large scFv clone populations. The CAR Factory platform employs Jurkat NFAT-fluorescent protein reporter 
cells displaying pre-enriched scFv libraries in a modular and flexible CAR format, which can be selected and 
enriched for functional activity upon stimulation with cognate target cells. Here, I present a proof-of-concept 
for this phenotypic screening approach, which led to the discovery of functional CARs directed against human 
TEM1 and mesothelin.  
 5.1 Introduction	
Chimeric antigen receptors (CARs) are synthetic tumor targeting receptors, elegantly combining an 
extracellular recognition domain, typically a scFv, and an activating intracellular signaling domain including 
the CD3z chain of the T cell receptor (TCR) complex159,162. In this way, antigen specificity can be redirected in 
order to target tumor cells expressing a specific cell surface antigen. While first-generation CARs only 
contained the intracellular CD3z signaling domain (signal 1), second- and third-generation CARs additionally 
include one or more co-stimulatory endodomains derived from CD28, 4-1BB and/or OX40 (signal 2), thereby 
mimicking co-stimulation as provided by antigen-presenting cells (APCs)163,164. Finally, fourth-generation 
CARs, or TRUCKs, are further engineered to secrete activating mediators, such as pro-inflammatory 
cytokines165.  
CARs directed against the lineage marker CD19 have shown great promise for the treatment of refractory B 
cell malignancies, achieving complete remission in a substantial proportion of patients167-171,180,369. However, 
this powerful therapeutic approach can be accompanied by serious cytokine release syndromes and other 
severe side effects related to the massive activation of T cell effector functions170,171,369. Much current 
research and development activity — including that aimed at advancing the technology and utility of CAR T 
cell therapy to solid tumor indications — therefore seeks to balance potency and safety, for instance through 
the introduction of engineered safety switches399,400, or related innovations designed to improve target-
specific T cell activation183-188. In principle, the CAR technology allows retargeting of effector cells towards 
any extracellular antigen, provided that a suitable and specific targeting moiety — usually an antibody 
fragment — is available.  
Commonly, methods for the generation of specific targeting antibodies rely on the use of recombinant 
antigen. This can be used as an immunogen to elicit polyclonal antibody responses in vivo, and/or as the 
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target antigen for in vitro library technologies such as phage or yeast display. However, the need for 
recombinant protein production and purification may present a challenge for some ‘difficult’ classes of cell 
surface molecules, such as G-protein coupled receptors or molecules with extensive post-translational 
modifications. In some cases, recombinant protein expression and immobilization may also lead to (partial) 
unfolding or altered protein conformation. Therefore, it is not uncommon for antibodies elicited against such 
molecules to show significantly altered, or even no recognition of the target protein in its native context. 
Furthermore, it cannot be assumed that any given antibody or derivative fragment isolated purely on the 
basis of raw antigen targeting criteria will be effective, or function as expected, in the context of a CAR. For 
example, scFvs with insufficient stability and/or solubility that have a greater propensity to aggregate or 
oligomerize may trigger undesirable non-specific or constitutive CAR T cell ‘tonic’ activation leading to 
impaired function and/or toxicity378,401. Additionally, immune synapse formation between effector and target 
cells is, for any given extracellular spacer/hinge, dependent on the ability of scFvs to engage those specific 
epitopes that result in optimal bridging geometry and facilitate appropriate levels of CAR clustering to drive 
effective signal transduction199-202. Thus, the identification of a functional CAR retargeting domain with the 
desired behavioral properties often requires extensive empirical testing of many scFv binders.  
As an alternative to traditional screening campaigns, some efforts have been undertaken to develop 
phenotypic screening approaches for the direct selection of “functional” scFv targeting moieties. In a proof-
of-concept study, Alonso-Camino et al. have described a mammalian cell-based antibody display platform, 
using the expression of the early T cell activation marker CD69 as a read-out for successful antibody-antigen 
interaction402. They later employ the same technology to isolate activating binders to tumor-associated 
antigens (TAA) from a human scFv library, which they displayed on the surface of Jurkat cells as a first-
generation CAR construct403. Similarly, Rydzek and colleagues designed a CAR-screening platform by 
equipping Jurkat cells with a dual nuclear factor kB (NF-kB)/ nuclear factor of activated T cells (NFAT) 
reporter, which enabled them to select functional CAR constructs in a reproducible and time-efficient 
manner404. During T cell activation, the transcription factors NF-kB and NFAT translocate into the nucleus 
upon phosphorylation of CD3z and subsequently mediate effector functions, such as the expression of 
cytokines32,405. Both NF-kB and NFAT responses are indicators of the magnitude of the TCR signal385 and 
therefore represent ideal reporters for the selection of functional CAR ‘warheads’.   
Hence, we decided to investigate the feasibility of establishing a phenotypic screening platform (CAR Factory) 
for the selection of functional CARs using human Jurkat T cells engineered to express a fluorescent reporter 
protein under the control of a NFAT-responsive promoter. Following on from previously published studies402-
404, which essentially describe variations of spiking experiments that did not result in the isolation of any 
novel scFvs, we have sought to further develop this strategy for practical accelerated CAR discovery, starting 
from large and minimally pre-selected naïve scFv libraries. In this way, we aim to demonstrate that functional 
scFv-context specific phenotypic screening can successfully bypass classical laborious discovery campaign 
approaches that primarily enrich for and emphasize those clones that perform best in affinity-driven assays. 
In the following chapter, a proof-of-concept for the successful isolation of functional CARs from human scFv 
libraries that were pre-enriched for binding of recombinant antigen by phage display is presented. 
Importantly, we demonstrate differential outcomes of traditional recombinant screening versus phenotypic 
screening using the CAR Factory approach and identify novel functional CAR candidates against three target 
moieties.   
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5.2 Results	5.2.1 Experimental	design	for	CAR	Factory	phenotypic	screening.	
Since the NFAT signaling pathways of human T cells are generally conserved in the human T cell lymphoma 
line Jurkat406, we considered that Jurkat cells containing an NFAT-responsive mCherry reporter gene would 
be a useful starting point for the development of a functional screening platform. These engineered cells 
were then further modified via lentiviral transfection to express a 2nd generation CAR construct comprising 
an N-terminal scFv targeting moiety fused to a fixed CAR scaffold comprising the spacer, transmembrane 
(TM) and cytosolic domains of CD28 fused to a CD3ζ immunoreceptor tyrosine-based activation motif (ITAM). 
 
Figure 5.1. The CAR Factory phenotypic screening platform. 
(a) Schematic representation of the CAR Factory phenotypic screening platform. A library of potential targeting scFvs is initially pre-
selected by phage display and cloned into a 2nd-generation CAR cassette containing an in-frame monomeric eGFP. The resulting CAR 
population is introduced into Jurkat NFAT-mCherry reporter cells via lentiviral delivery (1). Reporter cells displaying the CAR library 
are stimulated with tumor cells expressing a native tumor antigen (2). Jurkat cells harboring a CAR with a functional activating 
targeting scFv express mCherry and can be collected by cell sorting (3). Selected reporter cells are expanded and subjected to a 
subsequent round of phenotypic screening. Alternatively, mRNA is isolated and the scFv region is sequenced to identify enriched 
clones (4). (b) As a proof-of-concept, a single CD19-specific CAR (FMC63) was spiked into 106 irrelevant clones, comprising the 
combined R2 phage display output resulting from selections against mesothelin, TEM1(ECD) and TEM1(Dn). By incubating the 
resulting population of CAR-expressing Jurkat cells with CD19+ Raji cells, activating (mCherry+) clones are enriched during two rounds 
of phenotypic screening. (c) Sequencing of the selected population revealed a 5x104-fold enrichment of the CD19-specific clone 
FMC63. Pie segments represent discrete clone sequences. 
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In order to track CAR expression, an enhanced monomeric GFP domain was fused in-frame and downstream 
of the CAR signaling domains. The Jurkat NFAT-mCherry reporter system has been functionally validated 
using various discrete scFvs housed in our second-generation CAR, which upon stimulation with cognate 
target cells, induce potent and robust expression of mCherry (for example, Fig. 4.6a). A process schematic is 
shown figure 5.1a. We therefore hypothesized that, by extension, the Jurkat reporter cell system could 
potentially be used to enrich directly for functional activating scFv ‘warheads’ from a library of scFv-CAR 
clones displayed on the cell surface. 5.2.2 Enrichment	of	a	single	functional	scFv-CAR	from	a	pool	of	irrelevant	clones.		
The de novo isolation of functional CARs from large, minimally pre-selected Jurkat libraries will require the 
reliable and robust enrichment of a presumed small population of activating clones from a large pool of non-
functional and/or non-specific CARs. We therefore first set out to test the feasibility of retrieving a single 
functional CAR from a large population of ‘irrelevant’ clones. To do so, we spiked one Jurkat-mCherry cell 
expressing a CAR containing the clinically validated anti-CD19 scFv FMC63 into 106 Jurkat reporter cells 
displaying other, irrelevant scFv-CAR clones. Those comprised the combined R2 output of phage display 
selections against recombinant mesothelin and two different TEM1 antigen fragments, all with a typical size 
of ~105 different clones. Due to the pre-selection by phage display, some dominating clones were enriched 
in these binder pools (see Fig. 5.a, d). The resulting population of Jurkat cells was then cultured with CD19+ 
B cell lymphoma cells (Raji) at an effector-to-target (E:T) ratio of 1:1 in order to induce NFAT signaling through 
the CD19-specific CAR. After 24 h of co-incubation, the cells were recovered and activated GFP+/mCherry+ 
double-positive cells were isolated by FACS sorting. The resulting cell population was expanded and 
submitted for another round of phenotypic selection (as depicted in Fig. 5.1a). As expected, only a minor 
fraction of Jurkat cells expressed mCherry during the first round of stimulation, but the percentage of 
mCherry-positive cells was clearly enriched at the second round of screening (Fig. 5.1b). Subsequent recovery 
of scFv sequences after two rounds of selection revealed that ~5 % of the clones corresponded to FMC63, 
the CD19-specific CAR (Fig. 5.1c and Supplementary table 5.1). This represents an impressive 50,000-fold 
enrichment over the initial starting spiked Jurkat library and provides encouraging validation for our 
phenotypic CAR experimental design. In addition to FMC63, a couple of other clones from the irrelevant 
background starting pool also appeared enriched. Some of these already dominated the pre-selected starting 
libraries and were likely carried over due to their frequency. Other clones may be cross-reactive or to some 
extent non-specific, suggesting that further experiments aimed at de novo discovery would likely benefit from 
the inclusion of appropriate cell deselection steps.  5.2.3 Phenotypic	 screening	 of	 phage	 display	 outputs	 against	 cognate	 antigen	 leads	 to	demonstrable	enrichment	of	CAR-activating	clones.	
Following our initial proof-of-concept spiking experiment with FMC63, we sought to evolve this method for 
the true de novo isolation of CAR-activating scFvs present in early outputs from phage display selections. 
Traditionally, following phage display selections, hundreds to many thousands of binder clones would be 
randomly and individually arrayed and entered into a primary plate-based screening cascade, initially as 
soluble scFv or scFv-phage, in order to evaluate antigen binding. In this process, some signal amplitude 
acceptance criteria are usually applied to filter hit numbers. Collated hits are typically only then reformatted 
to better reflect the functional context of interest before conducting activity testing.  
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Figure 5.2. Phenotypic screening of pre-selected scFv libraries for the de novo isolation of functional CARs. 
(a) Jurkat NFAT-reporter cells were transduced with diluted lentiviral supernatants, aiming to achieve 10-20 % transduction in order 
to avoid reporter cells transduced with more than one CAR. Three libraries, each pre-selected for binding of recombinant cognate 
antigen, were sampled. Meso, human mesothelin; TEM1, human tumor endothelial marker 1; TEM1(Dn), N-terminally truncated 
fragment of TEM1, comprising only the sialomucin stalk; LV, lentivirus; NT, non-transduced. (b, c) The transduced Jurkat CAR libraries 
were stimulated with cognate target cells, or irrelevant cells at an effector-to-target (E:T) ratio of 1:1. After 24 h of co-culture, Jurkat 
cells were collected and assessed for CAR expression (GFP) and NFAT activation (mCherry). (b) Proportion of GFP+/mCherry+ cells 
prior to cell screening and sorting. (c) Proportion of GFP+/mCherry+ cells after three rounds of cell screening and sorting. Utilized 
target cell lines are AsPC-1 pancreatic adenocarcinoma (NT and mesothelin), A673 Ewing’s sarcoma (TEM1 and TEM1(Dn)) and 
HEK293-6E (control). 
 
 
Thus, screening emphasis is principally driven by clone affinity and soluble expression/’fitness’ characteristics 
of an arbitrary sampling of a phage selection output. We reasoned that this screening paradigm may not be 
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optimal for the isolation of scFv CAR ‘warhead’ clones whose productive functional activity is determined by 
a more complex and subtle interplay of several co-dependent variables that govern cell-cell receptor 
interactions. 
To investigate this hypothesis, we used existing phage display selection outputs that were generated in the 
course of performing classical selection and screening campaigns against three recombinant antigen targets: 
hTEM1 (ECD, upstream of the stalk region), the truncated membrane-proximal sialomucin stalk domain of 
hTEM1 (TEM1(Dn)), and human mesothelin. These diverse scFv populations were cloned into 2nd generation 
CAR constructs and packaged into lentiviral particles for delivery into Jurkat-NFAT-mCherry reporter cells to 
generate the corresponding phenotypic CAR libraries. Importantly, to avoid transduction with multiple 
constructs, which could confound downstream sequence deconvolution, we titered the experiment to obtain 
a transduction efficiency of 10-20 %, as determined by flow cytometry on the basis of GFP-CAR expression 
(Fig. 5.2a), whilst using sufficient cells to ensure representation of all scFv clones. Ten days after lentiviral 
transfection of the CAR libraries, the resulting Jurkat cell populations were enriched for GFP expression by 
fluorescent cell sorting. In order to deplete for scFv clones that non-specifically activate NFAT signaling in the 
absence of cognate cell antigen, we stimulated the libraries with irrelevant HEK293-6E cells, a line reported 
as being negative for mesothelin and having negligible TEM1 expression based on our own RT-PCR analysis 
(see Fig. 3.2b). Jurkat populations stimulated in this way were subsequently sorted for mCherry negatives. 
Finally, the transduced Jurkat reporter cells were incubated with relevant tumor cell lines expressing the 
native TAA. After 24 h of co-culture, the cells were collected and analyzed for CAR expression (GFP) and bulk 
activation (mCherry) (Fig. 5.2b; see Fig. 5.1a for a schematic of the CAR Factory phenotypic screening 
platform). While only a small proportion of JurkatTEM1 and JurkatTEM1(Dn) were positive for mCherry at baseline, 
the mesothelin library apparently already contained a substantial number of activating clones. This 
observation suggests clear differences between the two antigens as prospective CAR targets. Moreover, even 
though we had aimed for 10-20 % transduction efficiency, the GFP expression in this experiment indicated a 
lower (5-10 %) proportion of successfully transduced cells (Fig. 5.2b).  
All target-specific GFP/mCherry double-positive cells from this first round were collected by FACS sorting and 
expanded for 14 days to ensure recovery and to allow mCherry levels to return to basal, unstimulated, levels. 
Subsequently, the enriched Jurkat-CAR libraries were subjected to two additional rounds of phenotypic 
screening, again using native antigen presented on tumor cells to stimulate the CAR-induced expression of 
mCherry, as described above. After three rounds of cell screening (CS03), we observed a substantial 
enrichment of GFP+ CAR-expressing cells for all three libraries, as well as a strong enrichment of mCherry+ 
activated CAR-T cells (Fig. 5.2c). Although clearly enriched, the fraction of target-specific double-positive 
Jurkats differed markedly for the different antigens, as did the proportion of cells expressing mCherry upon 
stimulation with irrelevant cells, with the two TEM1 fragment libraries showing significant residual HEK293-
6E binding (Fig. 5.2c).  
The latter could be accounted for by a possible cryptic context-specific expression of TEM1 (a possibility 
alluded to briefly in chapter 4), or by the inadequate depletion of cross-reactive off-target scFv-CARs. The 
molecular characteristics of the target antigen itself may contribute significantly in this regard.   
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Figure 5.3. Identification of novel CARs targeting relevant tumor antigens. 
(a) Sequencing of the JurkatTEM1(Dn) library after three rounds of phage display (PD03) or cell screening (CS03) revealed strong 
enrichment of different clones. (b) Efficiency of Jurkat reporter cell transduction with individual CAR constructs, as measured by GFP 
expression. (c) Induction of T cell/NFAT signaling in CAR-expressing Jurkat cells stimulated with different target cells for 24 h (E:T, 
1:1), as measured by mCherry expression. Single live cells were gated on GFP. Utilized target cell lines are A673 Ewing’s sarcoma 
(hTEM1+), AsPC-1 pancreatic adenocarcinoma (hTEM1-), and H-226 mesothelioma (hTEM1-). (d) Sequence diversity of Jurkatmeso and 
JurkatTEM1 libraries before (PD02) and after (CS03) phenotypic screening. Enriched clones highlighted in the right panel were selected 
for further characterization. Clone 3B6 had been identified previously by traditional ELISA screening using recombinant TEM1. (e, f) 
Jurkat reporter cells transduced with individual CARs were stimulated with cognate target cells, or irrelevant cells at an effector-to-
target (E:T) ratio of 1:1. After 24 h of co-culture, Jurkat cells were collected and assessed for CAR expression (GFP) and NFAT activation 
(mCherry). (e) Activation of mCherry reporter signals by individual CAR constructs selected against hTEM1. Grey dots represent cells 
stimulated with TEM1-negative AsPC-1 cells. Red dots represent cells stimulated with TEM1-expressing A673 cells. (f) Activation of 
mCherry reporter signals by individual CAR constructs selected against mesothelin. Grey dots represent cells stimulated with meso- 
A673 cells. Blue dots represent cells stimulated with meso+ AsPC-1 cells. 
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In the case of the highly O-glycosylated TEM1(Dn) stalk fragment, common glycan motifs may contribute 
significantly to epitope features recognized by the library scFvs. As the starting point for this experiment was 
a phage display output generated against TEM1(Dn), produced (and glycosylated) in HEK293-6E cells, it is not 
surprising that resultant clones may recognize, to varying extents, such recognition elements in the context 
of other cell surface glycoproteins, thus accounting for higher control activation signals against this cell line. 5.2.4 Phenotypic	cell	screening	efficiently	enriches	clones	independently	of	their	frequency	in	the	starting	phage	display	pools.	
To identify selected scFv clones, mRNA was isolated from the CS03 sorted Jurkat cell population as well as 
the naïve libraries and the scFv domain was amplified and subcloned. For each target library, 96 clones were 
randomly selected and sequenced. Sequence analysis revealed that the majority of clones comprised full-
length in-frame VH and VL chains without internal stop codons or indels (see Supplementary tables 5.2-5.7). 
In the pre-selected JurkatTEM1(Dn) library, one clone, 7A6, was highly abundant, and comprised 96 % of all 
sequenced clones. Thus, this clone had been strongly enriched in the preceding phage display selection steps 
against the recombinant TEM1(Dn) protein (Fig. 5.3a). In contrast, phenotypic screening using the CAR 
Factory approach effectively and strikingly reversed this enrichment in favor of a different clone, 7G22, which 
was massively amplified from the residual diverse background of low frequency clones present in the starting 
pool (Fig. 5.3a). To explore this observation further, we generated discrete CAR constructs for both 7A6 and 
7G22 in Jurkat NFAT-mCherry cells. Both CARs were expressed as indicated by the presence of a GFP-positive 
population, albeit to different extents (Fig. 5.3b). When co-cultured with TEM1+ target cells, 7G22 induced 
NFAT-dependent expression of mCherry. However, the dominant phage display output clone 7A6 appeared 
to activate TCR/NFAT signaling non-specifically, both in the presence of TEM1+ cells and when co-cultured 
with irrelevant, TEM1-negative cell lines (Fig. 5.3c) with no obvious discrimination. Alternatively, the 
observed mCherry levels may reflect background ‘tonic’ signaling. Collectively, these observations highlight 
an extreme example of divergence between scFv clones isolated according to classical soluble expression 
screening and affinity criteria, and clones whose isolation is dependent on functional context.  5.2.5 Identification	 and	 characterization	 of	 novel	 CARs	 targeting	 the	 TEM1	 ECD	 or	 the	mesothelin	tumor	antigen.		
In contrast to the JurkatTEM1(Dn) library, the original clone libraries directed against mesothelin and TEM1 were 
more diverse, although the Jurkatmeso library displayed some clear clone enrichment preference (Fig. 5.3d). 
Although the majority of clones analyzed represented unique sequences, ~20 % of the sequences in the 
Jurkatmeso starting library encoded two distinct enriched clones (M3B06 and M3E04). The function-based 
enrichment of activating CARs over the three rounds of phenotypic selection constrained the composition 
and diversity of both libraries substantially, with clone M3E04 now constituting 49 % of all sequences (Fig. 
5.3d). For TEM1 ECD, the initially very broad library diversity was similarly constrained after the cell-based 
selection rounds and 65 % of all clones now shared the same sequence (T3A09). Additionally, a variant of this 
clone was found using a slightly different light chain (T3G09; Fig. 5.3d). Interestingly, only one clone (3B6) 
was found to overlap with the ELISA screening campaign performed following the initial phage display 
selection (see Table 3.1 and Fig. 3.1e). 
Jurkat NFAT-mCherry reporter cells were subsequently transfected with individual CAR constructs comprising 
scFv ‘warheads’ corresponding to the functionally enriched clones. With the exception of clone T3G09, 
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functional testing of the individual clones revealed only very modest TEM1-specific mCherry activation 
potential for the TEM1-selected clones, despite strong CAR-GFP expression (Fig. 5.3e). In comparison, Jurkat 
cells expressing CARs selected against mesothelin displayed significantly reduced GFP expression and two of 
the selected clones barely showed detectable GFP signals (Fig. 5.3f).  
Figure 5.4. CARs identified by phenotypic screening specifically activate NFAT signaling in the presence of cognate target cells. 
(a) Novel CARs enriched for functional binding of TEM1-expressing cells were individually introduced into Jurkat NFAT-mCherry 
reporter cells. One clone, 3B6, previously identified by recombinant screening, served as positive control. 7 days after lentiviral 
transduction, CAR expression and binding of biotinylated recombinant hTEM1 (ECD) was assessed by flow cytometry, detecting APC-
conjugated streptavidin. (b) Jurkat NFAT-mCherry cells expressing newly identified anti-mesothelin CARs or the previously identified 
clone 6B11 were assessed for binding of recombinant human mesothelin protein. Binding was revealed with an iFluor647-conjugated 
anti-his tag antibody. (c) Anti-TEM1 CAR expressing Jurkat cells were co-cultured with TEM1+ A673 cells (red dots) or TEM1- Raji cells 
(grey dots) at a 1:1 ratio. After 24 h, CAR-bearing Jurkat cells were tested for activation induced mCherry expression. Cell populations 
are shown gated on single live GFP+ cells. (d) NFAT-induced mCherry expression by CAR-transduced Jurkat reporter cells was 
measured after 24 h of co-culture with meso+ H-226 cells (blue dots) or meso- A673 cells (1:1 cell ratio). Cell populations are shown 
gated on single live GFP+ cells. 
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Nevertheless, two of these CARs, when stimulated with native mesothelin presented on tumor cells, induced 
measurable mCherry expression. Surprisingly, the strongly enriched clone M3E04 did not seem to activate 
robust NFAT signaling, but it expressed at higher levels (~44 % GFP+ cells) compared to most of the other 
clones, raising the possibility that additional ‘fitness’ criteria and/or sorting carryover could account for its 
robust representation in the final pool. 
Subsequently, several prospective activating clones were chosen for further characterization. Those CAR 
constructs were reintroduced into Jurkat NFAT-mCherry reporter cells by lentiviral transduction. After 10 
days of expansion, the transduced reporter cells were assessed for CAR expression and soluble cognate 
antigen binding. (Fig. 5.4a, b). For both TEM1 ECD and mesothelin antigens, binders that had been identified 
following classical phage display screening campaigns were included as positive controls. For the selected 
anti-TEM1 CARs, the transduction efficiency was high (86.3 % for T3A09 and 74.4 % for T3G09), but only the 
T3A09 CAR seemed to bind appreciably to recombinant hTEM1 protein (Fig. 5.4a). In contrast, neither of the 
CAR Factory selected anti-mesothelin CARs were stained with monomeric recombinant mesothelin protein 
(Fig. 5.4b). In addition, although higher than in previous experiments, the proportion of GFP expressing cells 
was rather low (28.6 % for M3B03 and 26.6 % for M3E03), especially compared to the previously identified 
anti-mesothelin clone 6B11 (90.5 %; Fig. 5.4b). 
Nevertheless, we proceeded to test all CARs for specific T cell activation in a co-culture experiment. 
Surprisingly, T3G09, which did not show any binding to recombinant monomeric TEM1, induced NFAT-driven 
mCherry expression specifically in the presence of TEM1+ cells. As observed previously (see Fig. 4.6a), the 
previously identified clone 3B6, which recognized TEM1 protein, failed to mediate any differential mCherry 
response. Clone T3A09 showed a similar binding/activation pattern (Fig. 5.4c). Similarly, both novel anti-
mesothelin CARs specifically induced T cell signaling in the presence of mesothelin expression cancer cells, 
leading to mCherry expression in a substantial proportion of Jurkat reporters (Fig. 5.4d). Together, despite 
the apparent lack of recombinant antigen binding (discussed below), a subset of CAR targeting moieties 
identified using the CAR Factory phenotypic screening platform appear functional and merit further 
investigation in primary T cell Selective killing assays.  
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5.3 Discussion	
In the present study, we have explored phenotypic cell-based screening as an alternative approach for the 
rapid identification of functional CAR scFv ‘warheads’ from complex starting libraries. Employing an NFAT-
driven mCherry reporter system, we have shown that this ‘CAR Factory’ platform is capable of retrieving rare 
scFvs from a pool of irrelevant clones, which are capable of driving CAR activation. In this preliminary study, 
we have identified and partially characterized novel CAR-active scFv clones specific for three distinct antigen 
fragments.  
In our experimental framework, scFvs that drive CAR activation are expected to represent a subset within 
larger pools of general ‘binders’ that have undergone some preliminary capture/enrichment on immobilized 
recombinant antigen protein. As these CAR-compatible clones would appear to have no defined competitive 
advantage in terms of either soluble expression fitness or raw binding affinity, they may enrich only slowly 
— if at all — during conventional phage display selections, and be disregarded (or just not sampled) during 
typical primary ELISA or protein-interaction assay cascades.  
The TEM1(Dn) recombinant domain study described above illustrates such a scenario. Here, the 
immunodominant phage display-selected scFv (7A6) was unable to compete in a phenotypic functional 
context. Despite the extreme over-representation of 7A6 in the phage output, phenotypic selection using 
native antigen-expressing cells enabled the retrieval and enrichment of the low frequency, but apparently 
superior, 7G22 clone, which displayed significant TEM1 selective activation potency at low apparent CAR 
expression levels (GFP basis; Fig. 5.3a-c). Interestingly, 7G22 not only activated NFAT signaling in Jurkat CAR 
reporter cells, but was able to potently and specifically redirect primary T cell effector functions as both a 
CAR and a soluble T cell engager (see chapter 4). Similarly, the fact that functional molecules appear to be 
rare in the JurkatTEM1 library, despite the high ELISA hit rates in the phage display primary screening (see Table 
2.2 and Fig. 3.1b), supports the hypothesis that binding does not necessarily predict functionality. Overall, 
this clearly demonstrates how the specific discovery/screening method can impact on the enrichment of 
desirable scFv candidates. 
As observed in our lab, and in line with many published and anecdotal accounts, antibodies raised against 
isolated antigens in solution often do not perform as expected against the respective proteins in their native 
membrane-bound forms407,408. Such discrepancies may be attributable to several non-mutually exclusive 
possibilities, such as the masking of epitopes on the cell due to complexation with other membrane 
components, differences in key post-translational modifications that impact on epitope structure, or more 
simply, incorrectly folded recombinant protein used in the selection campaign. Moreover, certain antigen 
epitopes or protein regions can assume different main- or side-chain conformations or dynamic 
conformation equilibria that may be distinct between recombinant antigen in solution and membrane-bound 
forms409. This may be particularly relevant for large or complex multidomain proteins such as TEM1. Thus, an 
intriguing possibility is that a sub-population of selected library phage may recognize such flexible regions of 
a recombinant antigen with particularly weak affinity constants, but nevertheless will propagate through 
selection rounds. Such scFv ‘passenger’ clones, if subsequently challenged against the corresponding native 
membrane antigen, may encounter stabilized structures or dominant conformations that facilitate better 
paratope interactions and the apparent restoration of binding.  
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Conversely, and equally compelling is the possibility that an apparent affinity gain could be achieved by subtle 
conformational shifts in the folded scFv molecule, brought about by a switch from prokaryotic (phage display) 
to eukaryotic (CAR format) expression. Such a hypothesis merits further investigation, but could account for 
situations, such as we describe above, whereby phage outputs selected on recombinant antigens contain 
scFv clones that have apparent target-specific functional activity against their cognate native antigens, but 
do not appear to recognize soluble recombinant antigen.  
Indeed, the existence of variant conformational epitopes leading to differential antibody binding to soluble 
versus membrane-bound protein has been suggested for mesothelin and other glycosylphosphatidylinositol 
(GPI)-anchored proteins409-411. Asgarov and colleagues describe the identification of a novel anti-mesothelin 
antibody, which preferentially recognizes mesothelin-expressing cells, but does not bind to cleaved nor 
recombinant full-length mesothelin409. Since high concentrations of shed mesothelin in the serum of cancer 
patients can, in principle, act as an antigen sink and hinder the therapeutic effect of targeted therapies, 
antibodies specific for membrane-bound mesothelin may prove advantageous in the clinic412. However, 
validation of CAR Factory clones that appear to differentially recognize cognate native cell membrane 
antigens, but not the corresponding recombinant soluble reagents, would ideally require the availability of 
specific KO lines. In addition, such tools could prove useful as true null subtraction cell lines for use during 
the enrichment/sorting procedure.  
Our current phenotypic screening workflow exploited relatively pre-enriched scFv libraries, which had 
undergone two rounds of phage display on recombinant antigen. As discussed above, this may introduce an 
undesired bias towards certain epitopes. Therefore, and in order to explore the full potential of the CAR 
Factory phenotypic screening approach, we next plan to sample minimally preselected scFv libraries that 
have undergone just a single round of phage display against recombinant antigen. This should ensure capture 
of all clones in the library that recognize the antigen across the widest range of epitopes and with the widest 
range of binding affinities, whilst reducing the scFv clone population to a number compatible with our CAR 
Factory library process (105-106 as a typical R1 clone output). In addition, the absence of a second phage 
amplification round should ensure that the rarest binder clones are retained in the experiment. In this way, 
we hope to further develop and adapt the potential of our CAR Factory platform approach to enable the 
optimal, unbiased, de novo discovery of rich panels of CAR-active scFv clones. 
Finally, the modular CAR scaffold used in our studies has been designed to be fully compatible with CAR 
constituent element cloning, allowing full portability of linker/spacer regions, TM domains, ITAMs and 
costimulatory domains — all of which can have a major impact on T cell engagement and 
activation189,196,199,202,378,401,413. As previously discussed, optimal bridging distance is influenced not only by the 
scFv and its target epitope, but also by the length and structure of the linker/spacer region connecting the 
scFv to the CAR TM domain193,199-202. Hence, one can envisage future CAR Factory experiments where de novo 
isolated CAR-active scFv pools are further permutated against defined panels of linkers, TM domains and 
ITAM repertoires before being fed back into the phenotypic NFAT reporter screen to search for optimized 
and/or novel modular CAR assemblages.  
In summary, we have shown that phenotypic CAR screening has the potential to accelerate (and rescue) the 
discovery of functional CAR warheads via context-appropriate mining of scFv libraries. Further development 
and refinement of the technology and its scope is ongoing, as is the validation of the identified CARs in 
primary T cells.  
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5.4 Materials	and	Methods	
Cell culture 
All target cell lines were sourced from the ATCC via LGC Standards and cultured as described in chapter 2. 
Jurkat NFAT-mCherry reporter cells were a kind gift from Melita Irving’s lab, UNIL. They were maintained in 
RPMI-1640 Glutamax (Life Technologies, #61870010) containing 10% fetal bovine serum (FBS; Biowest # 
S1810-500, lot #S1614151810) and 100 U/ml penicillin/streptomycin (Gibco, Life Technologies, #15140122). 
All cells were cultured at 37 °C, 5 % CO2 in a humidified incubator and regularly tested for mycoplasma (GATC 
service). 
Construction of CAR libraries 
Phage display selection outputs stored as bacterial glycerol stocks were thawed and plasmid DNA was 
isolated using the ZymoPURE II Midiprep kit (Zymo Research, # D4201). The scFv gene was extracted by 
digestion with NheI-HF/SalI-HF (NEB, # R3131S and # R3138S) for 3 h at 37 °C. The corresponding DNA band 
(~800 bp) was extracted from a 1 % agarose gel using the ZymoCLEAN gel DNA recovery kit (Zymo Research, 
# D4002) and ligated into the cloning site of a modified pRRL vector harboring a spacer/hinge, TM region, 
hCD28-derived intracellular costimulatory domain and hCD3z signaling domain, followed by an in-frame 
monomeric GFP (TagGFP2, Evrogen) in the format of a 2nd generation CAR. Ligation was performed using T4 
DNA ligase (1000 U, NEB # M0202S) and incubating at RT for 2 h followed by o/n at 16 °C. The ligations were 
purified using the Zymo DNA Clean & Concentrator kit (NEB, # D4006) before heat shock transformation (45 
s at 42 °C) into E.cloni 10G chemically competent cells (Lucigen # 60107-2). pRRL plasmid DNA of successfully 
transformed clones was isolated with the ZymoPURE Maxiprep kit (Zymo Research, # D4202) and 
concentrated to 1 µg/µl.  
Lentiviral transduction of Jurkat NFAT-mCherry cells 
Lentivirus was produced in HEK293T cells transiently transfected with the resulting pRRL libraries and 
pCMVR8.74 and pMD2.G packaging plasmids (origin of lentiviral plasmids: Didier Trono lab, EPFL) using 
Turbofect transfection reagent (Life Technologies, #R0532) and protocol. Viral particles were harvested after 
48 h and concentrated by ultracentrifugation. Concentrated lentiviral supernatants were diluted in a 2-fold 
dilution series (up to 1:32) and added immediately to 1 x 106 Jurkat NFAT-mCherry cells. Transduced cells 
were expanded and assessed for GFP expression by flow cytometry after 7 days. Cell populations containing 
10-20 % transduced cells were selected and expanded for another 3-7 days before cell sorting.  
CAR activation and phenotypic screening assays 
The Jurkat libraries were first enriched for scFv.CAR.GFP expressing cells by sorting unstimulated 
GFP+/mCherry- cells. The resulting enriched scFv.CAR.GFP expressing population was expanded for 7 days 
and subsequently stimulated with irrelevant, antigen negative HEK293-6E cells. Therefore, 3 x 106 HEK293-
6E cells were co-cultured with 3 x 106 scFv.CAR.GFP library expressing Jurkat cells in sterile 6-well plates in a 
total volume of 2 ml. Additionally, non-transduced Jurkat NFAT-mCherry cells were stimulated with phorbol 
myristate acetate (PMA)/iomomycin cell stimulation cocktail (Thermo Fisher Scientific # 00-4970-03) as a 
positive control. After 24 h incubation at 37 °C, 5 % CO2, the cells were resuspended and washed once with 
2 ml 5 % FBS, PBS (FACS buffer) before proceeding to FAC sorting of GFP+/mCherry- cells into single tubes. 
The resulting cleaned Jurkat libraries were expanded again for 7 days and then stimulated with target cells 
expressing the antigen of interest for a phenotypic cell sorting. To this end, adherent target cells (A673 cells 
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for JurkatTEM1 and JurkatTEM1(Dn) libraries and AsPC-1 for the Jurkatmeso library were harvested with trypsin-
EDTA, counted and adjusted to 4 x 106 cells in a 6-well plate. Library-expressing Jurkat populations were 
added at 4 x 106 cells to obtain an effector-to-target (E:T) ratio of 1:1. Jurkat cells were stimulated for 24 h at 
37 °C, 5 % CO2 and subsequently harvested and washed as described above. Again, non-transduced Jurkat 
NFAT-mCherry cells stimulated with PMA/ionomycin served as a positive control. GFP+/mCherry+ cells from 
each library were sorted and expanded for 14 days prior to a subsequent round of cell stimulation and sorting. 
For all sorting experiments, dead cells were stained with 4ʹ,6-Diamidino-2-phenylindole (DAPI, 1:2000 
dilution). Cells were sorted using a FACSAria III cell sorter equipped with FACSDIVA software (BD Biosciences). 
Isolation, cloning and sequencing of selected scFvs 
Before and after three rounds of phenotypic screening and cell sorting, mRNA was isolated from 107 sorted 
Jurkat pools using the Dynabeads mRNA DIRECT purification kit (Thermo Fisher Scientific, # 61011), following 
the manufacturer’s instructions. Subsequently, 1 µg of the resulting mRNA served as the template for cDNA 
synthesis using the PrimeScript 1st strand cDNA kit (Takara, # 6110B) and oligo-dT primers. The scFv sequence 
was amplified from the cDNA template using Phusion High-Fidelity PCR Master Mix with GC Buffer (NEB # 
M0532S) and the following primer set: HT-CAR_amplif.FW1: CCT GCT AGT ACT CTT CTG GGC and HT-
CAR_amplif.REV1: AGG TGG AGG ATA CAT AAC TTC GT. Successfully amplified scFv pools were purified from 
1 % agarose gels using the ZymoCLEAN gel DNA recovery kit (Zymo Research, # D4002) and cloned into the 
in-house developed pCHV101 phagemid vector (see chapter 2) using NheI-HF/SalI-HF, as described above for 
the construction of CAR libraries. Single colonies of successfully transformed cells were picked and sequenced 
using the high-throughput plate sequencing service of Microsynth.   
Flow cytometry assays 
For co-culture NFAT activation assays, adherent cells were detached using 10 mM EDTA, counted and 
resuspended in fresh, complete culture medium. 0.5 x 106 target cells were seeded into 24-well assay plates 
and 106 CAR-transduced Jurkat NFAT-mCherry cells were added in a total volume of 1 ml complete RPMI. 
After 24 h of co-culture, the cells were harvested and washed once with 2 ml FACS buffer (5 % FBS, PBS). 
Antigen binding by anti-TEM1 CAR expressing Jurkat cells was assessed by incubating 0.5 x 106 Jurkat cells 
with 1 µg/ml bio-hTEM1 (produced in-house, see chapter 2) and APC-conjugated streptavidin (1:2000; 
Biolegend #405207), diluted in FACS buffer. Anti-meso CAR expressing Jurkat cells (0.5 x 106) were incubated 
with 1 µg/ml his-tagged human mesothelin protein (amino acids 296-580; R&D Systems #3265-MS-050) 
instead. Incubation with the antigen or staining mix was performed for 30 min on ice followed by three wash 
steps with 100 µl FACS buffer. Binding of recombinant mesothelin was revealed using an iFluor647-
conjugated anti-His tag antibody (GenScript #A01802-100), diluted 1:1000 in FACS buffer. After another 30 
min incubation on ice, stained cells were washed again three times. Immediately before data acquisition, 
dead cells were stained with 4ʹ,6-Diamidino-2-phenylindole (DAPI, 1:2000 dilution). Data was acquired using 
an LSR-II flow cytometer equipped with FACSDIVA software (BD Biosciences). Data analysis and plotting were 
carried out using FlowJo v10 (FlowJo LLC). 
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5.5 Supplementary	Information	
clone 
HC LC 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
C10    SSNIGAKYG ETT GA 0 
C11    QTILYSSNNKNY WAS HQYYSIPHT 0 
B02    QSVNSWH STS  0 
C05 GFTFSSYG ISYDGSNK AKAALLGGYSYGFNWFDP KLGDKY QDV QAWDSSHVV 2.5 
M3F06 GFTFDDYA ISWNSGSI AKDLAPYYYYMDV QSISSR RAS QQFNTYPLT 2.5 
A01 GFTFSSYA ISGSGGST AKGGGLFGY SSNIGSNT SNN AAWDDSLNGLV 2.5 
FMC63 GVSLPDYG IWGSETT AKHYYYGGSYAMDY QDISKY HTS QQGNTLPYT 5.0 
A12 GYTFTGYY INPNSGGT ARAGRLGWFDP NIGRKN RDS QVWDSSGDPVV 2.5 
D04 GFTFSSYS ISSSSSYI ARAPNSVGYAFDI QSLLYTNGYNY TLS MQRIEFPFT 2.5 
C08 GYSFIDHY INPKGGDT ARDKYYYLIDY QDISNY DAS QQYDNLPPT 2.5 
B01 GGSISSSNW IYHSGST ARDNPWGYGMDV QSISSY AAS QQSYSTSIT 2.5 
B06 GFTFSSYA ISYDGSNK ARDPSMIVGFDL SSDIGSNT SNN AAWDDSLNGHYV 2.5 
A06 GYTFTSYG ISAYNGNT ARDQSGDFWSGYFYYYGMDV QGISSY AAS QQLNSYPPV 2.5 
C02 GYTFTSYG ISAYNGNT ARDSGRRWLQSYFDY QSISSY AAS QQSYSTPWT 2.5 
D10 GFTFSSYA ISYDGSNK AREEGSGWYSVRSYWYFDL NIGSKS DDS QVWDSSSDHPV 2.5 
M3E04 GGSISSGDYY IYYSGST ARESVVAGAFDI QSISSY AAS QQSYSTPYT 10 
D03 GYTFTSYD MNPNSGNT ARGEDSGSYYRAGY QSVSTY DAS QQRSKWPPV 2.5 
A11 GGTFSSYA IIPIFGTA ARGLNTRGGGY QSLVYSDGNTY KVS MQGTHWPPT 2.5 
B07 GYTFTGxY INPNSGGT ARGVSSSPLISSxTFDP xSNIGSNA SNN AAWDDSLSGWV 2.5 
D08 GYSFTNYW IYPGDSDT ARRYYDSSGYYSLSAFDI SSNIGNNY ENN GTWDSSLSAGV 2.5 
B04 GYTFTGYY INPNSGGT ARSGYYYDSSGYYSDYFDY SSNIGSDY NND AAWDDSLSGPNYV 2.5 
A07 GYTFTSYG ISAYNGNT ARTFWGRTPFDY QSVLYRSNNRNY WAS QQYYSIPLT 5 
A02 GGSFSGYY INHSGST ARVPLIAVAGTGYYYYGMDV QSIANY AAS QQSYSIPPT 2.5 
B12 GYTFSSHA INVFNGNT ARVSLRRGGDYFYDY QSISSY AAS QQSYSTPLT 5 
B09 GGTFSSYA IIPILGIA ARVVLPLYGMDV QTVSSAF ATS QHYSGSPPVYT 5 
D11 GGTFSNYG IIPIFGTA ARVYSGAGDNRGYYFVY    2.5 
B10 GYTFSSNA INAGNGNT ASFDYDY QSVSSY DAS QQRSNWPGT 2.5 
B05 GYTFTSYY INPSGGST ASSAWISDFDY GSDFNY DVT HSHAARGTLSYI 2.5 
C01 GYTLTELS FDPEDGET ATEWELLHDRNDAFDI TSNIVHNS DDS ATWDTTLSAVV 5 
C09 GFTFSSSD IGLADDT VREGLSGNWDNWYFDL QSIRSH GAS QQSYSDPPT 2.5 
Supplementary Figure 5.1. CDR sequences and diversity after phenotypic selection against CD19+ Raji cells. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly after 2 rounds of cell selection on CD19+ Raji 
cells (CD19 spike; see Fig. 5.1b, c). 
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clone 
HC LC % 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3  
B09 GYTFTSYD MNPNSGNT  QSLLHSNGYNY LGS MQALQTPLT 1.04 
H12    ESLLHTNGYNY LAS MQSLE 1.04 
G08    QSVSSSY GET LNGHH 1.04 
H04    VRVLAA DAS QQRGTGLSLSxGxWKSN 1.04 
E08 GYTFTGYY INPNSGGT AGDYDFWSGFDP SSDVGGYNY DVS SSYTSSSTWV 1.04 
D04 SISSNSGAWN YRSKWYN AGGTHYNGMDV QSISRY TTS QQGYSRPAT 1.04 
A04 GFSLTTTAVG IYWDGAQ AHRQNLPASTWHHFDT QSVGSY AAS QQTYSPPNT 1.04 
G10 GFTFDDYA ISWNSGSI AKASDSSGWPSSYFDY QNIRSW KAS QQYNSYPVT 1.04 
C01 GFTFDDYA ISWNSGSI AKDIEYSYGAFDY QNIRSW KAS QQYNSYPVT 1.04 
M3F06 GFTFDDYA ISWNSGSI AKDLAPYYYYMDV QSISSR RAS QQFNTYPLT 3.13 
A03 GFTFDDYA ISWNSGSI AKDLEVVPAAIDY QSISTW KAS QQYDSYPLTLGGGSKVDIK 1.04 
E04 GFTFDDYA ISWNSGSI AKDLSSGWYLTGAFDI SSNIGARDD GDT QSYDSVSGFV 2.08 
B11 GFTFDDYA ISWNSGSI AKDNGSSGYYTGFDY QSISSY AAS QQSYSTPRS 4.17 
F07 GFTFSTYA IxPNSERT AKGGGSGTHQRSPDY QSVGNW RAS QQYNSYPWT 1.04 
E11 GFTFGDYA ISWNSGSI AKGLDRGYDPSDY QSISGW KAS QQYDGYPLT 1.04 
A02 GYTFTSYY INPSGGST ARAARVDILTGGLDY QSISSW KAS QQYSSYPLT 1.04 
H10 GFTFSSYA STYDGSIK ARDGHSSGWYDHGGFDF QSVSSY GAS QQYGSYT 1.04 
C06 GYTFTSYY INPSGGST ARDGLTVAGLNWFDP QSVSSN GAS QQYNNWPS 1.04 
B07 GYTFTSYG ISAYNGNT ARDHDFWSGYSPFDY QSISSY AAS QQSYSTPYT 1.04 
M3B06 GYTFTSYG ISAYNGNT ARDSGRRWLQSYFDY QSISSY AAS QQSYSTPWT 5.21 
D10 GYIFSSYG INSYAGNT ARDVYGGVFDK QSISSY AAS QQSYSTPLT 1.04 
F10 GYTFTGYY INPNSGGT ARDVYGGVFDK QGIRND AAS LQDYDSPYT 1.04 
C09 GFTFSSYS ISSSSSTI ARDYYDSSGYFKFDY SSDVGGYNY EVS SSYTTSSTWV 1.04 
M3E04 GGSISSGDYY IYYSGST ARESVVAGAFDI QSISSY AAS QQSYSTPYT 7.29 
A12 VSSNSAAWN YRSKWYN ARGDSEWGSGNWFDP QSISSY AAS QQSYSTPGT 2.08 
H02 GGTFSSYA IIPIFGTA ARGRYDLVG QSVSSS DAS QQYNNWPLT 1.04 
E12 GYTFTSYG ISAYNGNT ARGSASGPLI SSNIGAGYD GNS QSYDSSLSGWV 1.04 
E07 GYTFTGYY INPNSGGT ARKNSGWYDYYFDY QSISSY AVS QQSYSTPYT 1.04 
H03 GYTFTNYY INPGGGTT ARKSLGGHSFGAFDD QSIGRN NAS HQSANLPWTFGQWTKVDIK 1.04 
E01 GGSISDSY VYYSGST ARSPVSSGWTPYFDL QSVSSSY GAS QHYGSSPRWT 1.04 
H11 GYTFTDYY INPNSGGT ARVGIDRKATRDYYYVMDV QGISNS AAS QQYYSTPQT 1.04 
G02 GYTFTSYG ISAYNGNT ARVGRGSSRD SSNIGAGYD GNN QSSDNNMSGLV 1.04 
M3B03 GYTFSSHA INVFNGNT ARVSLRRGGDYFYDY QGIRND AAS LQDYDSPYT 3.13 
G07 GGTFSSYA IIPIFGTA ASQRGPRSGVDY SSNIGAGYD GNN QSSDNNMSGLV 1.04 
H07 GFTFSSYS ISSGSSTI LVSARGFDYWxPGEPWSPSLQ SSDVGSYNL EVI SSYTSSSTLERV 1.04 
A08 GFTFSSYA ISSNGGST V*AMGGGFSSA QSISGSY WAS QQYYTTPLT 1.04 
G01 GGTFSSYA IILPLVQ VRECWTPTxTTVWTSGAKGPRSPSPQ SSNIGNNY DNN GTWDSSLSAGV 1.04 
Supplementary Figure 5.2. CDR sequences and diversity of the Jurkatmeso library prior to phenotypic selection. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly prior to phenotypic selection. 
  
Development of a phenotypic reporter-based screening platform for the rapid de novo discovery of Chimeric Antigen Receptors (‘CAR-Factory’). 
 
 
117 
clone 
HC LC 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
B01 GFTFSSYG ISYGGSNK AKGAMGYYYYYVMDV QSVGSSH GTS QQYETSPTT 1.04 
H05 GFTFSIYG IRYDGGNK AKRDASGTGSGYYYMDV SSNIGNHY NNR GTWDSSLSAGI 1.04 
D06 GDSISSGYY IYHDGNT ARAASTVTTRWFDP QSISSY AAS QQTYSTWWT 1.04 
E08 GFTFSSYS ISSSSSYI ARDGAVAGYFTLDY SSNIGSKA TNN AAWDDSLNGWV 1.04 
C11 GGTFSSYA IIPIFGTA ARDGGGYSYGPHYYYYGMDV QSVLYSSDNKNY WAS QQYYSIPYT 1.04 
G11 GYTFTSYA INAGNGNT ARDGLGSSSWYGAFDI SNNVGNQG RNN SAWDSSLSAVV 1.04 
G02 GGTFSSYA IIPIFGTA ARDGYSWDY SSDVGGYNY DVS AAWDDSLNGLYV 1.04 
E10 GFTFSSYA ISYDGSNK ARDHISASSGWYRYDAFDI QSVGSF DAS QQRSNWPPYT 1.04 
E02 GFTFSSYA ISYDGSNK ARDQVAVAGNYYYYYGMDV QSVSSN GAS QQYGSSQFT 1.04 
E05 GFTFSTYS ITSDSSTI ARDRGDNYYFDY SSNIGSNT SNK AAWDDSLNGVV 1.04 
B04 GDSFSSYA IIPMFGST ARDRNMMAEFFYHGMDV QGISSY AAS LQDYNYPLT 1.04 
A10 GGTFSSYA IIPIFGTA ARDSLYYFDY RSNIGAGYP ANT QSYDSSLSAVV 1.04 
C06 GFTFSSYS ISSSSSYI ARDTAMALDY NAKIGNTY RNN AAWDDGLRGWV 1.04 
B10 GYSFTSYG ISAYNGNT ARDTGWYGSDY SSNIGSNT SNN AAWDDSLNGLYV 1.04 
D09 GFTFSSYA ISYDGSNK ARDVSFSGDWTYPGVDY QSISSW KAS QQYGSSPFT 1.04 
G01 SSNSAAWN YRSKWYN AREEGSGWGPDFDY    1.04 
A05 GGTFSSYA IIPIFGTA AREGDITGTNYNFDY NIGSKS DDS QVWDSSSDHVV 1.04 
D02 GYTFTSYY INPSGGST AREGEETGTAFGY QSVLYRSNNRNY WAS QQYYSIPLT 1.04 
H03 GYTFTSYG ISAYNGNT AREPGYSYGYSFDI QSISSY AAS QQSYSTRT 1.04 
F12 GFTFSSYA ISYDGSNK ARGGDMDI SSNIGAGYD GYS QSYDSSLSGYV 1.04 
C02 GGSFSGYY INHSGST ARGGIVVVPAASALSRRW RSVLYSSDNSNF WAS QQYFDTPYT 1.04 
D03 GYTFTNYG ISPYNGNT ARGGRGSGWAYDYFDP QSISTW KAS QQYKSYPT 1.04 
E12 GGTFSSYA IIPIFGTA ARGGSYYVFDY NIGSKS QDS QAWDSSSVV 1.04 
H12 GYTFTSYG ISAYNGNT ARGPEYYDFWSGYYGSGYGMDV    1.04 
F05 GYTFTGYY INPNSGGT ARGPRLVQVGNWFDP QSVSSSH GAS QQFGGSPRGA 1.04 
B09 GGSISSYY IHYSGST ARGSSWNYYYGMDV QSLLYSDGNTY KAS MQLAHWPPT 1.04 
D12 GYTFTNYA INAGNGNT ARGTAVAGPVRVLQH SSNIGAGYD GNS QSYDSSLSGYV 1.04 
A09 GGTFSSYA IIPIFGTA ARGYSSSSPFDY SSNIGSYT SNI AAWDDSLNGVV 1.04 
F01 xHCL C*RSLHPS ARNFDSNGYGIDF    3.13 
B08 GGSISSSSYY IYYSGST ARRAIFNKRFDP QSISTY GAS QQSYSTQYT 2.08 
D04 GFTFSSYW INSDGSST ARRGYGMDV SLRSFY GKN HSQDTSANHLRVFAGGTKLTVL 1.04 
G12 GGSISSSSYY IYYSGST ARRPLTSPDFDY QSISSY AAS QKYNSAPFT 1.04 
H11 GYTFTSYY INPSGGST ARRRSSGPYGMDV SSNIGSNL SNN AVWDNSLNGRV 1.04 
D11 GYTFTGYY INPNSGGT ARSGYYYDSSGYYSDYFDY QSLLYSNGYNY LGS MQALQTPLT 1.04 
D05 GGTFSSYA IIPIFGTA ARVGGSGRPFDY GSRIGVAS NDN AAWDDSLNTYV 1.04 
H06 GFTVSSNY ISSSSSYI ARVGSKWLRFNHYYGMDV QSISSY AAS QQSYSTPRT 1.04 
E11 GYTFKNYG ISAYNGNI ARVPPGYCSGGRCSFDH QGISSA DAS QQFNSYLPT 1.04 
G05 GYTLTELS FDPEDGET ASLYSSGWYPSGDAFDI NIGSDS YDT QMWESDTDHRGV 1.04 
C12 GFTFSSYA ISYDGSNK ASPVGSGYYYSSLAFDI SSNIGAGYD GNS QSYDSSLSGYV 1.04 
E06 GFTFSNYA ISSDGSSK ATEGFDI QDISNY DAS QQYDNLPIT 1.04 
G08 GFTVxNNY IYxGGGT ATHPSLGV HVVHxSY xLNS QTWGTxIWV 1.04 
B07 GFTFSSYE ISSSGSTI ATYGDSSPFDY SSNIGARYD GSK QSYDRSLSGWV 1.04 
D08 GFSLSSSGMC IEGDDEK SRIFSSGCPPQFDY QGIRND AAS QQYYSTPLT 1.04 
E03 GFTFSDAW IKSKTDGGTA TSPRGLLH QSVSSN GAS QQYNNWPPMYT 1.04 
B05 GFTFSSYG ISYDGSNK TTAPNYGDYGVGRQSYMDV QSISSY AAS QQSYSTPWT 1.04 
E07 GGTFSSYA IVPIFGTA VLDGYSPFDY RSNIGSNY DNN ETWDSSLSAAV 1.04 
A04 GFTFNKYA VRSKGGST VRGASLGSPPLDY SSNIGSRT TDT AVWDDSLSGWI 1.04 
Supplementary Figure 5.3. CDR sequences and diversity of the JurkatTEM1 library prior to phenotypic selection. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly prior to phenotypic selection. 
Development of a phenotypic reporter-based screening platform for the rapid de novo discovery of Chimeric Antigen Receptors (‘CAR-Factory’). 
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clone 
HC LC 
%  CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
A01 GYTFTSYY INPSGGST  SSNIGANYD GNN QSYDTDLRASV                          1.22 
A06 GYTFTSYA ISYDGSNK ARDPDYSKSFDY SSNIGSNY RNN AAWDDSLSGLYV                           1.22
D12 GYTFTSYY ISYDGSNK ARDPSMIVGFDL SSNIGANYD GNN QSYDTDLRASV                            1.22 
D09 GYTFTSYY IYPGDSDT ARYGEAVAGFDY QSVSSSY GAS QQYGSSQWT                              1.22 
7A6 GYTFTSYY INPSGGST ASSGGATRASDAFDI SSNIGANYD GNN QSYDTDLRASV                            94.94 
Supplementary Figure 5.4. CDR sequences and diversity of the JurkatTEM1(Dn) library prior to phenotypic selection. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly prior to phenotypic selection. 
 
clone 
HC LC 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
M3F06 GFTFDDYA ISWNSGSI AKDLAPYYYYMDV QSISSR RAS QQFNTYPLT 5.95 
A01 GYTFTNYY INPSGGST ARDLLGATSPDY TSNVGTNF DNT GTWDRSLGIFV 3.57 
H05 GYTFTSYD MNPNSGNT ARDRGVIPDFDY TSNVGTNF DNT GTWDRSLGIFV 2.38 
M3B06 GYTFTSYG ISAYNGNT ARDSGRRWLQSYFDY QSISSY AAS QQSYSTPWT 11.90 
M3E04 GGSISSGDYY IYYSGST ARESVVAGAFDI QSISSY AAS QQSYSTPYT 26.19 
M3G03 SVSSNSAAWN YRSKWYD AREVRGAFDI QDISNY DAS QQYGSSPLT 9.52 
M3E03 GYTFTSYG ISAYNGNT ARGMATATHYYYYGMDV QSVNKY AAS QQSYSKPLT 4.76 
B05 GYTFTSYG ISAYNGNT ARGSASGPLI SSNIGAGYD GNS QSYDSSLSGWV 1.19 
G06 GYTFTDFY IHPNSGDT ARRGPTRGLDY QSISSY AAS QQSYSTPRT 1.19 
C06 GYTFTSYA INAGNGNT ARSHTTNWNYVWFDT QSISSY AAS QQSYSTPWT 1.19 
M3B03 GYTFSSHA INVFNGNT ARVSLRRGGDYFYDY QSISSY AAS QQSYSTPLT 4.76 
Supplementary Figure 5.5. CDR sequences and diversity of the Jurkatmeso library after phenotypic selection. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly after three rounds of cell sorting (CS03). 
 
clone 
HC LC 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
D08 GFTFSSYA ISGSGGST AKDFWLTGALEY QSVSSY DAS QQYYTTPFT 1.19 
H10 VSSNSAAWN YRSKWYN AREEGSGWGPDFDY QGISSY WAS QQYYSSPRT 1.19 
H07 GYTFTGYY INPNSGGT AREGWGSYAFDI SSNIGAGYD GNS QSYDSSLTRLTV 1.19 
A07 GGSISSYY ISYSGTI ARRTPRGNFFDF QDISGY TTS QQGFSLPIT 1.19 
T3F09 GYTFTGYY INPNSGGT ARSGYYYDSSGYYSDYFDY SSNIGSNT NND AAWDDSLSGPNYV 11.90 
T3G09 GYTFTGYY INPNSGGT ARSGYYYDSSGYYSDYFDY SSNIGSNT SNN AAWDDSLSGPNYV 2.38 
3B6 GYTFTGYY INPNSGGT ARVRGSHPWFDP SSNIGINT STY ATWDDSLNGVV 2.38 
C08 GYSFTTYW IYPYDSDT ARYPGYCSGGSCYSWYFDV QSVSSTY GAS QQYGSSPQT 1.19 
T3A09 GGTFSSYA IIPIFGTA ASPGYSYGYLS RSNIGSNT SNN AAWDDSLNGYV 64.29 
B04 GGTFSSYA IIPIFGTA ASSSSGYYYYGMDV SSNIGSDY NND AAWDDSLSGPNYV 1.19 
A11 WRG*PCHGIS VYDNGKT TLATPDQHQLLSEVFAS x x x 8.33 
C10 GFTFSNAW IKSKTDGGTT TTSAVVVPAENDY QGISSY AAS QQFSSYPLT 1.19 
T3C11 GYTFTSYG ISGYNGNT VRDRSYYDFWSGYGSAFDI SSNIGSNT SNN AAWDDSLSGPNYV 3.57 
Supplementary Figure 5.6. CDR sequences and diversity of the JurkatTEM1 library after phenotypic selection. 
CDR amino acid sequences and frequencies of a subsets of clones selected randomly after three rounds of cell sorting (CS03). 
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clone 
HC LC 
% 
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3 
7G22 GFTFSSYA ISGSGGST AKAPGFDY SSNIGSNT SNN AAWDDSLNGPV 89.58 
7A6 GYTFTSYY INPSGGST ASSGGATRASDAFDI SSNIGSNT GNN QSYDTDLRASV 2.08 
Supplementary Figure 5.7. CDR sequences and diversity of the JurkatTEM1(Dn) library after phenotypic selection.  
CDR amino acid sequences and frequencies of a subsets of clones selected randomly after three rounds of cell sorting (CS03). 
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 Conclusions	&	Discussion	
 
Cancer immunotherapy was deemed “breakthrough of the year” in 2013 and continues to emerge as one of 
the most promising approaches to fight cancer. Generally, many immunotherapeutic approaches aim at 
harnessing the cytotoxic potential of T cells to target malignant cells. To this end, T cells can be equipped 
with a synthetic CAR or they can be redirected towards tumor cells via a soluble T cell engager molecule. 
Some of the key challenges of both approaches are the identification of suitable tumor-specific antigens, the 
rapid and reliable development of specific and tunable targeting moieties, balancing exceptional potency and 
safety and, importantly, increasing tissue penetration and infiltration into solid tumors.  
Specifically, this thesis aimed to contribute to the development of novel potent and specific antibody-derived 
targeting moieties for cancer immunotherapy and beyond, with the following conclusions arising from the 
presented work:  
 Conclusion	 1:	 The	 integration	 of	 SpyCatcher/SpyTag	 covalent	 fusion	 tag	technology	into	phage	display	workflows	led	to	the	discovery	of	a	novel	panel	of	fully	 human	 scFv	 binders	 targeting	 TEM1,	 among	 which	 the	 affinity-matured	clone	1C1m	represents	a	promising	candidate	for	(pre)-clinical	development.	
A prerequisite for the development of antibody-based cancer therapies is the availability of antibodies that 
meet the desired biochemical and biophysical properties, such as specificity, affinity, stability, solubility and 
low immunogenicity. Robust methods for the de novo discovery of antibodies are therefore indispensable. 
One of the process bottlenecks of display technologies for the rapid discovery of antibodies is the production 
and purification of sufficient quantities of native, correctly folded  antigen that accurately recapitulates the 
endogenous (cell surface or tumor milieu) target. 
To address this challenge, chapter 2 presents the practical utility of the covalent SpyC/SpyT interaction as a 
tagging/immobilization tool for de novo antibody hit discovery, selection, screening and 
characterization331,361. By expressing a number of mammalian cell-surface antigens as SpyC fusions, we 
demonstrated that therapeutically relevant antigens can be captured and immobilized directly onto 
streptavidin surfaces pre-coated with SpyT, circumventing the requirement for traditional antigen 
purification/processing. We showed that antigens immobilized in this way were fully compatible with 
antibody discovery by phage display as well as downstream applications such as hit screening and affinity 
maturation, and could survive the associated  prolonged incubations and extensive washing steps361. 
Representing a minimal, cost-effective solution to mammalian cell-surface antigen production and bypassing 
the need for laborious purification and biotinylation steps, the dCI methodology using SpyC/SpyT could in 
principle be integrated into any other binder discovery platform involving solid-phase antigen capture, i.e. 
ribosome display or phage display selections using non-immunoglobulin or synthetic libraries.  
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Using the SpyC/SpyT dCI methodology, we isolated a number of functional antibody candidates recognizing 
different therapeutic targets, notably mesothelin and TEM1, with the latter being the focus of this work. Our 
diverse panel of fully human TEM1 binders specifically recognize recombinant TEM1 protein as well as 
endogenous TEM1 expressing cell lines, but not TEM1-negative cells. While all of our scFv clones display good 
thermostability in an scFv-Fc format and PBS buffer context, their target affinities vary from mid-nanomolar 
to low single-digit nanomolar in the case of an affinity-matured variant, 1C1m. Also, scFv binders were 
isolated in two separate and distinct campaigns using both a relatively membrane-distal fragment of TEM1 
containing the five extracellular domains (ECD), and an N-terminally truncated fragment (TEM1D(n)) 
comprising only the membrane-proximal sialomucin stalk. Thus, our anti-TEM1 strategy was intentionally 
conceived to drive the isolation of scFv clones distinct from the published sc78 benchmark molecule, which 
binds an epitope thought to reside within the junctional region separating these two fragments306. 
Additionally, several of our clones, including the affinity-matured variant 1C1m, display cross-reactivity 
towards murine TEM1, opening the possibility of readily translatable pre-clinical testing in endogenous 
murine models. Together with the greatly reduced immunogenicity risk of using fully human targeting 
scFvs364, these properties make our novel TEM1 antibody panel attractive starting candidates for the 
development of antibody-based therapeutics. 
The reduced risk of immunogenicity using fully human scFv sequences confers an important advantage over 
antibodies isolated by traditional immunization approaches, such as MORAb004 (ontuxizumab). Despite 
humanization efforts, some residual murine sequence motifs may remain that can raise immune responses 
against the therapeutic antibody364. Also, the fact that our new clones arise from a naïve IgD/IgM, essentially 
germline, library with minimal donor-specified somatic mutations further reduces the risk of immunogenicity 
in the clinical setting. 
In addition, the quality and source of antigen used for binder selection is of paramount importance for the 
specificity of the selected antibody panel. For instance, antigens produced in mammalian expression systems 
retain native folding and post-translational modifications typical for eukaryotic proteins414. In contrast, 
antigens produced in prokaryotic cells typically lack post-translational modifications, such as glycosylation. 
For heavily glycosylated proteins such as TEM1, the lack of these added glycans may strongly impact on 
protein folding and epitope accessibility. Therefore, antibodies that have been isolated using antigens 
derived from prokaryotic expression systems, such as sc78, which was isolated against a GST-fused TEM1-
ECD fragment (residues 25-395) produced in E.coli306, have to be assessed carefully for specific binding of the 
native target antigen expressed on the cell surface. Indeed in our hands sc78 occasionally showed signs of 
non-specific binding, in contrast to our panel of scFv clones which were isolated against TEM1 fragments that 
were expressed in human HEK293-6E cells and immobilized directly with minimal intermediary handling361. 
The rapid, small-scale capture of TEM1 protein from fresh expression supernatants may well have 
contributed to retaining the native protein conformation of this antigen, which had previously appeared 
unstable in traditionally produced and purified formats.  
The development of a panel of TEM1-specific antibodies, among which 1C1m emerged as our lead candidate, 
opens the door to the evaluation of multiple diagnostic and therapeutic applications. Based on its highly 
preferential expression within the stroma and neo-vasculature of tissues undergoing active angiogenesis, 
TEM1 has been proposed as a biomarker for the detection, monitoring and therapeutic targeting of human 
cancer304,307,308,365. Classical strategies to exploit such biomarkers include the development of optical tracers 
for tumor imaging as well as the antibody-mediated delivery of radio-, chemical- or biological toxins to the 
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tumor site. In this context, the previously described clone sc78 has been investigated as an optical tracer for 
tumor imaging, including positron emission tomography (PET) and near-infrared (NIR) optical imaging of 
cancerous lesions365,308. In addition to neo-angiogenesis, TEM1 is commonly expressed by cancer cells of 
mesenchymal origin, notably sarcoma cells276,309. Thus, a number of studies focused on the development of 
ADC therapeutics directed against TEM1304,305,309. Among them, sc78 has been proposed as a targeting entity 
for ADC therapeutics309,335. Even more so than for optical imaging, efficient antigen binding and high 
specificity are critical for the development of clinically employable and safe ADCs. Therefore, high affinity 
binding is usually a prerequisite for a successful antibody candidate. In this regard, our affinity-matured clone 
1C1m could represent a promising candidate, as it binds both human and murine TEM1 with a monovalent 
affinity constant of 1 nM and 6 nM, respectively. This clone thus compares favorably with the previously 
published clone sc78, the affinity of which was reported as 5.6 nM against human TEM1306. Moreover, the 
data presented in chapter 3 and 4 highlights the exquisite apparent specificity and encouraging biophysical 
properties of our lead candidate 1C1m. Building on these promising results, the potential of 1C1m is currently 
being explored by collaborators as a tumor targeting entity for both radio-imaging, (Prior, J., CHUV Lausanne; 
Rocha Paulo, A., Instituto Superior Técnico Lisbon), and for real-time image guided surgery using 1C1m IR-
dye conjugates (Van Driel, LUMC; Goun, E., EPFL). Additional interest has led to a study using an antibody-
drug conjugated form of 1C1m in the context of melanoma and TEM1-expressing cancer associated 
fibroblasts (Homicsko C., EPFL).  
Finally, given the high incidence of TEM1 expression within the tumor vasculature266,267,272,280, and the 
apparent restriction to the tumor tissue in adults271,280, TEM1 could represent an attractive target for 
engineered cancer immunotherapy. In light of the outstanding potency of T cell-based therapies, the 
specificity of the targeting antibody is of paramount importance. Moreover, in contrast to more traditional 
antibody applications, affinity is not always the key determinant for effective CARs or bispecific T cell 
engagers193,194. Other parameters, such as epitope location and binding geometry can equally impact on the 
efficiency of T cell retargeting199,200,248.  Thus, our panel of fully human anti-TEM1 scFv clones enabled us to 
explore the anti-tumor potential of redirecting T cells towards TEM1-expressing target cells. 
 Conclusion	 2:	 TriloBiTEs	 derived	 from	 novel	 anti-TEM1	 scFvs	 potently	 and	specifically	 redirect	 the	 cytotoxic	 effector	 functions	 of	 primary	 human	 T	 cells	towards	TEM1-expressing	target	cells.	
Both CARs and soluble T cell engagers directed against CD19 have generated impressive results in the 
treatment of B cell malignancies169,171,214,215,368,369. Many attempts have since been undertaken to apply these 
strategies for the therapy of solid tumors. However, the availability of suitable tumor-restricted antigens has 
proven a limiting factor for the broad application of both CARs and soluble engager molecules. In light of its 
expression profile and prevalence among human cancer samples, my thesis work aimed to investigate 
whether our newly developed anti-TEM1 antibodies would effectively redirect T cells when embedded in a 
bispecific format. 
Despite the tremendous clinical impact of the minimalistic BiTE format (tandem scFv1-scFv2), it may not be 
generally applicable or effective against many target antigens. For example, very low abundance targets (10-
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100 of copies per cell) require supra-physiological low picomolar monovalent affinity (e.g. ImmTacs)389 
against the target to achieve threshold levels of functional T cell activation. The need for such exceptional 
binding in the case of low-density antigens can be circumvented to some degree by exploiting avidity-driven 
stabilization/rebinding through the use of bi- or oligovalent targeting formats242,245.  In our study, we initially 
attempted to explore T cell engagement with our anti-TEM1 scFvs using the classical monovalent BiTE 
paradigm. However, despite making several variant molecules on this theme, we observed only negligible T 
cell activation potency in cell assays. We thus asked whether a structurally distinct, heterodimeric engager 
format comprising a bivalent anti-TEM1 ‘warhead’ could overcome these deficits. To this end, we designed 
the modular TriloBiTE format, drawing inspiration from the murine ‘tribody’ scaffold first reported by 
Schoonjans and colleagues382. However, unlike ‘tribodies’ our TriloBiTEs are constructed on a dimerizing 
CH1/Ck human Fab core that we have further stabilized through the incorporation of interface mutations.   
Strikingly, TriloBiTEs equipped with bivalent dual-arm anti-TEM1 targeting moieties effectively redirected 
primary human T cells to lyse TEM1+ target cells in vitro, as described in chapter 4. Notably, the two higher-
affinity clones sc78 and 1C1m consistently mediated stronger T cell responses in our initial comparative 
experiments and lower affinity clones consistently performed sub-optimally. Thus, affinity plays a crucial role 
for efficient TEM1 engagement, and it is possible that additional maturation of 1C1m could result in further 
improvement of T cell engagement and activation. Although the sc78-tB induced the secretion of higher 
levels of IFN-g and IL-2, we occasionally observed non-specific sc78-tB mediated T cell activation in the 
presence of TEM1-negative cells (Fig. 4.3a), suggesting either some structural instability 
(aggregation/oligomerization) or some off-target specificity. In addition, 1C1m also showed potential as a 
targeting moiety for human CAR-T cells, while sc78, surprisingly, did not seem to be active in this format (Fig. 
4.6), possibly reflecting misfolding of the scFv or geometric/flexibility constraints in engaging the human 
TEM1 epitope when in the membrane anchored context.   
Although 1C1m clearly stimulates cytotoxic effector functions both as a TriloBiTE and as a CAR, cytokine 
production, especially IL-2 secretion, is triggered less efficiently, especially compared to TriloBiTEs directed 
against other targets such as mesothelin (compare Fig. 4.1h and Fig. 4.3f). However, this weak apparent 
cytokine response may well be sufficient to sustain initial proliferation and cytotoxic T cell effector 
functions415-417. Lower levels of cytokines may rather affect long-term expansion and memory 
formation392,418,419, which may pose a problem for CARs, the efficacy of which depends on initial expansion 
and persistence. In contrast, a soluble T cell engager, which is administered repeatedly, will constantly (re-) 
trigger a polyclonal T cell response without the need for long-term persistence of individual T cell clones. In 
this case, the exact role and requirement of individual cytokines is less clear. Interestingly, a recent study 
reports that elevated cytokine responses elicited by T cell engaging bispecifics, particularly mediated by T cell 
derived TNF-a, are dispensable for cytotoxic activity415. In fact, the authors propose to block TNF-a signaling 
prior to biAb administration in order to prevent CRS415. Thus, a more subtle and more transient cytokine 
response, such as observed with 1C1m-tB, might prove advantageous, especially in light of the severe side 
effects (CRS) caused by excess cytokine production (CRS) in response to T cell therapy215,367. 
Besides 1C1m, another clone, 7G22, isolated for binding to the membrane-proximal sialomucin stalk region 
of TEM1, potently redirected primary human T cells towards TEM1+ target cells, both as a TriloBiTE (Fig. 4.4c-
e) and as a CAR (Fig. 4.6). Cell binding experiments, as well as the fact that it was isolated from a naïve human 
antibody library suggest that the monovalent binding affinity of 7G22 is relatively low. Although this will need 
to be confirmed experimentally, the in vitro activity of 7G22 highlights the importance of epitope location 
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for efficient TEM1 targeting. Several studies have established that the potency of both T cell engagers and 
CAR-T cells strongly depends on the location of the target epitope, with membrane-proximal epitopes usually 
mediating stronger T cell activation200,202,247,248. Underlying these observations is the architecture of the 
immune synapse, where the membranes of T cell and target cell/APC are brought into close proximity, 
excluding large phosphatases such as CD45197. The sialomucin stalk of TEM1 followed by five ECDs suggests 
a bulky structure protruding from the membrane, which could require membrane-proximal targeting in order 
to achieve the appropriate positioning of T cell and target cell. However, no crystal structure of the TEM1 
ECD is available to date, and so any advantage of membrane-proximal epitopes will have to be determined 
empirically. In any case, the promising in vitro activity of 7G22 warrants further investigation in vitro and in 
vivo. 
As a perspective, the TriloBiTE format offers the possibility to design a trivalent engager molecule, utilizing 
two distinct tumor-targeting scFvs as an alternative to bivalent tumor binding. These could be directed 
against different tumor targets, tuning the respective affinities according to the desired functionality. In this 
way, logic-gated T cell engagers could be designed which either redirect T cells to kill tumor cells based on 
binding to either antigen independently (‘OR’ logic), or preferentially induce killing of cells that express both 
targets (‘AND’ logic). In both cases, the efficacy of such a trispecific molecule would be driven by the 
engagement of targets in close proximity through avidity and/or rapid cell rebinding. Another trispecific 
option includes the integration of a co-stimulatory specificity, for instance by engaging both CD3 and CD28 
on the T cell251,420. Similarly, two epitopes on the same TAA could be targeted with a biparatopic TriloBiTE, 
for instance using 1C1m and 7G22 combined in the same molecule. Such biparatopic targeting421 has proven 
effective in the case of therapeutic antibodies and ADCs directed against Her2 and MET, both by increasing 
binding strength through avidity effects, and by cross-linking the antigen, leading to increased receptor-
mediated internalization and degradation422,423. Moreover, a biparatopic T cell engager directed against Her2 
has been reported, exhibiting strong antigen binding and superior cytotoxicity against breast cancer cells 
expressing low levels of Her2424. Thus, in order to further explore the concept of biparatopic T cell engagers, 
we are planning to investigate the anti-tumor potential of a TriloBiTE variant combining 1C1m and 7G22 
tumor-targeting scFvs. 
Importantly, we are also planning to expand our in vivo studies in order to determine the full potential of 
TEM1-targeting TriloBiTEs. In a preliminary murine xenograft study, the systemic administration of 1C1m-tB 
appeared to show significant T cell retargeting activity, preventing the outgrowth of A673 tumor cells co-
inoculated with human T cells. This initial experiment presents a first in vivo indication that TEM1 can be 
targeted via an immunotherapeutic soluble engager molecule. Subsequent experiments will aim to robustly 
verify these findings, and to investigate whether 1C1m-tB can induce regression of pre-established tumors. 
In this context, it would also be desirable to characterize the in vivo activity of the membrane-proximal binder 
7G22-tB. However, the described xenograft studies only model the targeting of tumor cells that directly 
express TEM1. Clinically, far more patients could benefit from therapies directed against TEM1 expressed by 
the tumor neo-vasculature. Thus, investigating the potential of anti-TEM1 TriloBiTEs to mediate tumor 
regression in syngeneic tumor models with endogenous TEM1 expression within the tumor stroma and 
vasculature would be key to fully explore the potential and risks of immunotherapeutic targeting of TEM1. 
Although the strong cross-reactivity of 1C1m towards murine TEM1 is directly compatible with translation to 
such syngeneic models, the anti-CD3 clones employed in the current TriloBiTE core binds only to human CD3. 
Hence, for syngeneic models, where endogenous T cells need to be recruited to the tumor site, a murine CD3 
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surrogate tB would need to be constructed and thoroughly validated in vitro. One further attraction of a 
surrogate molecule would be to better evaluate the safety implications of co-incidental targeting of 
endogenous levels of TEM1 present in non-tumor cell compartments.  
As mentioned above, the molecular expression pattern of TEM1 suggests two different therapeutic 
applications. Firstly, since the majority of human sarcoma expresses TEM1276,304,309, TEM1-targeted 
immunotherapies could be applied for the treatment of this rare but aggressive cancer type. Additionally, 
the expression of TEM1 within the neo-vasculature of many solid tumors offers the possibility of “universal” 
tumor-targeting independent of the tissue of origin. In this context, it remains to be investigated whether 
eliciting a targeted and durable T cell killing response against the supporting neo-vasculature can be achieved 
and, further, would translate into a significant therapeutic potential. Conceptually, disrupting the neo-
vasculature/stromal compartment could lead to (limited) tumor cell death and to a subsequent spreading of 
tumor-associated antigens, as was observed with a cancer vaccine directed against TEM1310. This in turn could 
improve any existing anti-tumor immunity, possibly assisted by combinatorial immune-enhancing 
treatments, such as PD1-blockade425. These concepts would however require careful validation, since tumor 
vascular targeting, for instance via VEGFR blockade, have been found to favor therapy resistance and the 
outgrowth of more aggressive cancer cells254.  
Collectively, this work presents a proof-of-principle for the immunotherapeutic targeting of TEM1, both using 
soluble T cell engagers and human CARs. Our promising in vitro results with 1C1m and 7G22 in both formats 
thus lay the foundation for subsequent studies aiming to assess the potential of TEM1 targeting within the 
tumor vasculature. In addition, we present the TriloBiTE platform as a tractable and potent modular T cell 
engager format, allowing the fine-tuning of affinity and avidity for optimal T cell engagement.  
 Conclusion	 3:	 Phenotypic	 reporter-based	 cell	 screening	 offers	 the	 potential	 to	accelerate	the	de	novo	discovery	of	functional	engager	immunotherapeutics.	
Both potency and safety of engineered T cell therapies largely depend on the availability of a suitable 
targeting antibody. As discussed above, a number of parameters can impact on the efficacy of T cell 
engagement, such as affinity, relative epitope location, linker/spacer length and targeting geometry193,199-202. 
Currently, warheads for both soluble engager molecules and CARs have to be validated empirically, especially 
for novel and poorly characterized targets, leading to labor-intensive iterative screening campaigns. In 
addition, clones that show promising functional and biophysical properties as soluble antibodies do not 
always function adequately in the context of a membrane-embedded CAR, as we have observed with sc78 
(Fig. 4.6). To overcome this bottleneck, we aimed to develop a phenotypic screening platform for the de novo 
discovery of functional targeting moieties for CARs.  
As described in chapter 5, we employed Jurkat reporter cells to display pre-selected scFv libraries and 
subsequently enriched cells harboring a functional CAR construct. As a proof-of-principle, we identified novel 
CARs against mesothelin and TEM1, among them the TEM1 mucin stalk binder 7G22, which proved to be 
functional both as a CAR and as a TriloBiTE. In principle, as an integrated phenotypic screening pipeline, the 
CAR Factory approach could allow the isolation of functional CAR targeting moieties directed against any 
given cell surface antigen. 
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Recombinant antigens, however well produced and quality controlled, may differ from native antigens 
expressed in the context of the cell surface. Glycosylation and other PTMs as well as neighboring or 
interacting molecules may impact on protein folding or mask certain epitopes. Therefore, binder selection 
against recombinant versus native antigens can yield very different outcomes, as observed in our study for 
TEM1(Dn). The fact that 7G22 did not flag as a strong binder of recombinant TEM1(Dn) protein, but later 
appeared to be functional both as a CAR (Fig. 4.6e, f) and as a TriloBiTE (Fig. 4.4c-e), highlights the 
shortcomings of traditional binder selection for “difficult” cell-surface antigens. Despite labor-intensive 
screening and reformatting efforts, the functional clone 7G22 would have been missed. In summary, this 
example demonstrates how phenotypic screening of clone repertoires pre-formatted as CARs, can, as 
compared to typical phage display screening, lead to apparently superior outcomes (in terms of desirable hit 
clone characteristics) against heterogeneous and complex targets such as TEM1(Dn).  
In addition, the observation that 7G22 is functional both as a CAR and as a TriloBiTE raises the interesting 
possibility that our phenotypic CAR screen may enrich concomitantly for scFvs with characteristics that are 
also required by soluble engagers. Hence, this approach may have considerable general utility for 
immunotherapeutic discovery.  
Preliminary activation experiments in Jurkat NFAT-mCherry reporter cells suggested specific CAR signaling 
with the novel CAR scFvs identified against TEM1(ECD) and mesothelin in the presence of relevant target 
cells (Fig. 5.4). Although clearly activating, some of these CARs, including 7G22, induce mCherry expression 
only in a proportion of CAR-expressing Jurkat cells. This could indicate suboptimal T cell engagement or 
activation, which will have to be assessed in primary T cells. Beyond the targeting moiety, the length and 
structure of the CAR linker/spacer domain has a major impact on T cell engagement and synapse 
formation199,202. Furthermore, the choice of intracellular co-stimulatory domain can strongly influence T cell 
activation, proliferation and persistence378. Thus, by leveraging the modular cloning nature of our CAR 
Factory vector scaffold, libraries of CAR components other than scFvs could be integrated into the phenotypic 
selection workflow. We envisage that cell-based screening of such combinatorial CAR libraries could then 
permit the direct selection of CAR clones comprising optimal or ‘tuned’ assemblages of scFv, linker, and TM 
domain. These latter library elements — which will be modest in number and well-defined — could be 
screened either by direct permutation against the initial scFv input library, or sequentially, after having 
identified suitable targeting scFvs (hierarchically). As a starting point, we have designed a panel of 12 
different extracellular linkers/spacers derived from the membrane-proximal regions of natural human 
transmembrane proteins and comprising various lengths, molecular weights, cysteine- and glycan content as 
well as domain structures. Preliminary investigations suggest an impact of the length and nature of the CAR 
linker on the activation potential of the 1C1-CAR, paving the road for further studies using the same CAR 
linker/spacer panel. 
Following initial discovery, early in vitro and in vivo efficacy and safety studies of CARs and T cell engagers 
provide only limited insights into the potential for successful clinical translation. A number of complex and 
cooperating factors are known to strongly impact on the efficacy of T cell therapies in the clinic. Key among 
these are the often hostile, immunosuppressive TME, possible unwanted side effects, and, in the case of 
CARs, the proliferation and persistence of the infused T cells160. Moreover, it will have to be confirmed that 
any T cell activation observed in vitro leads to a lasting anti-tumor response in vivo. Thus, the true potential 
of any novel CAR or T cell engager will only be revealed in early clinical studies. 
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Over the last decade, immunotherapy has revolutionized cancer therapy, yielding a plethora of potential new 
treatment concepts. Besides checkpoint blockade and personalized therapies aiming to mount an immune 
response against individual neo-antigens, antibody-based retargeting of T cells has emerged as a powerful 
strategy to combat cancer. The work presented in this thesis contributes to the field in three ways. First, the 
described and published novel methods for the direct capture and immobilization of antigens, when 
combined with a phenotypic screening platform for CARs, greatly accelerates the de novo discovery of 
functional targeting moieties. With both workflows in place, we are now in the position to rapidly generate 
tailored antibody warheads with the required biophysical and functional properties. Secondly, several of my 
anti-TEM1 scFv candidates are the subject of a patent application, with one molecule currently undergoing 
investigation by 3rd party collaborators for radio/IR-conjugate clinical imaging applications. Finally, this work 
presents a proof-of-concept for redirecting T cells towards human TEM1 and lays the foundation for further 
investigations and the development of TEM1-targeted therapies.  
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